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Abstract 
Clustered, regularly interspaced, short palindromic repeats and CRISPR-
associated proteins (CRISPR-Cas) constitute a bacterial and archaeal adaptive 
immune system. The ongoing arms race between prokaryotic hosts and their 
invaders such as phages led to the emergence of anti-CRISPR proteins as 
countermeasures against the potent antiviral defense. Since the first examples of 
anti-CRISPRs were shown in a subset of CRISPR-Cas systems, we endeavored 
to uncover these naturally-occurring inhibitors that inactivate different types of 
CRISPR-Cas systems. In the first part of my thesis, we have identified and 
characterized Type II anti-CRISPR proteins that inactivate several Cas9 
orthologs. We share mechanistic insights into anti-CRISPR inhibition and show 
evidence of its potential utility as an off-switch for Cas9-mediated mammalian 
genome editing. Although the RNA programmability of Cas9 enables facile 
genetic manipulation with great potential for biotechnology and therapeutics, 
limitations and safety issues remain. The advent of anti-CRISPR proteins 
presents opportunities to exploit the inhibitors to exert temporal, conditional, or 
spatial control over CRISPR. In the second part of my thesis, we demonstrate 
that anti-CRISPR proteins can serve as useful tools for Cas9 genome editing. In 
particular, we have demonstrated that anti-CRISPRs are effective as genome 
editing off-switches in the tissues of adult mammals, and we further engineered 
anti-CRISPR proteins to achieve tissue-specific editing in vivo. Taken together, 
my thesis research aimed to mine for natural anti-CRISPR protein inhibitors and 
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repurpose these proteins to complement current Cas9 technologies in basic and 
clinical research.  
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1 
Chapter 1 Introduction 
1.1 Introduction to CRISPR-Cas systems 
1.1.1 The diversity and biology of CRISPR-Cas systems 
Clustered, regularly interspaced, short palindromic repeats (CRISPR)-CRISPR 
associated (Cas) is an adaptive immune system found in archaea and bacteria 
that protects against mobile genetic elements (MGEs) such as phages by 
targeting and destroying their nucleic acids (Barrangou et al., 2007; Brouns et al., 
2008; Marraffini & Sontheimer, 2008). Distributions of CRISPR-cas loci are 
represented in a substantial majority of archaea (~90%), including almost all 
hyperthermophiles, and in ~40% of bacteria, underscoring the prevalence and 
importance of their existence (Makarova et al., 2020). Although CRISPR-Cas 
systems are highly abundant and diverse, they share core architectural and 
functional similarities. A typical CRISPR locus consists of cas genes and a 
CRISPR array, a series of identical repeat sequences interspaced by short 
spacer sequences, which are fully or partially complementary to foreign genetic 
elements called protospacers. The spacer and repeat sequences are typically 
transcribed into a long precursor CRISPR RNA (pre-crRNA), which is further 
processed into mature CRISPR RNAs (crRNAs). Proteins involved in different 
processes of CRISPR-mediated immunity are encoded by cas genes in the 
vicinity of the CRISPR array (Makarova et al., 2020). In the biological context, 
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crRNAs and Cas proteins from the CRISPR locus function together hand-in-hand 
to form an RNA-guided effector protein complex to target matching protospacers 
when encountered by MGEs. 
The diversity of CRISPR-Cas systems 
Although an increasing wealth of genomic and metagenomic data will likely 
continue the expansion of the CRISPR-Cas systems, current systems are 
broadly grouped into two classes and further categorized into 6 types and 33 
subtypes (Makarova et al., 2020) (Figure 1.1). A number of cas genes encoding 
important proteins in the CRISPR-Cas pathway have been identified to date and 
divided into functional modules: adaptation, expression, interference, and 
ancillary. Although no genes are shared by all CRISPR-Cas systems, the only 
proteins that are almost universal are Cas1 and Cas2, which are key enzymes 
that function in the adaptation module. In most class 1 systems, Cas6 is directly 
involved in processing crRNAs. In class 2 systems, some Cas proteins (such as 
in subtype V-A and type VI) can have RNase activity and process their own 
crRNAs while Type II (and some Type V subtypes) systems rely on the bacterial 
host RNase III. The latter types are also distinguished from the rest by having an 
additional RNA component, known as a trans-activating RNA (tracrRNA). The 
partial pairing between the direct repeat region of a crRNA and tracrRNA forms a 
stable duplex that is processed by RNase III (E. Charpentier et al., 2015; 
Deltcheva et al., 2011). This mature guide RNA (crRNA-tracrRNA) remains 
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bound to an effector protein for interference. The effector protein(s) in the 
interference module is extremely diverse and forms the basis for classification 
schemes of different CRISPR systems. In the case of class 1 systems, multiple 
proteins form a complex with crRNA for interference step while class 2 CRISPR 
systems use a single, multi-domain effector protein that essentially serves the 
same purpose of an entire effector complex of class 1. The ancillary module is 
composed of genes that are linked or predicted to be associated with CRISPR 
but are not yet fully explored.  
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Figure 1.1 Classifications of CRISPR-Cas systems. Top: a generic 
organization of class 1 and 2 CRISPR loci. Two classes are distinguished by 
either a multi-effector complex or single effector protein. Bottom: each class is 
further divided into six types based on the genetic, structural, and functional 
organizations: class 1 includes Types I, III, and IV while class 2 includes Types II, 
V, and VI. Figure adapted from Makarova et al. with permission (see the List of 
Third Party Copyright Information) (Makarova et al., 2020).  
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The biology of CRISPR-Cas systems 
CRISPR-Cas systems function against invading genetic materials in three key 
steps: adaptation, biogenesis, and interference (Figure 1.2). Adaptation is a key 
aspect of CRISPR-Cas adaptive immunity that provides hosts with protection 
from continuous invasions by MGEs. This is facilitated by adaptation in which 
hosts acquire new spacers from the foreign genetic materials by incorporating 
them into CRISPR loci (McGinn & Marraffini, 2019). The acquisition of spacers 
from the previous encounter serves as a memory reservoir to effectively destroy 
the invading genome upon future infection (Brouns et al., 2008; Garneau et al., 
2010; Hale et al., 2009; Rouillon et al., 2013; Sapranauskas et al., 2011). Most 
CRISPR loci make a single long transcript of pre-crRNA that must be processed 
into individual crRNAs during the expression stage (Brouns et al., 2008; Carte et 
al., 2008; E. Charpentier et al., 2015; Deltcheva et al., 2011). The processing is 
mediated by either Cas protein(s) or host RNases depending on different 
CRISPR systems (Carte et al., 2008; Deltcheva et al., 2011; Haurwitz et al., 
2010). During the interference step, the complementarity between the spacers of 
crRNAs and protospacer sequences of invading genomes such as viruses or 
plasmids triggers the cleavage of nucleic acid targets by Cas nuclease(s). In 
some systems such as Type I and II, a PAM flanking the target sequence is 
required for cleavage of the protospacer sequence in the invading nucleic acids. 
PAMs also serve an important role in protecting host’s own genome by avoiding 
“self-targeting," which is the cleavage of the spacer sequence in the CRISPR 
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array (Deveau et al., 2008; Mojica et al., 2009). This is a simplified summary of 
key functionalities of CRISPR-Cas systems but there are many details and 
aspects that are unique for different systems. 
  
 
 
7 
 
  
Figure 1.2 A schematic of the three major stages of CRISPR-Cas immunity. 
Step 1: Adaptation is the acquisition of a protospacer from invading MGEs and 
integration as a spacer into the CRISPR array. Step 2: expression and 
maturation involve transcription of pre-crRNAs containing spacer sequences and 
processing into mature forms. Step 3: interference is executed by Cas effector 
protein(s) guided by crRNAs to target the protospacers in the invading genome. 
Figure adapted from Hampton et al. with permission (see the List of Third Party 
Copyright Material) (Hampton et al., 2020). 
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1.1.2 Class 2 CRISPR-Cas systems 
Although class 1 is far more abundant than class 2 in most groups of bacteria 
and archaea, class 2 remains nearly exclusive to bacteria. The near-absence of 
class 2 in archaea can be partly explained by the absence of RNase III, which is 
required for crRNA processing in many class 2 systems. Class 2 effector 
proteins, especially those from Type II systems, are known to play important 
roles in adaptation, crRNA processing, and interference steps. In particular, 
Cas9, Cas12, and Cas13 are the signature effector proteins from Types II, V and 
VI, respectively, that have gained great attention for their biotechnological uses 
(Figure 1.3). Each of these types is discussed in more detail below.  
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Figure 1.3 Overview of class 2 CRISPR-Cas systems. A schematic of the 
effector complex consisting of protein, target DNA, crRNA and tracrRNA (for 
Types II, V and VI) is shown. Red bars indicate a PAM (protospacer adjacent 
motif) or a PFS (protospacer flanking sequence). Red triangles show cut sites in 
the target DNA or RNA. dsDNA, double-stranded DNA; ssRNA, single-stranded 
RNA. Nuclease domains, canonical PAM/PFS preferences, target substrates, 
and cleavage patterns are summarized. Figure adapted from Shmakov et al. with 
permission (see the List of Third Party Copyright Material) (Shmakov et al., 
2017). 
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Type II 
Cas9 is an effector protein of Type II systems that became a focus of the 
CRISPR field relatively early. A Cas9 ribonucleoprotein (RNP) complex with 
crRNA and a trans-activating (tracrRNA) cleaves DNA in an RNA-guided fashion 
(Gasiunas et al., 2012; Jinek et al., 2012). Cas9 contains two nuclease domains, 
an HNH (His-Asn-His) domain and a RuvC-like domain, that are responsible for 
creating a double-strand break (DSB) by cleaving the target strand that pairs with 
the spacer and the displaced non-target strand, respectively.  
Cas9 is one of the best-studied CRISPR-Cas systems because of its initial 
demonstration as a programmable RNA-guided genome editing platform using a 
Type II-A Cas9 from Streptococcus pyogenes (S. pyogenes Cas9 - SpyCas9) 
(Cho et al., 2013; Cong et al., 2013; W. Y. Hwang et al., 2013; W. Jiang, Bikard, 
et al., 2013; Jinek et al., 2013; Mali et al., 2013). Today, many Type II Cas9 
orthologs have been repurposed as tools for genome engineering. Type II 
CRISPR systems are further subdivided into three subtypes based on the degree 
of homology between Cas9 proteins, and the presence or absence of an 
additional Cas protein involved in adaptation. Type II-A and II-B systems include 
Csn2 and Cas4, respectively, while most Type II-C systems are characterized by 
a lack of both Cas4 and Csn2 (Mir, Edraki, et al., 2018). [An additional variant of 
Type II-C CRISPR system (type II-C2) has been identified in archaea that shares 
similarity with Type II-C Cas9s but also contains Cas4 (Burstein et al., 2017)]. 
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Moreover, Type II-C CRISPR arrays have internal promoters embedded in each 
repeat sequence, generating nested pre-crRNAs as a source of mature crRNAs 
instead of processing a single pre-crRNA transcript (Y. Zhang et al., 2013). 
Another feature of all Type II Cas9s is the requirement of a PAM sequence in the 
target DNA. PAM recognition by a Cas9 is thought to be required prior to the 
initiation of unwinding and cleavage of double-stranded DNA (dsDNA) at a 
sequence upstream of PAM. Although PAM lengths and sequences are unique to 
each Cas9, most are GC-rich. 
Type V  
Type V systems differ fundamentally from Type II by the domain architecture of 
effector proteins. While Type II effector proteins contain two nuclease domains, 
Type V effectors (Cas12) only have RuvC-like domains that are responsible for 
DSB induction. Although effectors of subtypes V-A (Cas12a) and V-B (Cas12b) 
have been investigated in detail, there are currently 10 subtypes of Type V. 
Various Cas12 effectors possess different properties, including dsDNA cleavage 
and nicking and collateral cleavage of single-stranded DNA and RNA (Yan et al., 
2019). In particular, Cas12a (formerly known as Cpf1) is a prototype Type V 
effector protein that has been extensively studied structurally and functionally. A 
key distinction of Cas12a is its ability to process its own crRNA and its lack of a 
tracrRNA. Cas12a also differs from most Cas9s by generating a staggered 
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dsDNA cleavage pattern; furthermore, it cleaves distal from the PAM sequence, 
which tends to be AT-rich. 
Type VI  
The Type VI effector protein, Cas13, is the first and thus far only variant in class 
2 to target only RNA, presumably transcripts of invading genomes since RNA 
viruses are less common than those with DNA genomes. It is characterized by 
the presence of two HEPN (Higher Eukaryotes and Prokaryotes Nucleotide-
binding) RNase domains that possess RNA cleavage and binding activities 
instead of a DNA-targeting mechanism. In addition, target RNA recognition of 
Cas13-crRNA complex triggers its nonspecific RNase activity, and collateral RNA 
degradation induces dormancy in hosts infected with the targeted virus (Meeske 
et al., 2019). Type VI systems seem to be less diverse and less abundant than 
Types II and V, although new subtypes may be discovered in the future. 
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1.2 CRISPR-Cas systems for genome engineering 
1.2.1 Applications of CRISPR-Cas 
Due to its ease of programmability and simplicity, different Cas proteins have 
been repurposed for genome engineering applications in many heterologous 
contexts. It has successfully been used for genetically modifying plants and 
animals, for gene therapy for human diseases, and development of research and 
diagnostic tools (Doudna, 2020; Pickar-Oliver & Gersbach, 2019; Porteus, 2019). 
To date, most applications of CRISPR systems have focused on the 
programmable DNA-targeting activity of Cas9. The cleavage activity of Cas9 can 
be harnessed for genome editing while catalytically inactive (‘dead’) variants of 
Cas9 (dCas9) have been used for transcriptional control, epigenetic 
manipulation, and chromatin imaging. Most recently, nickase versions of Cas9 
(nCas9) have been used in base editing as well as prime editing (Anzalone et al., 
2019; Komor et al., 2018; Rees & Liu, 2018a). All of these advances also have 
their own limitations, such as the potential for off-target effects and challenges 
that are associated with delivery (Doudna, 2020). Thus, alternative tools for 
CRISPR technologies are in high demand.  
The diversity of CRISPR systems such as in the nature of their targets (DNA vs. 
RNA), PAM specificities and sizes provide opportunities for enhancing and 
expanding the capabilities of our toolbox for biomedical research and 
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biotechnology. For example, Cas12a from Type V-A lacks a tracrRNA and has 
an AT-rich PAM, yielding in a simpler, single crRNA-guided and highly specific 
enzyme that can target AT-rich genomes. Cas13a from Type VI also opens a 
door for RNA-targeting technologies that enable us to manipulate RNA 
transcripts in cells. Both Cas12a and Cas13a have been used in diagnostics for 
viral infection (Ackerman et al., 2020; J. S. Chen et al., 2018; Gootenberg et al., 
2017).  
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Outcomes of CRISPR-Cas gene editing repair 
In engineered systems, the crRNA and tracrRNA can be fused into a single-guide 
RNA (sgRNA) (Jinek et al., 2012). Cas9 can use an sgRNA to target virtually any 
sequence next to a cognate PAM and introduce a DSB. As DSBs are inherently 
detrimental for genomic integrity, they are resolved by cellular repair pathways. In 
most mammalian cells, DSBs are repaired via non-homologous end-joining 
(NHEJ) that can sometimes introduce insertions and deletions (indels) at the cut 
site by imprecise repair process, which may inactivate the target gene. When the 
NHEJ machinery restores the original sequence by directly ligating the blunt ends 
of DNA without indels, the intact sequence is subjected to Cas9-mediated 
cleavage again, ultimately resulting in indels. Indels may be useful for knocking 
out a gene of interest or perturbing functional elements of a gene. An alternative 
major repair pathway known as homology-directed repair (HDR) requires a 
template DNA that has sequences homologous to the region surrounding the 
DSB. The source of a template DNA can be an endogenous allele or an 
exogenous donor. The donor DNA can be used to introduce a precise 
modification such as correction, insertion, or deletion into the target DNA. 
However, HDR has limitations in its availability in dividing cells only, and in its 
inefficiency compared to NHEJ. Unlike NHEJ, which operates throughout the cell 
cycle, HDR is largely restricted to the S and G2 phases of the cell cycle (Hustedt 
& Durocher, 2016). 
 
 
16 
Although the two major DSB repair pathways, NHEJ and HDR, are dominant in 
the repair of a conventional DSB, there are other alternative DSB repair 
pathways that are less prevalent. DSBs introduced by Cas9 result in different 
repair outcomes depending on the types of repair machinery that are available, 
genomic context, cell types, cell-cycle stages, and target sites. Therefore, editing 
efficiencies and outcomes vary considerably from site to site, depending on 
sgRNA expression, DNA accessibility, and other factors (Scully et al., 2019).   
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Cas9 applications based on DNA binding 
There are numerous applications that can be harnessed without introducing 
DSBs (Figure 1.4). A catalytically impaired dCas9 with both nuclease domains 
inactivated can be fused to an effector protein such as a transcriptional regulator 
or an epigenetic modifier for gene expression, as well as fluorescent proteins for 
live-cell imaging (Adli, 2018). A nickase Cas9 with only one nuclease domain 
active can cleave only one strand of dsDNA. Cas9 nickases fused to accessory 
enzymes such as deaminases or reverse transcriptases have opened up new, 
emerging technologies such as base editing and prime editing (Anzalone et al., 
2019; Rees & Liu, 2018a).  
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Figure 1.4 Applications of catalytically impaired CRISPR-Cas effectors. (A) 
Gene regulation using transcription activators or repressors. (B) Epigenome 
editing deposits epigenetic markers such as methylation and histone 
modifications. (C) Deaminases fused to either dead Cas9 (dCas9) or nickase 
Cas9 (nCas9) allow base editing. (D) In prime editing, a reverse transcriptase is 
fused to a nCas9 and uses a prime editing guide RNA (pegRNA) as a template to 
encode new genetic information. Figure adapted from Wang et al. with 
permission (see the List of Third Party Copyright Material) (D. Wang et al., 2020). 
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CRISPR interference and activation (CRISPRi/a)  
Once dCas9 binds strongly to the DNA target sequence, this tight binding can 
interfere with the activity of other endogenous DNA binding proteins such as 
transcription factors and RNA polymerases (Qi et al., 2013). This has been 
exploited to develop the CRISPR interference (CRISPRi) approach in which 
dCas9 binding activity blocks the transcriptional process, resulting in gene 
knockdown (Qi et al., 2013). The downregulation of gene expression can be 
further enhanced by fusing a strong repressor complex such as Kruppel-
associated Box (KRAB) to dCas9 (Gilbert et al., 2013). Similarly, the dCas9-
targeting platform can be repurposed for transcriptional activation (CRISPRa). To 
achieve robust induction of gene expression, different transactivation domains 
such as VP64 (composed of four tandem copies of VP16) or improved 
complexes such as those composed of VP64, p65, and Rta (VPR) proteins, have 
been used (Cheng et al., 2013; Maeder et al., 2013; Mali et al., 2013; Perez-
Pinera et al., 2013). 
Epigenome editing 
The epigenome is defined as regulatory elements such as post-translational 
modifications and other chromatin features that change genome function in a 
manner that does not involve changes in DNA sequence. Epigenetic markers 
such as DNA methylation and histone modifications play crucial roles in proper 
gene expression and genome organization. To better understand the functional 
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roles of various epigenomic features, the programmable capacity of dCas9 has 
been exploited to recruit epigenetic writers and erasers to specific loci. DNA 
methylation is well-studied in chromatin biology to regulate gene expression 
(Razin & Riggs, 1980). Generally, DNA methylation at promoters or distal 
regulatory elements is associated with transcriptional repression. To manipulate 
gene expression through DNA methylation, the dCas9 system has been used to 
both deposit DNA methylation marks using a catalytic domain of DNA 
methyltransferase such as DNMT3A (Amabile et al., 2016) and to remove DNA 
methylation using catalytic domains of endogenous demethylases such as ten-
eleven translocation (TET) proteins: TET1, TET2, and TET3 (X. S. Liu et al., 
2016). In addition to understanding chromatin biology, these types of 
technologies may provide an opportunity to manipulate aberrant disease-
associated DNA methylation. For example, dCas9 fused to a DNA demethylation 
enzyme TET1 was used to demethylate the CGG trinucleotide repeat expansion 
in fragile X syndrome that results in silencing of the FMR1 gene due to 
hypermethylation of CGG repeats (X. S. Liu et al., 2018). 
Base editing 
A prominent advance in the field is the development of a base editing platform 
that enables the installation of desired nucleotide changes independently of 
DSBs and HDR. A DNA base editor consists of a catalytically disabled nuclease 
fused to a deaminase enzyme, and in some cases, a DNA glycosylase inhibitor 
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(Komor et al., 2016). Upon binding to its target site in genomic DNA, base pairing 
between the guide RNA and target DNA strand forms a displaced single-
stranded DNA (ssDNA) known as an “R-loop,” which is subjected to deamination 
enzymes. Two classes of base editors, adenine BE (ABE) and cytosine BE 
(CBE), convert an A•T base pair to a G•C base pair and C•G base pair into a T•A 
base pair, respectively. Using a nickase Cas9 improved the efficiency by 
generating a nick in the unedited strand and thus directing cells to repair the non-
edited strand using the edited strand as a template (Gaudelli et al., 2017; Komor 
et al., 2016; Nishida et al., 2016). Collectively, CBEs and ABEs can mediate all 
four possible transition mutations (C → T, A → G, T → C, and G → A). RNA 
base editors achieve similar targeted adenosine conversion to inosine using 
Cas13-guided RNA-targeting methods (Cox et al., 2017). Although some 
bystander editing within a window of several base pairs and Cas9-dependent off-
target editing may cause undesired changes, newer generations of base editors 
have emerged from extensive efforts to refine the editing window and increase 
editing precision (Thuronyi et al., 2019). Overall, programmable DNA and RNA 
base editors greatly expanded the CRISPR-based toolbox for a diverse array of 
animal, plant, and microbial organisms. 
Prime editing 
The latest game-changer is prime editing (Anzalone et al., 2019), which allows 
gene editing beyond the capabilities of base editors to include additional point 
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mutations (including transversions) as well as insertions and deletions. In prime 
editing, Cas9 nickase is fused to a reverse-transcriptase (RT) enzyme and the 
guide RNA is re-engineered as a prime editing guide RNA (pegRNA) to contain 
the sequence intended to correct the mutations. Like conventional sgRNA, 
pegRNA dictates target DNA specificity. However, it also hybridizes with the 
nicked single-stranded DNA to provide a template for reverse transcription, 
thereby encoding the desired sequence information. The fusion enzyme nicks the 
DNA and the upstream ssDNA of the nick binds to the extended portion of the 
pegRNA in accordance with Watson-Crick base pairing, and then RT uses the 
pegRNA as a template to synthesize corrected DNA. Cellular factors mediate 
removal of the flap containing the redundant portion of the original DNA and 
ligation of the two ends of ssDNA, and then the mismatch repair machinery 
corrects the unedited, complementary DNA strand using the edited strand as a 
template. Prime editing is an unprecedented, versatile genome editing platform 
that enables not only transition and transversion point mutations but also small 
indel mutations. This opens the possibility of highly precise and efficient repairing 
mutations in human diseases (Urnov, 2020).  
 
 
23 
1.2.2 Therapeutic gene editing using CRISPR-Cas effectors 
The idea of gene therapy to treat genetic diseases has been around for decades. 
However, delivering a functional gene copy to replace a mutated protein is not 
always applicable to other types of diseases, for example, those that are caused 
by gain-of-function pathogenic mutations. Directly correcting a mutated gene, 
thereby restoring the gene’s function, in its natural context may address some of 
the limitations of traditional gene therapy (High & Roncarolo, 2019). This led to a 
rise of gene-editing tools such as zinc-finger nucleases (ZFNs), transcription 
activator-like effector nucleases (TALENs), and other types of meganucleases 
(Zheng et al., 2020). The rise of CRISPR-Cas9 has contributed tremendously to 
basic research but also holds enormous therapeutic potential for human 
diseases. 
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Therapeutic gene editing strategies 
Many therapeutic editing strategies currently employed use nuclease activities of 
Cas effector proteins (Figure 1.5). Simply targeting a mutated gene and inducing 
NHEJ can have a therapeutic benefit by knocking down or out a dysfunctional 
protein, inducing the skipping of a mutated exon to rescue partially functional 
protein, and other strategies (D. Wang et al., 2020). Furthermore, by exploiting 
the predictable and reproducible indel spectra at many target sites, frameshift 
and microduplication mutations can be restored in-frame (Iyer, Suresh, et al., 
2019; Shen et al., 2018; van Overbeek et al., 2016). With the capability of 
multiplexing sgRNA, Cas9 can be deployed for larger genomic DNA 
rearrangements (Mani & Chinnaiyan, 2010). Precise repair by HDR is another 
option to directly correct disease-causing mutations by supplying a corrected 
DNA template (Jasin & Rothstein, 2013). However, HDR is less efficient than 
NHEJ and is ineffective in non-dividing cells (Lieber, 2010). An alternative 
approach known as homology-independent targeted integration (HITI) methods 
have been developed for insertion of exogenous DNA sequences into the 
genome (Suzuki et al., 2016). 
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Figure 1.5 Therapeutic editing using CRISPR-Cas effectors. (A) Indels via 
NHEJ can knock out a gene. (B) In some cases, targeting can be directed to a 
specific mutant allele without affecting the wild-type allele. (C) Precise repair of a 
mutation mediated by HDR in the presence of a donor. (D) Seamless knock-in of 
a therapeutic gene can be achieved by either HDR or HITI. (E) Two simultaneous 
targeting events can result in a segmental deletion of a gene harboring a 
mutation. (F) Targeting intronic sequences can induce allelic exchange through 
translocation between homologous chromosomes to convert a compound 
heterozygous genotype to heterozygous. (G) RNA targeting achieves gene 
silencing by degrading RNA instead of DNA. Figure adapted from Wang et al. 
with permission (see the List of Third Party Copyright Material) (D. Wang et al., 
2020).  
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1.2.3 Ex vivo and in vivo delivery for gene editing 
Ex vivo gene editing 
In ex vivo delivery, genome editing reagents are first introduced into human cells 
(either from a patient or a healthy donor) in a dish, and an expanded cell 
population carrying the desired genetic modification(s) is then grafted back into 
patients (Doudna, 2020; High & Roncarolo, 2019). Ex vivo delivery provides a 
few advantages: 1) existing robust delivery methods such as lentivirus 
transduction and RNP electroporation can make a gene modification easy and 
efficient, 2) the ability to select cells that meet the efficiency and accuracy 
requirements can help ensure safety and efficacy when introduced in patients, 
and 3) a host immune response to Cas9 proteins can be avoided. Due to these 
reasons, many preclinical and clinical studies employ CRISPR-Cas9 ex vivo 
gene editing approaches for targeting multiple blood disorders such as disrupting 
CCR5 in T cells for HIV infection, engineering immune cells to combat cancer, 
and editing the BCL11A gene in hematopoietic stem cells for treating 
hemoglobinopathies (Y. Li et al., 2020; Porteus, 2019).   
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In vivo delivery by AAV vectors 
Ex vivo approach is limited to cell types that can be isolated, manipulated, and 
re-engrafted, but most cell types are differentiated, post-mitotic, and only 
functional in vivo. Deploying CRISPR-based therapeutics directly into the human 
body holds great promise for treating a broader range of diseases that cannot be 
addressed by the ex vivo approach. However, efficient delivery is a hurdle for any 
in vivo gene editing platform. Currently, the adeno-associated virus (AAV) vector 
is the leading delivery modality for in vivo delivery (D. Wang et al., 2019, 2020). 
An engineered AAV, known as a recombinant AAV (rAAV), is composed of a viral 
protein capsid and a single-stranded DNA genome that encodes a therapeutic 
gene expression cassette in place of viral protein-coding sequences. The AAV 
genome is also flanked by inverted terminal repeats (ITRs) of viral origin that are 
necessary for genome replication and packaging. A traditional gene therapy 
approach has successfully used rAAVs to deliver functional proteins in patients, 
paving the road for in vivo CRISPR-gene editing (D. Wang et al., 2019, 2020). 
A key to the success of in vivo genome editing is the safe and effective delivery 
of genome editing reagents to target tissues and cell types, and AAV offers many 
desired advantages: well-characterized tissue tropism, safety, and efficient 
expression. 
The tissue tropism of AAV is largely determined by the interaction between the 
viral capsid and target cell surface receptors such as glycoproteins. A 
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combinatorial recognition of co-receptors may also participate in cell entry. 
Different AAV serotypes are presumed to facilitate spatial distribution across 
different tissue- and cell- types. New natural variants of AAV and engineered 
capsids may diversify tissue tropism profiles for either broad or specific in vivo 
delivery. 
The safety profile of AAV is one of its most promising attributes. AAVs are known 
for low genotoxicity and minimal immunogenicity. The prevailing thought is that 
AAV genomes remain predominantly episomal without host genome integration, 
although the integration of the AAV genome may be facilitated by ITRs in some 
cases (Miller et al., 2004). This may result in varying frequencies of integration 
events that have been detected at on-target DSBs (Hanlon et al., 2019; Jarrett et 
al., 2017; Maeder et al., 2019; McCullough et al., 2018; Nelson et al., 2019). 
Moreover, it is presumed that the lack of coding sequences of viral origin 
contributes to their low immunogenicity and cytotoxicity when delivered in vivo. 
Efficient expression is important to achieve durable therapeutic efficacy in gene 
therapy. Although the AAV vector genome largely remains episomal inside host 
cells, it can mediate long-term, stable transgene expression. The AAV genome 
undergoes circularization and concatemerization to stabilize its presence as 
episomal DNA, resulting in persistent expression in postmitotic cells (D. Duan et 
al., 1998, 1999). 
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1.2.4 Challenges of CRISPR-mediated therapeutic editing 
Therapeutic gene editing using CRISPR-Cas9 has rapidly moved into clinical 
studies for the treatment of cancer (ClinicalTrials.gov Identifier: NCT03399448), 
β-thalassemia (NCT03655678), and sickle cell disease (NCT03745287). The first 
human application using AAV delivery directly to the eye targets a CEP290 
mutation that encodes a faulty protein resulting in Leber congenital amaurosis-10 
(LCA10), a leading cause of blindness in childhood (Maeder et al., 2019). In 
addition, clinical trials to use genome editing for degenerative diseases such as 
muscular dystrophies are on the rise. Although the success and long-term 
outcomes remain to be evaluated in the future, currently CRISPR gene editing is 
by no means devoid of challenges. 
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Delivery 
Despite the promising outlook for current CRISPR technologies, efficient delivery 
of editing components to the intended cell and tissue types has remained 
challenging. Currently, the most popular form of ex vivo delivery is the 
electroporation of Cas9-sgRNA RNP (Fajrial et al., 2020). In vivo delivery, which 
is the biggest bottleneck for somatic-gene editing, has both viral (e.g. AAVs) and 
non-viral (e.g. lipid nanoparticles carrying Cas9 mRNA and sgRNA) approaches 
(D. Wang et al., 2019; Yin et al., 2014). Each delivery modality offers different 
advantages and suffers from its own limitations (Figure 1.6).  
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Figure 1.6 A summary of delivery modalities for CRISPR-Cas9. Deliverable 
Cas9 cargo may be DNA or mRNA molecules or it may be delivered as a 
functional ribonucleoprotein (RNP). A variety of viral and nonviral methods have 
been derived to achieve successful delivery across the cell membrane. CPP, 
cell-penetrating peptide; NLS, nuclear localization signal; NLP, lipid nanoparticle, 
AuNP, gold nanoparticle. Figure adapted from Glass et al. with permission (see 
the List of Third Party Copyright Material) (Glass et al., 2018).  
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Two major drawbacks of AAV delivery are the limited genome-packaging 
capacity of the AAV vector and potential undesired editing from prolonged 
expression in non-target cell or tissue types. The packaging size for the AAV 
genome is limited to the maximal length of ~4.7 kb for the transgene expression 
cassette. A widely used SpyCas9 alone is ~4.2 kb without any regulatory 
elements such as a promoter and a polyadenylation signal. Other genome editing 
components like sgRNA and HDR/HITI donor must be packaged into another 
AAV. This dual-vector AAV delivery system is adopted for many applications but 
potentially limits efficacy to the cells that have taken up both vectors. To 
circumvent this limitation, smaller Cas9s that are amenable to all-in-one AAV 
delivery have been either naturally discovered or engineered (Edraki et al., 2018; 
Ibraheim et al., 2018; E. Kim et al., 2017; Konermann et al., 2018; J.-J. Liu et al., 
2019; Ran et al., 2015; Teng et al., 2018). A Type II-A Staphylococcus aureus 
(SauCas9) has a gene size of 3.2 kb, allowing a single AAV vector to express 
SauCas9 together with one or two sgRNAs (Ran et al., 2015). Recently, an all-in-
one AAV was reported to express a DNA donor template as a third component in 
a single AAV vector (Krooss et al., 2020). In particular, Type II-C Cas9 orthologs 
are attractive due to their naturally high accuracy and compact size: Nme1Cas9 
[1,082 amino acids (aa)] (Amrani et al., 2018; Esvelt et al., 2013; Hou et al., 
2013; Ibraheim et al., 2018), CjeCas9 (984 aa) (E. Kim et al., 2017), GeoCas9 
(1,087 aa) (Harrington, Paez-Espino, et al., 2017), and AceCas9 (1,138 aa) 
(Hand et al., 2018, 2019; Tsui et al., 2017). Despite their advantages, some of 
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these Cas9 orthologs also are limited by a longer and more complex PAM 
requirement (Mir, Edraki, et al., 2018). Recently, Nme2Cas9 has been reported 
to have a shorter (5’-N4CC3’) PAM and is efficient for in vivo gene editing after 
all-in-one AAV delivery (Edraki et al., 2018). Cas-effector fusion platforms such 
as base editors and prime editors exceed the cargo size and cannot be delivered 
in a single AAV. To overcome such a barrier, strategies have been developed to 
split the large transgene into two or more segments into AAV vectors and 
reconstitute the functional, full-length proteins (Tornabene & Trapani, 2020). 
A benefit of stable transgene expression from AAV in traditional gene therapy is 
actually a disadvantage for CRISPR-gene editing since a mutation is 
permanently corrected after gene editing. Long-term expression is unnecessary 
and a safety concern since it has been shown to increase off-target cleavage 
(Zuris et al., 2015). Transient expression is preferred and, to this end, non-viral 
delivery methods may be useful (F. Chen et al., 2020; Finn et al., 2018; Wan et 
al., 2019; C.-F. Xu et al., 2019; Yin et al., 2014). In addition to controlling the 
duration of gene editing, avoiding the exposure of editing reagents to unintended 
tissues and cell types will be necessary to ensure clinical safety profiles that are 
suitable for in vivo therapeutics. Although different AAV serotypes provide a 
spectrum of tissue tropism, they often differ only in the tropism strength but not 
absolute specificity.  
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Safety 
To ensure safety in clinical applications, the specificity of gene editing and 
immunogenicity in hosts must be addressed. Specificity can be defined by the 
accuracy and precision of editing. While the accuracy refers to the ratio of on- 
versus off-target site editing, the precision is achieving the desired modification at 
the on-target site compared to other types of mutations as a product of gene 
editing. Cas9 may result in various sequence changes at the desired site due to 
a mixture of repair outcomes or even induce larger, more complex genomic 
rearrangements or deletions (Kosicki et al., 2018; Maddalo et al., 2014). 
Development of thorough detection methods will be required to monitor and 
evaluate both the accuracy and precision of genome editing in clinical settings 
and ultimately to eliminate undesired editing outcomes. Extensive efforts have 
been put forth in making the CRISPR gene editing platform safer by engineering 
Cas9 to be more accurate to minimize the off-target activity (D. Kim et al., 2019). 
In addition, platforms such as base editing and prime editing that do not require 
DSBs have been developed as an alternative approach, although these 
strategies face delivery challenges due to their larger size. 
The host immune responses to AAV vectors complicate the safety profile of in 
vivo gene delivery (Mingozzi and High, 2013). Furthermore, the immunogenicity 
of bacterially derived Cas9 proteins, as well as pre-existing antibodies against 
Cas9 orthologs derived from bacteria that colonize the human population, may 
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also compromise the safety and efficacy of CRISPR gene editing in vivo 
(Charlesworth et al., 2019; Crudele & Chamberlain, 2018; A. Li et al., 2020; 
Simhadri et al., 2018; Wagner et al., 2019). In an adaptive immune response, 
antibodies are important for coating pathogens to block their entry into cells and 
to mark them for destruction by the immune system. However, the actual killing 
of cells expressing foreign proteins is mediated through cellular immune 
responses (Crudele & Chamberlain, 2018). Activation of CD8+ cytotoxic T cells 
could lead to the killing of Cas9-expressing cells, rendering the gene therapy 
ineffective. 
To evade humoral immunity and T-cell responses, patients with neutralizing 
antibodies can be excluded from the clinical trials or immunosuppression drugs 
can be administered (Mingozzi and High 2013). Although there seems to be no 
apparent adversity reported to date after expressing Cas9 in vivo (L. Xu et al., 
2019), the immunogenicity issues can be circumvented by immune-orthogonal or 
less immunogenic Cas9 orthologs (Moreno et al., 2019). Genome-editing 
therapies that involve ex vivo editing are not as affected by either immunogenicity 
or pre-existing antibodies to Cas9 as the host will not be exposed to Cas9 due to 
the short half-life of residual Cas9 RNPs in edited cells ex vivo. 
Altogether, many hurdles ahead of CRISPR-mediated therapeutic gene editing 
seem conquerable with continuous efforts in enhancing and expanding the 
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current capabilities to eventually pave the way for the development of safe and 
effective clinical applications.  
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1.3 Introduction to anti-CRISPR proteins 
Bacteria are under constant attack from their invaders such as bacteriophages, 
which drives the evolution of numerous innate and adaptive immune systems to 
cope with this pressure. Bacteriophages have also evolved countermeasures to 
combat diverse anti-phage mechanisms and survive in co-existence with their 
bacterial hosts. The discovery and exploitation of CRISPR-Cas systems have 
concurrently led to the identification and characterization of novel anti-immunity 
mechanisms such as anti-CRISPR (Acr) proteins. Understanding the dynamics of 
their interactions in this ongoing arms race has spurred numerous implications, 
from understanding the microbial ecology and evolution to the development of 
biotechnological tools.  
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1.3.1 Evolutionary arms race between prokaryotic hosts and their invaders 
In 2013, Bondy-Denomy and Davidson et al. discovered a strange phenomenon 
in Pseudomonas aeruginosa susceptible to viral infection despite having active 
CRISPR-Cas systems targeting the phage genome (Bondy-Denomy et al., 2013). 
This led to their identification of “anti-CRISPR” proteins responsible for thwarting 
CRISPR interference. In the initial phase of anti-CRISPR discovery, most anti-
CRISPR proteins inactivated Types I-F and I-E systems (Bondy-Denomy et al., 
2013; Pawluk et al., 2014). Since then, the relatively young field of anti-CRISPRs 
has rapidly evolved, leading to the discovery of additional anti-CRISPR proteins, 
the understanding of their functional roles in nature, and the dissection of their 
inhibitory mechanisms, as well as how to repurpose them for genome 
engineering applications. 
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Figure 1.7 Viral mechanisms to evade CRISPR-Cas immunity. To overcome 
CRISPR-Cas defenses, phages make point mutations in the PAM or protospacer 
sequence, or modify or delete the DNA so that the DNA cannot be bound by Cas 
complexes. Phages can also encode anti-CRISPR proteins that inactivate 
CRISPR immunity. Jumbo phages produce a nucleus-like structure as a physical 
barrier to exclude Cas complexes. Figure adapted from Hampton et al. with 
permission (see the List of Third Party Copyright Material) (Hampton et al., 
2020). 
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The adaptive nature of CRISPR-Cas systems may be expected to provide a 
powerful barrier to the propagation of MGEs in bacteria, including phages, 
plasmids, and integrative and conjugative elements. Phages are unable to evade 
a CRISPR-Cas system by mutations alone when targeted by multiple and diverse 
CRISPR spacers; hence other types of mechanisms must be employed, such as 
the deployment of anti-CRISPR proteins or formation of a physical barrier that 
resembles a nucleus (Figure 1.7) (Malone et al., 2020). In particular, anti-
CRISPR proteins are remarkably effective in phage survival in that carrying at 
least one acr gene can prevent phage elimination in hosts carrying CRISPR-Cas 
systems (van Houte et al., 2016). While Type I CRISPR-Cas immune systems 
can eliminate lytic phages effectively, temperate phages capable of entering a 
lysogenic state cannot be eliminated in the bacterial population. In fact, imperfect 
matching of spacers to the prophage sequence imparts a fitness disadvantage, 
driving the loss of CRISPR-Cas systems from bacteria. In such circumstances, 
acr genes that suppress the host immune system provide a strong selective 
benefit for both the phage and the host (Rollie et al., 2020). The selective 
pressure from fitness costs may explain the loss or inactivation of cas genes in 
CRISPR loci and non-uniform distribution in bacteria phyla. Furthermore, the high 
diversity observed in CRISPR-Cas systems may be partly driven by the presence 
of equally diverse anti-CRISPR proteins and vice versa. This may also explain 
the occurrences of multiple CRISPR-Cas systems belonging to different types 
and/or subtypes in a single bacterial strain as well as anti-CRISPR proteins. 
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These and other studies underscore the fitness costs and benefits associated 
with CRISPR-Cas systems and anti-CRISPR proteins (W. Jiang, Maniv, et al., 
2013; Westra et al., 2015). 
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1.3.2 Functions of anti-CRISPR proteins in a host-pathogen arms race 
Role of an Aca protein as a transcriptional regulator 
Anti-CRISPR associated (Aca) proteins are frequently encoded downstream of 
the acr gene and are highly conserved in MGEs. To date, there are seven 
families of Aca proteins that share homology at the N-terminus of the HTH DNA-
binding domain (Marino et al., 2018; Pawluk, Amrani, et al., 2016; Pawluk, 
Staals, et al., 2016). Recently the function of Aca proteins in regulating the acr 
operon has been elucidated. It was speculated that acr genes must be expressed 
very rapidly to confer phage survival. Not surprisingly, the expression of acr 
genes were quickly ramped up in the early infection stage, driven by a strong 
promoter immediately upstream of acr genes (Stanley et al., 2019). In the same 
study, it was shown that Aca1 protein subsequently represses this high level of 
transcription. Lack of Aca repression resulted in phage lethality because the 
uncontrolled transcription from the strong Acr promoter disrupted the 
transcription of downstream genes (Stanley et al., 2019). Another study reported 
that a dimer of Aca2 proteins similarly binds to the promoter and regulates acr 
genes in the same operon (Birkholz et al., 2019). Altogether, the conserved role 
of Aca proteins is to mitigate the deleterious effects of strong constitutive 
transcription from acr promoters (Birkholz et al., 2019; Stanley et al., 2019). 
Interestingly, some anti-CRISPR proteins (AcrIIA1 and AcrIIA6) share N-terminal 
homology with Aca proteins, suggesting dual roles as both anti-CRISPR and Aca 
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proteins. Recently, it has been shown that AcrIIA1 indeed has a dual regulatory 
function (Osuna, Karambelkar, Mahendra, Sarbach, et al., 2020). The full-length 
AcrIIA1 uses its two-domain architecture to act as a ‘‘Cas9 sensor” and “anti-anti-
CRISPR.” The AcrIIA1 HTH motif in the N-terminus (NTD) responsible for acr 
repression is highly conserved across Aca orthologs, yet it is completely 
dispensable for Acr activity. Instead, the motif responsible for the Acr activity 
resides in the C-terminal domain (CTD) (Osuna, Karambelkar, Mahendra, 
Christie, et al., 2020). The AcrIIA1-CTD is necessary and sufficient to perform the 
anti-CRISPR function by binding to the catalytic HNH domain of Cas9. This 
triggers Cas9 degradation during the lysogenic phase in which phages integrate 
into the bacterial chromosome (becoming prophages). During lytic infection, 
AcrIIA1 alone was insufficient to inactivate CRISPR targeting and required 
additional Acrs to rapidly inhibit Cas9. These two studies together show that 
AcrIIA1 is a bi-functional Acr protein that performs anti-CRISPR and anti-anti-
CRISPR functions and shed light on how Acrs with varying inhibitory spectra 
(narrow vs. broad) play different roles in the lytic and lysogenic life cycles of 
phages. 
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Anti-CRISPR proteins provide phage resistance by cooperation 
A conundrum of how anti-CRISPR proteins can accumulate to effective 
concentrations immediately upon phage infection has been partially resolved by 
the observation of rapid and high expression of acr genes from a strong promoter 
(Stanley et al., 2019). Nonetheless, many infections of CRISPR-resistant hosts 
fail initially. Instead, Acr-producing phages display cooperative behavior on a 
community scale. Acrs from the first phage infecting an immunosuppressed host 
may not provide full protection from CRISPR-Cas, but enable productive infection 
for successive phages (Borges et al., 2018; Landsberger et al., 2018). Initial 
infections by phages produce inadequate levels of Acr proteins to completely 
inactivate CRISPR-Cas systems. Nonetheless, consecutive and unsuccessful 
infections accumulate Acrs in the immunocompromised host until a critical 
threshold level is reached. Low levels of Acr proteins in sacrificial phages result 
in infection failures, and the density of the phages needed largely depends on the 
potency of Acr, for instance, weaker Acr proteins requiring higher phage 
densities. This may also explain why multiple distinct acr genes are often found 
within the same acr locus: to neutralize CRISPR-Cas in different ways to 
maximize the likelihood of successful infection. The co-existence of anti-CRISPR 
proteins of varying strengths is also explained by different advantages each 
strong and weak Acr provides in a heterogeneous population and how it 
influences the evolution of CRISPR-Cas. Phages carrying anti-CRISPR proteins 
cooperate with each other to outpace CRISPR-Cas immunity by not only leaving 
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behind immunosuppressed hosts but also by limiting the emergence of resistant 
hosts in the population. 
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Roles of weak and strong anti-CRISPR proteins 
Anti-CRISPR proteins vary not only in their inhibitory spectra for different 
CRISPR-Cas systems but also in their potency in inhibiting the Cas proteins 
(Borges et al., 2017; Stanley & Maxwell, 2018). One possible explanation is that 
the strength of inhibition confers different advantages. For instance, strong Acrs 
enable bypass of CRISPR-Cas immunity against phages. At a community level, 
phages with Acrs benefit phages without the Acrs by limiting CRISPR resistance, 
thus providing indirect protection and allowing replication in the 
immunocompromised subpopulation of bacterial hosts (Nussenzweig & 
Marraffini, 2018). Since strong Acrs, but not weak Acrs, enable phages without 
the Acrs to exploit immunosuppressed CRISPR-resistant hosts, phages with the 
weaker Acrs provide greater advantages than stronger Acrs when competing 
with other phages without Acrs (Chevallereau et al., 2020). Therefore, in the 
early evolution of new acr genes, it is likely that weak Acrs would be more 
pervasive in the phage population. Nevertheless, this could be a transient 
phenomenon since in the longer-term, wherein phages with different Acrs have 
emerged and compete against each other, weak Acrs no longer provide the 
greatest fitness benefit. Strong Acr phages are favored in CRISPR-resistant 
hosts while both strong and weak Acr phages are equally fit in the CRISPR-
sensitive population; however, since pre-existing CRISPR immunity is not 
common, both strong and weak Acrs probably co-exist in nature (Chevallereau et 
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al., 2020). Overall, different Acrs of varying inhibitory spectrum and potency may 
help shape the evolutionary dynamics of host-phage populations.  
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1.3.3 The origins of anti-CRISPR proteins 
The sequence and structural plasticity of anti-CRISPR proteins make identifying 
the precursors of these proteins challenging. Although this is speculative, anti-
CRISPR proteins may have sprung from sporadic mutations in phage proteins in 
a convergent, de novo protein evolution until their function provided fitness 
advantages from anti-CRISPR activity (Pawluk et al., 2018). This hypothesis is 
plausible given that phages have a rapid mutation rate and short generation time, 
and anti-CRISPRs are mostly very small and often encoded near viral structure 
genes. In support of this hypothesis, a study reported a potential evolutionary 
origin of AcrIIC1 in the phage decoration protein gp87 based on the structural 
similarity between the AcrIIC1 and a β tulip domain of gp87 (Stone et al., 2018). 
It is likely that phage decoration proteins predated the evolution of AcrIIC1. 
Unlike most other β tulip proteins, AcrIIC1 uses a different side of the β tulip 
domain to bind the Cas9 HNH domain (Harrington, Doxzen, et al., 2017), 
suggesting that the interaction with the Cas9 HNH nuclease may have evolved in 
a decoration protein without disrupting its structural role. Other Acr proteins may 
have evolved from phage proteins as well, but their structural homologies may 
have been masked by the rapid evolution and insertion of new structural 
elements. Future studies are needed to underpin the evolutionary origins and 
drivers in the context of phages and bacteria with CRISPR-Cas immune systems. 
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1.3.4 Discovery approaches for anti-CRISPR proteins 
The diversity of anti-CRISPR sequences and structures noted above also impose 
challenges in the discovery of novel Acr proteins. To overcome these challenges, 
a number of approaches have been used to uncover anti-CRISPR proteins in 
nature: 1) guilt-by-association bioinformatics, 2) sequence-based searches for 
self-targeting spacers in bacterial genomes, 3) functional screens of virulent 
phages, 4) functional screening of metagenomic libraries, and 4) computational 
methods (Figure 1.8). 
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Figure 1.8 Different approaches for anti-CRISPR discovery. (A) A guilt-by-
association bioinformatic approach uses experimentally validated anti-CRISPR 
genes in association with an anti-CRISPR-associated (aca) gene encoding a 
helix-turn-helix (HTH) motif-containing protein. (B) A self-targeting bioinformatic 
approach takes advantage of spacers matching prophages within the same host 
genome that, in theory, should target their own genome for destruction. The co-
existence of a prophage and a self-targeting spacer indicates the presence of a 
possible anti-CRISPR within the prophage. (C) In phage screening assays, 
candidate acr genes are selected in phages that escape CRISPR targeting in the 
immunized bacteria strains carrying the spacers against the phage genome. (D) 
In functional assays, a high-throughput approach is used to discover anti-
CRISPR genes from metagenomic libraries based on their functional activity 
rather than sequence homology or genetic context. Figure modified from Uribe et 
al. and Stanley and Maxwell with permission (see the List of Third Party 
Copyright Material) (Stanley & Maxwell, 2018; Uribe et al., 2019). 
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1. “Guilt-by-association” bioinformatics 
One of the earliest methods used in the discovery of anti-CRISPR proteins is the 
guilt-by-association bioinformatics approach. This is a process of iterative BLAST 
searches using an aca gene as a bait that has co-occurrence with the existing 
anti-CRISPR genes. The first nine anti-CRISPRs found in P. aeruginosa were not 
similar to each other; however, they all shared a highly conserved gene 
downstream of the anti-CRISPR genes named as anti-CRISPR-associated gene 
1 (aca1). The aca1 gene encodes a predicted protein containing a helix-turn-helix 
motif commonly found in transcriptional regulators. Using Aca1 as a bait in a 
series of BLAST searches, additional Types I-F and I-E acr genes were identified 
upstream of aca1 genes in P. aeruginosa (AcrIF6-10) (Pawluk et al., 2014). The 
same BLAST searches with aca2, a homolog of aca1, led to the discovery of the 
first Type II anti-CRISPR proteins that act against Cas9 from Neisseria 
meningitidis harboring Type II-C CRISPR systems (AcrIIC1-3) (Pawluk, Amrani, 
et al., 2016). In pursuit of anti-CRISPR proteins in different types and subtypes, a 
similar set of “ping-pong” BLAST searches from one acr gene to another led to 
the discovery of both widespread anti-CRISPRs (acrIF11 and -12) and new aca 
genes (aca4 - aca7) (Marino et al., 2018).  
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2. Screening for self-targeting bacterial genomes 
Another bioinformatic approach that has yielded a number of discoveries for 
different types of Acrs involves searching for bacterial genomes encoding both a 
functional CRISPR-Cas system and spacers that target sites within the same 
host genome. Survival of bacterial hosts despite the existence of a CRISPR-Cas 
system that can target its own genome suggests that there is an active 
mechanism that prevents self-targeting. This enabled the discovery of anti-
CRISPR proteins in Listeria monocytogenes (AcrIIA1-4) that not only inhibited 
LmoCas9 but, in some cases, also inhibited the widely used SpyCas9 (Rauch et 
al., 2017). In combination with the guilt-by-association method, Marino et al. 
reported Types I-C and V anti-CRISPR proteins by using acrIF11 that had a 
widespread occurrence as a bait to dissect acr loci in the genomes of bacteria 
that have the tolerance for self-targeting with Types I and V CRISPR-Cas 
systems (Marino et al., 2018). In particular, AcrVA1 (170 aa) found in Moraxella 
species is able to inhibit not only Moraxella bovoculi (Mb) Cas12a but also other 
commonly used Cas12a orthologs, AsCas12a and LbCas12a and (more 
modestly) FnCas12a from Acidaminococcus sp., Lachnospiraceae bacterium, 
and Francisella novicida, respectively (Marino et al., 2018). Concurrently, 
Watters et al. used a streamlined “Self-Targeting Spacer Searcher (STSS)” to 
uncover AcrVA1, AcrVA4, and AcrVA5 (Watters et al., 2018). Both AcrVA4 and 
AcrVA5 inhibit dsDNA cleavage for both MbCas12a and LbCas12a, but not 
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AsCas12a (Watters et al., 2018). The discovery of Type V-A anti-CRISPR 
proteins will be a useful tool for Cas12a-based genome editing applications.  
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3. Screening phages that escape CRISPR targeting 
Some anti-CRISPR proteins were discovered in phages themselves rather than 
in a prophage genome. AcrIIA5 and AcrIIA6 were identified in virulent 
Streptococcus thermophilus phages (Hynes et al., 2017, 2018). When strains of 
S. thermophilus with an active Type II-A CRISPR-Cas system were challenged 
with phages, a library of genes in the escape phage was cloned and tested in S. 
thermophilus by expressing candidate anti-CRISPR proteins and checking for a 
restored titer of a CRISPR-sensitive phage. From this approach, acrIIA5 and 
acrIIA6 were identified in virulent S. thermophilus phages (Hynes et al., 2017, 
2018). A similar phage screening approach was used to find the first archaeal 
anti-CRISPR that inactivates Type I-D CRISPR-Cas systems in a strain of 
Sulfolobus islandicus that harbors Types I-A, I-D, and III-B CRISPR-Cas systems 
(He et al., 2018). While the SIRV2 virus readily infected S. islandicus despite 
having a spacer, the SIRV2 mutant (SIRV2M) that lacked a fragment containing 
several genes failed to infect S. islandicus. By comparing and testing genes that 
are missing in SIRV2M, but are conserved in SIRV2 and SIRV3 that can infect S. 
islandicus, He et al. pinpointed acrID that supported the infectivity of the 
SIRV2M. AcrID1 inactivated the Type I-D CRISPR-Cas system by directly 
interacting with the Cas10d subunit.  
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4. Functional screening of metagenomics libraries 
With the growing availability of large sequencing data, two independent studies 
were conducted to screen functional anti-CRISPR proteins in the human oral, 
gut, and soil metagenomic libraries (Forsberg et al., 2019; Uribe et al., 2019). 
Both studies employed a technique based on the ability of anti-CRISPR proteins 
to inhibit CRISPR-Cas systems and, therefore, allow bacteria to survive on 
antibiotics when challenged by CRISPR-Cas systems targeting a plasmid 
encoding the antibiotic resistance gene. Bacteria that grow in the antibiotic 
indicated a presence of anti-CRISPR protein in the tested library. The anti-
CRISPR candidate genes were derived from various metagenomic samples. 
Four genes (AcrIIA7-AcrIIA10) inhibiting SpyCas9 were identified (Uribe et al., 
2019). From human oral and fecal metagenomic library, Forsberg et al. reported 
10 contigs that have confirmed inhibitory activity against SpyCas9 as well as 
AcrIIA11 (Forsberg et al., 2019). From a large library of candidate genes that 
have potential anti-CRISPR activity, both studies were able to narrow down to 
unique, non-overlapping genes distinct from previous studies. This suggests that 
there are plenty of new Acr genes to be uncovered that may have evolved 
independently from a variety of precursor proteins, which may be missed in the 
conventional methods described above.  
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5. Computational methods for prediction of anti-CRISPR proteins 
Since known anti-CRISPR proteins rarely share any sequence or structural 
homology, predicting novel acrs has been a challenge. With an increasing 
number of anti-CRISPR proteins in the database, Eitzinger et al. recently 
reported a machine learning-based method (AcRanker) using only amino acid 
composition information to help identify additional families of Acrs (Eitzinger et 
al., 2020). The model can be used to predict candidate Acr proteins in the 
prophage regions within self-targeting bacterial genomes. These additional 
features are important as they can increase the probability of finding true anti-
CRISPR proteins. Using this method, the authors have discovered and 
biochemically validated two previously unknown anti-CRISPR proteins: AcrIIA20 
and AcrIIA21. In their studies, candidate anti-CRISPR proteins (ML1-10) were 
tested against Streptococcus pyogenes, aureus, and iniae Cas9. AcRanker may 
be used to complement existing strategies to uncover additional Acrs by 
prioritizing candidate proteins for empirical validation of their function. Other 
groups also reported a similar computational approach to predict anti-CRISPR 
proteins (J. Wang et al., 2020; Yi et al., 2020). 
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1.3.5 Mechanisms of anti-CRISPR protein inhibition 
In less than a decade, numerous studies have reported detailed biochemical 
and/or structural characterization of anti-CRISPR proteins. Remarkably, among 
all known structures of anti-CRISPR proteins, there is little to no similarity, 
suggesting that the Acrs may have been derived from diverse and unique 
evolutionary origins. The diversity in sequences and structures of anti-CRISPR 
proteins is also reflected in the unique inhibitory mechanisms they employ to 
inactivate CRISPR-Cas systems (Figure 1.9). Some well-studied anti-CRISPR 
proteins’ mechanisms of action are discussed below. 
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Figure 1.9 Functions and mechanisms of anti-CRISPR proteins. The Acrs 
with known structures and functions in CRISPR-Cas adaptive immune systems 
are indicated. Aca proteins (pink) repress Acr (red triangles) expression within 
the same operon. Most Acrs of class 1 (left) and 2 (right) immune systems target 
the surveillance complex and block DNA binding or nuclease activity. Figure 
adapted from Wiegand et al. with permission (see the List of Third Party 
Copyright Material) (Wiegand et al., 2020).  
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Anti-CRISPRs in DNA-targeting CRISPR Class 1 and 2 Systems 
Class 1: Type I Systems 
Types I-F and I-E in P. aeruginosa are characterized by a multi-effector Csy 
complex composed of a Cas5-Cas8 heterodimer, Cas6, and six subunits of 
Cas7. These proteins form a surveillance complex along with the 60-nt crRNA. 
Once the Csy complex binds and unwinds the target DNA strand flanked by a 
PAM, Cas3 nuclease is recruited to cleave the target DNA. AcrIF1, AcrIF2, and 
AcrIF10 bind to different binding surfaces of the Csy complex to prevent target 
DNA binding while AcrIF3 and AcrIE1 block Cas3 recruitment (Bondy-Denomy et 
al., 2015). Subtype I-D, a hybrid between Types I and III systems, encodes 
variants of signature proteins, Cas3 and Cas10, that are unique for each type. 
AcrID1 binds to Cas10d, the large subunit of the I-D CRISPR-Cas complex (He 
et al., 2018). It is unclear yet which step AcrID1 is involved in since Cas10d is the 
large subunit that forms an effector complex and participates in target-cleavage. 
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Class 2: Type II Systems 
Type II anti-CRISPR proteins have been studied in the most detail due to their 
utility as off-switches for genome engineering applications.  
Preventing target DNA binding 
AcrIIA4 is a highly acidic protein that interacts with the PAM-interacting domain 
(PID) of sgRNA-loaded SpyCas9, thus occluding the PAM binding site and 
preventing target DNA binding (Dong et al., 2017; I. Kim et al., 2018; Shin et al., 
2017; H. Yang & Patel, 2017). It weakly binds to apo-Cas9 suggesting that 
SpyCas9 must undergo conformational changes upon sgRNA loading to expose 
the binding site for AcrIIA4. This also makes sense for the anti-CRISPR protein 
to inactivate the loaded form of SpyCas9 since it would most likely encounter the 
sgRNA-Cas9 complex in a natural context. Similarly, AcrIIA2 binds to the PID of 
SpyCas9 although AcrIIA4 and AcrIIA2 differ drastically in their structures and 
sequences, showcasing a convergent evolution where two different proteins have 
co-opted to bind a sensible and effective site (F. Jiang et al., 2018; L. Liu et al., 
2018). The PID is a suitable binding site for an Acr to inhibit as it can effectively 
prevent SpyCas9 binding to the target DNA. 
Inhibiting target DNA cleavage  
Some Acrs, however, still allow target DNA binding but instead inactivate 
nuclease function. AcrIIC1 identified in N. meningitidis has been shown to inhibit 
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other Type II-C Cas9 orthologs from Campylobacter jejuni and Geobacillus 
stearothermophilus, which are 42% and 36% identical to Nme1Cas9, 
respectively (Harrington, Doxzen, et al., 2017). AcrIIC1 binds to the HNH 
nuclease domain, one of the most conserved domains of Cas9s, and makes 
contact with highly conserved residues for catalysis, thus enabling inhibition of 
diverse Cas9 orthologs. AcrIIC1-bound Cas9 can still bind to the target DNA but 
is unable to cleave due to its interaction with the active site of the HNH nuclease 
domain.  
Inhibition by dimerization 
AcrIIC3 binds Nme1Cas9 and induces dimerization to form a 2:2 complex 
(Harrington, Doxzen, et al., 2017; Sun et al., 2019; Zhu et al., 2019). The 
dimerization is mediated by two AcrIIC3 proteins where one interacts with the 
HNH domain of the first Cas9 and the recognition (REC) domain of the second 
Cas9, while the other Acr does the opposite (Y. Kim et al., 2019; Zhu et al., 
2019). AcrIIC3 binds to the opposite side of the HNH domain that AcrIIC1 binds 
to and keeps it in an inactive state away from its cleavage site (Sun et al., 2019). 
In addition to inactivating target DNA cleavage by binding to the HNH domain, 
the dimerization via AcrIIC3 interaction with the REC lobe, which is highly 
variable among Cas9 homologs, may reduce the binding affinity to the target 
DNA. This may explain earlier observations for preventing DNA binding 
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(Harrington, Doxzen, et al., 2017; Pawluk, Amrani, et al., 2016), although 
inhibition of target DNA binding is not absolute (Sun et al., 2019). 
AcrIIC2 forms a homodimer with a negatively charged surface that interacts with 
the positively charged arginine-rich bridge helix (BH) domain that connects the 
REC lobe to the nuclease (NUC) lobe. The BH is also involved in sgRNA 
interaction (Thavalingam et al., 2019; Zhu et al., 2019). AcrIIC2, when bound to 
Nme1Cas9, prevents sgRNA loading, and cannot bind to a Cas9 that is already 
loaded by an sgRNA. Crystal structures and superimposition studies of AcrIIC2 
bound to Nme1Cas9 show that the AcrIIC2 dimer occupies the BH sites that 
contact the sgRNA and likely prevent sgRNA loading by steric hindrance. Without 
the sgRNA bound, apo-Cas9 is also more susceptible to intracellular proteases. 
This may reduce the accumulation of Cas9 proteins in mammalian cells and 
contribute to the reduced Cas9 activity observed previously (J. Lee et al., 2018; 
Thavalingam et al., 2019). The inability to inhibit the loaded form of Cas9 may 
explain the low efficiency of AcrIIC2 in inhibiting Nme1Cas9, since co-expression 
of components allows some Cas9 to form active complexes for editing (Pawluk, 
Amrani, et al., 2016).  
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Class 2: Type V Systems 
Type V anti-CRISPR proteins that inactivate Cas12a have also been reported 
with detailed mechanistic studies defined both structurally and biochemically. 
Cas12a is also a single effector protein that uses a crRNA and generates a 
staggered DNA cut using only RuvC-like nuclease domains. AcrVA1 can inhibit 
four Cas12a orthologs by occupying the PAM site in the cleft between REC and 
NUC lobes, and cleaves the crRNA bound to the Cas12 protein as a multi-
turnover catalytic enzyme (Knott, Thornton, et al., 2019). AcrVA5, which has a 
narrower inhibitory spectrum than AcrVA1, also possesses enzymatic activity that 
adds a covalent modification to MbCas12a. AcrVA5 mediates acetylation of 
K635, an important residue in MbCas12a involved in PAM interaction, thus 
thwarting DNA binding. A crystal structure of AcrVA5 revealed similarities to 
acetyltransferases (Knott, Thornton, et al., 2019). AcrVA4 acts as an allosteric 
inhibitor of Cas12a by inhibiting conformational changes to prevent target DNA 
binding (Knott, Cress, et al., 2019; Knott, Thornton, et al., 2019; H. Zhang et al., 
2019). The C-terminus of AcrVA4 binds to the REC domain where crRNA binds, 
while the N-terminus mediates a dimerization of Cas12a proteins, although the 
dimerization is not required for Cas12a inhibition (Knott, Cress, et al., 2019). 
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Despite sequence and structural diversity, Acrs across different types and 
subtypes share some mechanistic similarities. The most commonly used mode of 
action is to prevent DNA binding by directly interacting at or close to the PID of 
Cas9. Blocking DNA cleavage is the second most common strategy used by Acrs 
that interact with the nuclease domains of Cas proteins. Although AcrIIC2 can 
inhibit the formation of the guide-loaded Cas9 complex, Acrs generally are most 
effective if they can directly block the DNA binding and cleavage of the loaded 
CRISPR-Cas RNPs, as they would exist in nature when phages infect bacterial 
hosts. Another theme is the dimerization of some Acrs and Cas nucleases; 
however, why and how dimerization provides functional advantages is not fully 
understood. The Type V Acrs with enzymatic activities, such as crRNA cleavage 
and posttranslational modification, are very exciting, and new types of activities 
may surprise us in the future with the discovery and characterization of additional 
anti-CRISPR proteins.  
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Anti-CRISPRs in RNA-targeting CRISPR Class 1 and 2 Systems 
Anti-CRISPR proteins inactivating RNA-targeting Types III and VI are less known 
when compared to DNA-targeting systems.  
Type III CRISPR systems 
Not many examples of anti-CRISPR proteins have been reported or studied for 
Type III systems, perhaps due to their complexity. Type III CRISPR systems 
recognize a viral RNA and activate the effector protein, Cas10. Cas10 has a HD 
nuclease domain responsible for the degradation of a viral DNA via ssDNA 
cleavage and a cyclase palm domain that synthesizes a signaling molecule, 
cyclic oligoadenylate (cOA; such as cA4 or cA6) (Kazlauskiene et al., 2017; 
Niewoehner et al., 2017). Cyclic nucleotides are important in the activation of 
RNases (Csm6 in Type III-A or Csx1 in Type III-B) that are not part of the RNP 
complex but trigger non-specific RNA degradation. The added complexity of the 
multi-step CRISPR interference is still subject to anti-CRISPR inhibition. For 
example, an anti-CRISPR (AcrIIIB1) encoded by a phage that infects Sulfolobus 
specifically inhibits subtype III-B complexes by interacting with the effector 
complex that synthesizes cOAs. This enables the inhibition of collateral RNase-
related activities while Cas10 DNase and Cmr4 RNase activities remain 
unaffected (Bhoobalan-Chitty et al., 2019). The prevention of collateral RNA 
degradation likely prevents host cell entry into a dormant state that would 
otherwise suppress the viral life cycle (Rostøl & Marraffini, 2019). Soon after this 
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study was published, Athukoralage et al. reported the discovery of AcrIII-1, which 
targets the signaling molecule cA4 for degradation (Athukoralage et al., 2020). 
The viral ring nuclease AcrIII-1 binds the cA4 specifically, and uses a conserved 
active site for cA4 cleavage, allowing viruses to neutralize the Type III CRISPR 
defense system. Since AcrIII-1 family targets signaling molecules rather than 
CRISPR effector complexes, these Acrs have a broad host range as widely 
distributed in bacterial and archaeal viruses as well as proviruses (Athukoralage 
et al., 2020). 
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Type VI Systems 
The Cas13 effector proteins from Type VI systems (class 2) provides new 
CRISPR-derived capabilities by virtue of its RNA targeting activity. This has 
enabled the development of RNA editing and post-transcriptional degradation 
approaches, as well as detection methods for viral RNAs (Abudayyeh et al., 
2017; Ackerman et al., 2020; Cox et al., 2017; Gootenberg et al., 2017; 
Konermann et al., 2018; Myhrvold et al., 2018; Terns, 2018). Recently, Lin et al. 
took a comprehensive approach by integrating the STSS, guilt-by-association, 
and co-occurrence with known Acrs approaches to identify the AcrVIA1-7 
proteins that can function as off-switches for Cas13a activity (P. Lin et al., 2020). 
Interestingly, the most potent of these, AcrVIA5, could prevent dCas13a-
mediated RNA editing for A-to-I base editing using a fused ADAR (adenosine 
deaminase acting on RNA) enzyme, illustrating its use in controlling the nuclease 
during editing, knock-down and/or visualization of RNA molecules (P. Lin et al., 
2020). Concurrently, Meeske et al. screened temperate phages from isolates of 
Listeria spp., an organism that commonly harbors Type VI-A CRISPR-Cas 
systems, and landed on a prophage that encodes AcrVIA1 (Meeske et al., 2020). 
Based on a cryo-EM structure, AcrVIA1 interacts with the crRNA-exposed side of 
Cas13a, making contacts with both protein and crRNA residues to prevent 
binding of complementary target RNA in order to inhibit both target and non-
specific RNase activities of Cas13a (Meeske et al., 2020). In its natural host, 
AcrVIA1 can completely neutralize Type VI-A CRISPR-Cas immunity against 
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ϕLS46 listeriophage gradually. In Type VI CRISPR immunity, phage DNA is not 
cleared by hosts (Meeske et al., 2019), leading to continuous transcription and 
translation of AcrVIA1 until enough Acrs accumulate for Cas13a inactivation 
inside bacteria. 
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1.3.6 Applications of anti-CRISPR proteins 
The rapidly expanding palette of CRISPR-Cas technologies has led to a 
corresponding motivation to develop tools to control and modulate their activities. 
Acr proteins targeting Type II (Cas9) and Type V (Cas12a) effectors have drawn 
particular interest as they may provide temporal, spatial, or conditional control 
over established genome-editing systems.   
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Figure 1.10 Application and regulation of anti-CRISPR proteins. Top: types 
of CRISPR applications that can be controlled by Acrs. Bottom: methods of 
regulating anti-CRISPR proteins with conditional, spatial, and temporal control. 
Figure adapted from Marino et al. with permission (see the List of Third Party 
Copyright Material) (Marino et al., 2020).  
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Uses for gene-editing technologies 
One major application of Acr proteins is their use as off-switches for genome 
editing. Minimizing undesired off-target activity is important for CRISPR-Cas9 
technology, especially for therapeutic use. Although extensive efforts have led to 
Cas9 variants with enhanced specificity (D. Kim et al., 2019), excessive or 
prolonged Cas9 activity may increase the likelihood of off-target editing or 
cytotoxicity, necessitating a means to shut down the Cas9 activity upon achieving 
a desired outcome. In combination with engineered Cas9 variants and means to 
regulate Cas9 expression, Acr proteins can act as an additional safeguard to 
reduce potential adverse effects of Cas9. For example, timed delivery of AcrIIA4 
reduced the extent of off-target editing in cells by limiting the window of Cas9 
activity and taking advantage of kinetic differences of Cas9 editing at on- versus 
off-target sites (Shin et al., 2017). CRISPR technology has also been applied to 
the development of gene drives, which are genetic elements that force super-
Mendelian inheritance to disseminate desired traits in a population. A prominent 
example is the ongoing development of female sterility-inducing gene drives in 
mosquitoes to eradicate vector-borne diseases such as malaria (Nateghi 
Rostami, 2020). Effective control over the spread of a gene drive after its initial 
release is highly desirable as a safety measure. Acr proteins could be deployed 
to put a brake on the propagation of a CRISPR-based gene drive after the 
parental driver organisms are released into the relevant ecosystem. As a proof of 
concept, temporal control of AcrIIA2 and AcrIIA4 using an inducible promoter has 
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been demonstrated to halt or titrate the efficiency of a SpyCas9-based gene drive 
in yeasts (Basgall et al., 2018). 
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Uses for dCas9-based applications 
Nuclease-inactive dCas9 can be used to tether or recruit various effector proteins 
to genomic sites of interest. For example, chromatin visualization and targeted 
gene regulation can be achieved via fusion of fluorescent proteins (FPs) and 
transcriptional activators or repressors to dCas9. Technologies based on dCas9 
not only allow genome manipulation but also alteration of the epigenome via 
fusion of DNA demethylation enzymes (e.g., TET) or histone-modifying effectors 
(e.g., LSD1 or p300) (Adli, 2018). Acrs that limit DNA binding may also be used 
to regulate the activities of these functional domains. For example, Type II Acr 
proteins were used to control chromosome labeling by dCas9-FPs (Basgall et al., 
2018; Bubeck et al., 2018; J. Lee et al., 2018; Pawluk, Amrani, et al., 2016; 
Rauch et al., 2017), as well as demethylation by dCas9-Tet1 fusions in induced 
pluripotent stem cells (X. S. Liu et al., 2018). Moreover, Acr proteins have 
enabled programmable and dynamic gene regulation by controlling CRISPRi and 
CRISPRa (Hoffmann et al., 2019; J. Li et al., 2018; Nakamura et al., 2019). 
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Engineering anti-CRISPR proteins 
Acr proteins can often tolerate fusion to epitope tags and FPs without 
compromising their inhibitory potency. In the case of AcrIIC1, insertion of an 
exogenous domain, such as a mCherry fluorescent protein, at carefully selected 
AcrIIC1 surface sites dramatically improved the inhibition of Nme1Cas9 (Mathony 
et al., 2020). This offers opportunities to engineer Acr proteins through other 
domain insertions without losing the inhibitory activity. For instance, an AcrIIA4 
hybrid with a light-inducible LOV2 domain has been shown to control SpyCas9- 
and dSpyCas9 in optogenetics (Bubeck et al., 2018). A posttranslational control 
of Acr proteins was achieved by fusing an inducible destabilization domain that 
degrades the protein in the absence of an external ligand known as Shield1 
(Nakamura et al., 2019). Acrs can be further engineered from a synthetic biology 
perspective to alter the specificity and potency of Acrs (Aschenbrenner et al., 
2020; Mathony et al., 2020). Based on the structure of the Nme1Cas9 binding 
interface with AcrIIC1, AcrIIC1 can be converted from a Type II-C inhibitor to 
AcrIIC1X that inhibits Type II-A SauCas9 (Mathony et al., 2020). Similarly, the 
inhibitory potency can be modulated by using artificially weakened Acr proteins to 
finetune Cas9 activity for achieving an optimal kinetic balance of retaining on-
target editing and eliminating off-target editing events (Aschenbrenner et al., 
2020). 
Other uses of anti-CRISPR proteins 
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Inhibiting Cas9 can be a useful tool for the production of viral vectors that have 
been developed as a “self-cleaving” genome. A helper-dependent adenovirus 
(HDAd) vector for transient Cas9 expression in target cells, by design, encodes 
SpyCas9 and a guide that directs the cleavage of the vectors’ own genome after 
transduction of target cells, thereby allowing transient SpyCas9 expression and 
function (Palmer et al., 2019). However, self-cleavage during viral production 
also occurs, leading to genomic rearrangements that make virus production 
impossible. Anti-CRISPR proteins were used to inhibit SpyCas9 from initiating 
vector self-cleavage during the viral production, thus greatly improving yield 
(Palmer et al., 2019). Another potential use of Acr proteins is in the development 
of phage therapies as an alternative to antibiotics to treat bacterial infections 
(Nobrega et al., 2015). Phage therapies, however, may be compromised in 
pathogenic hosts with active CRISPR-Cas systems, such as Pseudomonas (van 
Belkum et al., 2015) and Neisseria (Y. Zhang, 2017). Because Acr proteins have 
been found in these and other pathogens, acr genes could be included in the 
engineering of therapeutic bacteriophages that circumvent multidrug resistance 
in pathogenic bacteria.  
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Chapter 2 Discovery and characterization of anti-CRISPR proteins 
2.1 Introduction 
Anti-CRISPR proteins of both Types I-E and I-F CRISPR-Cas systems (Bondy-
Denomy et al., 2013; Pawluk et al., 2014) occur widely in MGEs (e.g. phages and 
conjugative elements) of diverse bacterial species (Pawluk, Staals, et al., 2016); 
however, Acrs outside of Type I systems have not yet been discovered. Since 
Acrs confer strong evolutionary advantages to MGEs encoding them, we 
hypothesized that Acrs must exist for other CRISPR-Cas systems. Thus, we 
employed the “guilt-by-association” bioinformatic approach that successfully 
identified Type I anti-CRISPRs to search for inhibitors of Type II systems. As 
described below, collaborative efforts among Maxwell, Davidson and Sontheimer 
labs led to the discovery of three distinct anti-CRISPR protein families that 
potently inhibit the N. meningitidis Type II-C CRISPR-Cas system. For the first 
time, we show that these proteins can function as off-switches for Nme1Cas9 
genome engineering in mammalian cells (Pawluk, Amrani, et al., 2016). 
Furthermore, our initial discovery of anti-CRISPR proteins for Type II CRISPR-
Cas systems was a tip of the iceberg and the beginning of uncovering more Acrs 
that await our characterization. To this end, we took the working bioinformatics 
approach to identify two new Type II-C anti-CRISPRs and their cognate Cas9 
orthologs, validated their functionality in vitro and in bacteria, and defined their 
inhibitory spectrum against a panel of Cas9 orthologs. We demonstrate that they 
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act before Cas9 DNA binding, and document their utility as off-switches for Cas9-
based tools for mammalian genome engineering applications (J. Lee et al., 
2018). Additionally, we characterized the Type II-A anti-CRISPR (AcrIIA5) in 
more detail to understand its broad-spectrum inhibition against both Type II-A 
and II-C Cas9 orthologs (Garcia et al., 2019). The identification of diverse anti-
CRISPRs and definition of Acr inhibitory mechanisms afford deeper insight into 
the interplay between Cas9 orthologs and their inhibitors and provide a greater 
scope for exploiting Acrs for CRISPR-based genome engineering. 
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2.2 Results 
2.2.1 The discovery of anti-CRISPR proteins for Cas9 
The anti-CRISPR associated (aca) gene is often encoded downstream of known 
anti-CRISPR genes, which we used as a bait to search for candidate Acr proteins 
in the genomic localization of MGEs within the species harboring Type II 
systems. By conducting a series of BLAST searches with Aca1 and Aca2, we 
identified a candidate anti-CRISPR gene in a strain of Brackiella oedipodis lying 
directly upstream of the aca2 gene (Figure 2.1A). The most frequently observed 
CRISPR-Cas system among the species encoding homologs of the candidate 
Acr protein was Type II-C. Since some homologs (such as AcrIIC1Nme that shares 
29% identity) were identified in the strains of N. meningitidis, we tested whether 
these proteins possess inhibitory functions against Nme1Cas9. AcrIIC1Boe 
presumably inhibits BoeCas9 in its native context, but sufficient similarity with 
Nme1Cas9 (47% identical) may allow cross-species inhibition. We used the 
HTH-containing protein homologs (Aca3) downstream of acrIIC1Nme as a new 
bait to uncover two additional acrIIC2Nme and acrIIC3Nme in the MGE-like genomic 
regions of N. meningitidis strain. To assess the effect of these candidate anti-
CRISPRs on the enzymatic activity of Nme1Cas9, in vitro DNA cleavage assays 
were performed. While purified Nme1Cas9 loaded with in vitro transcribed 
sgRNA yielded in DNA cleavage without any Acr or with Type I-specific AcrE2, 
the addition of the N. meningitidis anti-CRISPRs (AcrIIC1-3) resulted in inhibition 
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of Nme1Cas9-catalyzed cleavage in a dose-dependent manner. DNA cleavage 
activity of SpyCas9 was not affected by the addition of any of the anti-CRISPRs 
since subtype II-A, which it belongs to is distantly related to Nme1Cas9 (Figure 
2.1B).   
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Figure 2.1 Three families of anti-CRISPR proteins inhibit Nme1Cas9. (A) A 
schematic of the genomic architecture of Type II-C acr and aca genes in B. 
oedipodis and N. meningitidis. Amino acid identity (%) for homologous genes are 
indicated. Known functions of genes annotated as the following: Rep, plasmid 
replication protein; Reg, transcriptional regulator; Tra, conjugal transfer protein; 
Rec, recombinase; Tail, phage tail structural protein; Lysis, phage lysis cassette; 
colored in gray, MGE-related functions and/or show clear evidence of horizontal 
transfer. Not drawn to scale. (B) In vitro cleavage of linearized plasmid DNA by 
purified, recombinant Nme1Cas9 (top) or SpyCas9 (bottom). Cas9 was pre-
incubated with purified anti-CRISPR proteins and then with cognate sgRNA. 
Mobilities of input and cleaved DNAs are denoted on the right. 
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2.2.2 Anti-CRISPRs inhibit Cas9 genome editing in mammalian cells 
Since Cas9 is widely adopted as a genome editing tool, we tested the possibility 
of using these anti-CRISPRs as off-switches for CRISPR-Cas9 genome editing in 
mammalian cells. We co-transfected HEK293T cells with three plasmids 
expressing Cas9, sgRNA, and each Acr, respectively. Genome editing efficiency 
was determined using an established T7 endonuclease 1 (T7E1)-based protocol. 
Each of the anti-CRISPRs greatly decreased the ability of Nme1Cas9 to create 
genomic lesions with AcrIIC3Nme appearing to be the most potent, although a 
variation in activities of Acrs may depend on their expression or stability in cells 
(Figure 2.2). Consistent with our in vitro results, the anti-CRISPRs had no effect 
on editing mediated by SpyCas9 targeting the same genomic site (Figure 2.2). In 
addition, AcrE2 had no significant inhibitory effect in any of these experiments. 
These results demonstrate the potential application of Type II anti-CRISPRs for 
controlling Cas9-mediated genome editing.  
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Figure 2.2 Type II-C anti-CRISPR proteins inhibit Nme1Cas9-mediated 
genome editing in mammalian cells. Co-expression of plasmids encoding 
AcrIIC1-3 families reduced genome editing indicated by T7E1 assays as shown 
for Nme1Cas9 (left), but did not affect SpyCas9 editing (right). Type I AcrE2 is 
used as a non-cognate anti-CRISPR that should not inhibit Type II Cas9 
orthologs. Editing efficiencies (“% lesion”) are quantified based on the signal 
intensity of bands using densitometry. 
 
 
  
 
 
83 
2.2.3 Anti-CRISPRs inhibit a dCas9 application in mammalian cells 
Encouraged by the anti-CRISPR functioning as an off-switch for gene editing, we 
explored the possibility of controlling other types of Cas9 applications. Nuclease-
inactive dCas9 orthologs that do not catalyze DNA cleavage have proven to be 
exceptionally useful for RNA-guided DNA binding since a wide range of domains 
and functionalities can be fused or tethered to the DNA-bound dCas9-sgRNA 
complex (Adli, 2018). If anti-CRISPR inhibition occurs before the stable R-loop 
formation and cleavage, anti-CRISPR could be used as an off-switch not only for 
genome editing but also for dCas9 DNA binding applications such as CRISPRi 
and CRISPRa (Adli, 2018). To determine whether our most potent genome 
editing inhibitor (AcrIIC3Nme) can prevent stable DNA binding by dNme1Cas9 in 
mammalian cells, we used a previously developed system in which superfolder 
(sf) GFP-labeled dNme1Cas9 and mCherry-labeled dSpyCas9 are 
simultaneously colocalized to telomeric loci by cognate sgRNAs upon co-
transfection of their expression plasmids in U2OS cells (Ma et al., 2015) (Figure 
2.3A). We readily observed colocalizing telomeric dNme1Cas9-(sfGFP)3 and 
dSpyCas9-(mCherry)3 foci as long as both of the telomere-directed sgRNAs were 
included for the two dCas9 orthologs (Figure 2.3B-D). When a third mTagBFP2-
marked plasmid carrying an anti-CRISPR expression cassette was included, 
AcrE2 had no effect on telomeric co-localization, as expected (Figure 2.3E). In 
contrast, the co-expression of AcrIIC3Nme prevented the formation of telomeric 
foci by dNme1Cas9-(sfGFP)3 (Figure 2.3F). We scored only cells that exhibited 
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mTagBFP2 and sfGFP fluorescence as well as mCherry telomeric foci for the 
presence or absence of co-localizing dNme1Cas9-(sfGFP)3 telomeric foci in a 
double-blinded fashion (Figure 2.3G). While telomeric dNme1Cas9-(sfGFP)3 foci 
were observed in most cells in the presence of the negative control AcrE2 
protein, we did not observe any co-localizing dNme1Cas9-(sfGFP)3 telomeric foci 
when AcrIIC3Nme was co-expressed. These results confirm the robust inhibitory 
effect of AcrIIC3Nme on stable, sgRNA-programmed DNA binding by dNme1Cas9, 
and indicate that it can be used as a potent off-switch not only for Nme1Cas9 
genome editing but also for dNme1Cas9-based applications in mammalian cells.  
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Figure 2.3 A potent AcrIIC3Nme can be used for a dNme1Cas9 application. 
(A) Schematic representation of plasmids used for expression of dNme1Cas9-
(sfGFP)3, dSpyCas9-(mCherry)3, and their respective telomeric sgRNAs. The 
plasmid encoding the anti-CRISPR protein is marked with the mTagBFP2. (B-F) 
Fluorescence images of U2OS cells transiently transfected with plasmids 
depicted in (A). Each row represents different conditions indicated on the right 
side. Scale bars, 5 µm. (G) Quantitation of dNme1Cas9-(sfGFP)3 telomeric foci, 
as scored by co-localization with dSpyCas9-(mCherry)3 telomeric foci. n, the 
number of cells that were evaluated in each condition.   
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2.2.4 Type II-C anti-CRISPRs are found in diverse bacterial species 
In sections 2.2.4 - 2.2.7, we report two novel anti-CRISPR families in strains of 
Haemophilus parainfluenzae and Simonsiella muelleri, both of which harbor Type 
II-C CRISPR-Cas systems. Although these novel Acrs are found in different 
bacterial species, we show that they can inhibit Nme1Cas9, demonstrating cross-
species inhibitory potential. Having identified functional anti-CRISPR proteins, we 
also speculated that these bacterial strains may harbor active CRISPR-Cas 
systems. We identified Cas9 orthologs from H. parainfluenzae and S. muelleri 
and demonstrated that the newly identified Acrs can inhibit Cas9 orthologs from 
these systems as well, and defined important features of their inhibitory 
mechanisms. The S. muelleri Acr (AcrIIC5Smu) is the most potent Nme1Cas9 
inhibitor identified to date. Although anti-CRISPRs from H. parainfluenzae and S. 
muelleri revealed cross-species inhibition against Nme1Cas9, more distantly 
related Type II-C Cas9s were not inhibited by these proteins. The specificities of 
anti-CRISPRs and divergent Cas9s appear to reflect the coevolution of their 
strategies to combat or evade each other. Finally, we validate these new anti-
CRISPR proteins as potent off-switches for Cas9 genome engineering 
applications.  
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Using the same bioinformatics approach that led us to the discovery of the first 
anti-CRISPR proteins for Nme1Cas9, we searched for open reading frames 
(ORFs) encoding uncharacterized small proteins immediately upstream of aca2 
orthologs in genomic regions near putative phage- or MGE-associated 
sequences. This led us to two putative Acr candidates in genomes of H. 
parainfluenzae strain and S. muelleri strain. Both are located upstream of 
apparent aca2 orthologs (Figure 2.4A). Both strains encode predicted Type II-C 
CRISPR-Cas machinery with Cas9 orthologs that exhibit 59% and 62% identity 
with Nme1Cas9, respectively. Based on these similarities, we first tested whether 
these candidates prevent DNA cleavage by Nme1Cas9 in vitro (Figure 2.4B). As 
each of the purified candidate Acrs was added to parallel reaction mixtures, 
cleavage was inhibited in a concentration-dependent manner with AcrIIC5Smu 
exhibiting the greatest potency (Figure 2.4B). 
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Figure 2.4 Identification and in vitro validation of two Type II-C anti-CRISPR 
proteins. (A) Schematic of candidate anti-CRISPR proteins and aca2 genes in 
the genomic context of H. parainfluenzae and S. muelleri. Gray genes are 
associated with MGEs, and known gene functions are annotated as follows: Reg, 
transcriptional regulator, Tail, phage tail morphogenesis, and Tra, transposase. 
The B. oedipodis aca2 gene is used as a query for BLAST searches, and percent 
identities of aca2 orthologs are denoted. Not drawn to scale. (B) In vitro cleavage 
of target DNA by the Nme1Cas9-sgRNA complex in the presence of anti-
CRISPR protein. Pre-formed Nme1Cas9-sgRNA RNP complex was incubated 
with purified anti-CRISPR proteins before the addition of a linearized plasmid 
with a protospacer and PAM sequence. Cleavage efficiencies estimated based 
on band intensity densitometry (“% cleaved”).  
 
 
89 
2.2.5 Characterization of two new Type II-C Cas9 orthologs 
Since little was known about the Cas9 orthologs from H. parainfluenzae and S. 
muelleri, we characterized Type II-C CRISPR-Cas systems in these species 
(Figure 2.5A). We identified a cas9 ORF for each and cloned for recombinant 
protein expression and purification for in vitro studies. Although we found 
tracrRNA:crRNA for HpaCas9, we could not detect tracrRNA for SmuCas9. 
Therefore, we took advantage of the nonorthogonality of sgRNAs to closely 
related Cas9 orthologs (Briner et al., 2014; Fonfara et al., 2014) and used the 
Nme1Cas9 sgRNA to test the cleavage activity of SmuCas9. To determine the 
PAM sequence for each ortholog, a library of short DNA fragments containing a 
unique protospacer flanked by 10-nt randomized PAM sequences was subjected 
to in vitro digestion using purified, recombinant Cas9 proteins and T7-transcribed 
sgRNAs. Next, digested products were gel purified and deep sequenced. PAM 
sequences were identified from the resulting sequencing data based on the 
frequency of nucleotides at each position of the digested products. We found that 
HpaCas9 had a strong preference for 5′-N4GNTT-3′ (Figure 2.5B) and SmuCas9 
had a strong preference for the 5′-N4C-3′ PAM sequence (Figure 2.5C). This 
single cytosine at the 5th position from the protospacer appears to be the most 
critical PAM nucleotide by far, although moderate preferences for other 
nucleotides at other positions cannot be excluded from this analysis. We 
validated these putative PAMs by performing in vitro cleavage of a 
nondegenerate substrate and confirmed efficient cleavage (Figure 2.5B-C). 
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We next examined whether AcrIIC4Hpa and AcrIIC5Smu inhibit their native, 
cognate Cas9 proteins in vitro DNA cleavage and showed that AcrIIC4Hpa and 
AcrIIC5Smu indeed inhibit their cognate HpaCas9 and SmuCas9 (Figure 2.5B-C). 
Given that some Type II Acrs can inhibit orthologous Cas9 within the same 
subtype, we tested other Type II-C Acr families from Neisseria (AcrIIC1Nme, 
AcrIIC2Nme, and AcrIIC3Nme) for inhibition of these two newly characterized Cas9 
proteins. We found that all three of these previously characterized Acrs also 
inhibit the DNA cleavage activity of both HpaCas9 and SmuCas9 (Figure 2.5B-
C).  
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Figure 2.5 Characterization of new Type II-C Cas9 orthologs. (A) A 
phylogenetic tree of Type II Cas9 orthologs from S. pyogenes, N. meningitidis, C. 
jejuni, G. stearothermophilus, H. parainfluenzae, and S. muelleri. Domains are 
drawn to scale and colored as follows: blue, RuvC-I, -II, and -III nuclease domain; 
pink, bridge-helix (BH); gray, recognition lobe (REC); yellow, HNH nuclease 
domain; green, PAM-interacting domain (PI). Percent identities (%) of Type II-C 
orthologs to Nme1Cas9 are indicated. (B-C) PAM preferences for H. 
parainfluenzae (B) and S. muelleri (B) Cas9 orthologs. The frequency of 
nucleotides at each PAM position were calculated and plotted as a WebLogo. 
Validation of HpaCas9 and SmuCas9 cleavage activity and inhibition by anti-
CRISPR proteins in vitro. The double asterisk (**) denotes sgRNA.  
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2.2.6 AcrIIC4 and AcrIIC5 inhibit genome editing in human cells 
To assess the inhibition of Nme1Cas9 genome editing, we co-transfected 
HEK293T cells transiently with plasmids encoding Cas9, sgRNA, and anti-
CRISPR and then used T7E1 digestion to estimate genome editing efficiency. In 
agreement with our in vitro data, the expression of AcrIIC4Hpa or AcrIIC5Smu 
reduced Nme1Cas9-mediated mutagenesis to undetectable levels (Figure 2.6A). 
In contrast, they had no effect on genome editing at the same genomic sites by 
SpyCas9 (Figure 2.6A). Additionally, we delivered a preformed RNP complex of 
Nme1Cas9, sgRNA, and each of the Acrs to HEK293T cells by electroporation. 
Then, we evaluated the inhibition of genome editing using tracking of indels by 
decomposition (TIDE) analysis (Brinkman et al., 2014) (Figure 2.6B). For more 
rigorous quantitation of Nme1Cas9 editing, we performed a titration experiment 
and used targeted deep sequencing at a distinct editing site (NTS1C) and its 
validated off-target site (Figure 2.6-D). We detected little to no editing at higher 
doses of AcrIIC4Hpa or AcrIIC5Smu plasmid transfections. Acrs displayed 
variations in their inhibitory activities with both plasmid and RNP delivery, 
suggesting that the differences in protein stability, off-rate, or other intrinsic 
properties may contribute to their efficacy in tested systems. Overall, both in vitro 
and in cells, AcrIIC4Hpa or AcrIIC5Smu consistently exhibited strong inhibitory 
potency comparable or superior to that of AcrIIC3Nme, which had previously been 
defined as the most potent Nme1Cas9 inhibitor in mammalian cells (Pawluk, 
Amrani, et al., 2016).   
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Figure 2.6 AcrIIC4Hpa and AcrIIC5Smu inhibit genome editing in human cells. 
(A) T7E1 assays of Nme1Cas9 or SpyCas9 editing efficiencies upon transient 
plasmid transfection of human HEK293T cells. Editing efficiency estimated by 
cleavage of target DNA (% lesion). (B) TIDE analysis upon RNP delivery of 
Nme1Cas9-sgRNA and Acr into HEK293T cells. Statistical significance was 
determined by two-tailed paired Student’s t-test. Means and standard deviations 
from three biological replicates are indicated with lines (*, P < 0.05; **, P < 0.01; 
***, P < 0.001). (C-D) Indel frequencies at on-target (C) and off-target (D) sites 
measured by targeted deep sequencing of PCR-amplified gDNA collected after 
transfection of Nme1Cas9 plasmid with or without Acrs at different dosages. 
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2.2.7 AcrIIC4 and AcrIIC5 prevent stable DNA binding by Nme1Cas9 
Next, we attempted to dissect the mechanisms of Nme1Cas9 inhibition by 
AcrIIC4Hpa and AcrIIC5Smu. First, we checked whether sgRNA loading onto the 
Nme1Cas9 is inhibited by either of the anti-CRISPRs. We carried out 
electrophoretic mobility shift assays (EMSAs) by incubating Nme1Cas9 and 
sgRNA with or without Acr, and then visualizing sgRNA mobility after native gel 
electrophoresis followed by SYBR Gold staining. Without Acr or with AcrE2 
negative control, incubation of Nme1Cas9 with its cognate sgRNA resulted in a 
gel shift that indicates the formation of a stable RNP complex (Figure 2.7A). 
Similarly, when incubated with AcrIIC4Hpa and AcrIIC5Smu, efficient 
Nme1Cas9:sgRNA complex formation was again observed, suggesting that 
neither Acr protein significantly affected the RNP assembly. 
To test if the target DNA engagement by the Nme1Cas9:sgRNA complex is 
affected by the new anti-CRISPRs, we performed EMSA and fluorescence 
polarization assays after pre-incubating the RNP with each Acr and then adding 
the target DNA (Figure 2.7B). To inhibit DNA target cleavage, we omitted divalent 
metal ions from the reaction mixtures. While the target DNA exhibited the 
expected mobility shift in the absence of Acr, or in the presence of AcrE2 or 
AcrIIC1Nme [as expected (Harrington, Doxzen, et al., 2017)], AcrIIC4Hpa and 
AcrIIC5Smu prevented binding of the Nme1Cas9 to the target DNA. In 
fluorescence polarization assays, we measured the equilibrium binding constants 
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of Nme1Cas9 RNP (0 to 2 µM) to target DNA (8 nM) (Figure 2.7C). Both Acrs 
impaired the DNA binding activity of Nme1Cas9:sgRNA, confirming our EMSA 
results (Figure 2.7B). 
To extend our findings from in vitro studies to mammalian cells, we evaluated the 
anti-CRISPR activity on stable dCas9 binding using previously established 
methods for live-cell imaging of telomeric foci (Figure 2.3A). We observed 
dNme1Cas9-(sfGFP)3 foci in approximately 80% of the cells in the absence of 
any Acr protein, in 70% of the cells expressing AcrE2 protein (negative control), 
and in 0% of the cells in the presence of AcrIIC3Nme (as a positive control) (Figure 
2.7D). In conditions where the two novel anti-CRISPRs were co-expressed, we 
did not detect any cells with foci formation (Figure 2.7D). These results confirm 
that AcrIIC4Hpa and AcrIIC5Smu inhibit stable DNA binding of dNme1Cas9 in 
cellular context, indicating their potential utility as potent off-switches for 
dNme1Cas9-based applications.  
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Figure 2.7 Mechanistic insights into AcrIIC4Hpa and AcrIIC5Smu inhibition. 
(A) A native gel of the sgRNA visualized by SYBR gold staining after co-
incubation of Cas9 and anti-CRISPR protein and then the addition of sgRNA. (B) 
A native gel of the FAM-labeled target DNA after co-incubation of 
Nme1Cas9:sgRNA complex with Acr and then the addition of the target DNA. (C) 
Binding of Nme1Cas9 to partially duplexed DNA measured by fluorescence 
polarization assays with or without the indicated Acrs. The graph shows the 
average values (±SD) of three replicates. The curve was fitted to the equation 
shown in Materials and Methods, and the resulting KD values (nM) for 
AcrIIC5Smu, AcrIIC4Hpa, AcrIIC1Nme, and “No Acr” were 450.7 ± 47.6, 
749.6 ± 157.7, 82.4 ± 6.5, and 85.9 ± 3.9, respectively. (D) Quantitation of 
dNme1Cas9-(sfGFP)3 telomeric foci, as judged by colocalization with dSpyCas9-
(mCherry)3 telomeric foci in live-cell fluorescence imaging of U2OS cells. Foci 
were scored blinded, i.e., without the experimenter knowing the sample identities. 
n, the number of cells that were scored under each condition over three 
biological replicates. 
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2.2.8 AcrIIA5 inhibits Cas9 from both Type II-A and -C systems 
A few known anti-CRISPR proteins such as AcrIIC1 and AcrVA1 can inhibit 
closely related Cas proteins, but their maximal inhibitory activity is generally 
restricted to specific Cas9 homologs belonging within the same subtype. To 
facilitate the practical exploitation of multiple Cas9 homologs, here we show that 
the previously reported AcrIIA5 (Hynes et al., 2017) potently inhibits nine diverse 
Type II-A and Type II-C Cas9 homologs, including those currently used for 
genome editing. Based on our observation of sgRNA cleavage in vivo, we 
speculate that the mechanism of AcrIIA5 inhibition involves RNA interaction.  
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Figure 2.8 AcrIIA5 displays a broad-spectrum inhibition against Type II 
Cas9 proteins. 
(A) Summary of Cas9 proteins used in the phage Mu targeting assays. The 
length in amino acids, a subtype classification, PAM sequences, and all-versus-
all pairwise sequence identities are shown. (B) E. coli phage Mu plaque assays 
for Cas9 systems. The inhibitory activity of all tested anti-CRISPRs against 
diverse Cas9 homologs is represented based on the ten-fold serial dilutions of 
phage Mu lysate. The darkness of the cell in the table indicates the degree of 
inhibition of the Cas9 by the indicated anti-CRISPR, with the darkest cell 
representing >106-fold inhibition of the Cas9 system (i.e., plaquing efficiency of 
phage Mu increases >106-fold in the presence of the anti-CRISPR). The lightest-
shaded cells indicate that the given anti-CRISPR displayed no inhibition of the 
Cas9. This figure represents data obtained through at least three biological 
replicates of each assay. (C) Genome editing in the HEK293T cells analyzed by 
T7E1 assays. AcrIIC1 and AcrIIA4 are used as positive controls for 
Nme1/CjeCas9 and SpyCas9 inhibition, respectively. The image shown has two 
technical replicates and is representative of at least three biological replicates. 
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To quantitatively compare the specificity profiles of a large number of anti-
CRISPR proteins, we used a phage-targeting assay in which Cas9 is co-
expressed with the sgRNA that targets phage Mu and prevents its replication by 
cleaving its genome (Harrington, Doxzen, et al., 2017). We expressed a diverse 
group of Cas9 homologs (Figure 2.8A) in E. coli with a cognate sgRNA to target 
phage Mu. These Cas9 homologs include SpyCas9, SauCas9, CjeCas9, and 
Nme1Cas9 as well as Cas9 homologs distributed across the phylogeny of Cas9s 
representing all three subtypes (II-A, II-B, and II-C), which range in pairwise 
sequence identity from 19% to 66% and use a variety of PAM sequences (Figure 
2.8A). We tested 10 previously identified anti-CRISPRs in the phage Mu 
targeting assay, including four that were shown to inhibit Type II-A and five that 
inhibit Type II-C CRISPR-Cas systems. The level of phage Mu plaquing in the 
presence of a particular Cas9/anti-CRISPR combination provides a quantitative 
measure of the effectiveness of the anti-CRISPR in inhibiting a given Cas9 
homolog. The targeted cleavage activity of Cas9 proteins reduced the plaquing 
efficiency of phage Mu by at least 105-fold compared to strains expressing the 
same Cas9 proteins with non-targeting sgRNA (lighter shade; Figure 2.8B). The 
co-expression of anti-CRISPRs can have a range of effects on the Cas9-
mediated reduction of plaquing efficiency. In some cases, the co-expression of 
anti-CRISPRs caused no increase or only a partial increase in plaquing 
efficiency. While some anti-CRISPRs, such as AcrIIA4, are highly specific, 
inhibiting one or a few CRISPR-Cas9 systems, others, such as AcrIIC1Nme, inhibit 
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many Type II-C Cas9s (Figure 2.8B). Overall, the strength and specificity of anti-
CRISPRs may vary over multiple orders of magnitude. In contrast to all of the 
other anti-CRISPRs tested, AcrIIA5 was able to completely inhibit every Type II-A 
and II-C Cas9 including a highly divergent Corynebacterium diphtheria 
(CdiCas9), emphasizing its unusually broad activity. It failed to block only the 
Type II-B Cas9 from Francisella novicida (Figure 2.8B). AcrIIA5 previously has 
been shown to inhibit CjeCas9 and a homolog of AcrIIA5 to inhibit Nme1Cas9 in 
vitro (Marshall et al., 2018). The uniquely broad specificity of AcrIIA5 inspired us 
to further investigate its properties. 
Although AcrIIA5 was previously shown to inhibit genome editing mediated by 
SpyCas9 and S. thermophilus Cas9 (St1Cas9) in mammalian cells (Hynes et al., 
2017), its activity against other Cas9 proteins in genome-editing applications had 
not been tested. To determine if AcrIIA5 could inhibit genome editing mediated 
by the four Cas9 homologs commonly used for genome-editing purposes in 
mammalian cells, we transiently co-transfected HEK293T cells with plasmids 
expressing anti-CRISPR proteins, Cas9s and their respective sgRNAs designed 
to target specific genomic sites. AcrIIA5 inhibited the activities of SpyCas9, 
Nme1Cas9, SauCas9, and CjeCas9 as confirmed by the T7E1 assay (Figure 
2.8C). Collectively, these results show that AcrIIA5 efficiently inhibits the 
genome-editing activity of four diverse Cas9 proteins in both bacterial and 
mammalian cells. Furthermore, AcrIIA5 inhibits genome editing with similar 
potency to previously reported anti-CRISPRs.  
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2.2.9 AcrIIA5 activity prevents DNA binding and leads to sgRNA cleavage 
To investigate how AcrIIA5 inhibits Cas9 activity, we developed a luminescence-
based bioassay in which we targeted the catalytically inactive dSpyCas9 (Gilbert 
et al., 2014) to a constitutively expressed artificial promoter that drives 
expression of the luxCDABE luminescence genes in E. coli (Figure 2.9A). 
Binding of dSpyCas9 to the promoter of the luxCDABE operon repressed 
transcription, and no luminescence was detected in the absence of anti-CRISPR 
proteins (Figure 2.9B). The expression of AcrIIA5 relieved this repression, 
leading to an increase in luminescence and suggesting that DNA binding was 
inhibited. Similarly, the expression of AcrIIA4, which was previously shown to 
inhibit SpyCas9 DNA binding (Dong et al., 2017; Shin et al., 2017; H. Yang & 
Patel, 2017), also led to an increase in luminescence. By contrast, the 
expression of AcrIIC1, which does not inhibit SpyCas9, showed no increase in 
luminescence, as expected. These results demonstrate that AcrIIA5 blocks 
binding of dSpyCas9 to target DNA and impedes its function as a transcriptional 
repressor. 
Although Nme1Cas9 lost its cleavage activity in vitro after the co-expression of 
His6-tagged Nme1Cas9 and AcrIIA5, AcrIIA5 did not co-elute with Nme1Cas9, 
while a control, AcrIIC1, did co-elute (Figure 2.9C). Thus, the co-expression of 
AcrIIA5 with Nme1Cas9 caused a loss of activity even though the anti-CRISPR 
did not form a stable complex with Nme1Cas9. Surprisingly, when we examined 
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sgRNA bound to the Nme1Cas9 purified in the presence of AcrIIA5, a sizable 
proportion was smaller compared to the sgRNA bound to the Nme1Cas9 
expressed without AcrIIA5 or with AcrIIC1 (Figure 2.9C, bottom gel). The full-
length and cleaved sgRNA molecules seen in these gels were excised, reverse 
transcribed into DNA, and sequenced. We found that a portion of the Nme1Cas9 
co-expressed with AcrIIA5 was bound to full-length sgRNAs that were 
indistinguishable from that of Nme1Cas9 controls. In addition, it was also 
frequently bound to truncated forms as mapped to stem-loops 1 and 2 of the 
sgRNA (Figure 2.9D). We tested whether Nme1Cas9 is responsible for the 
sgRNA cleavage as previously reported for RNA cleavage activity of the HNH 
endonuclease domain of Nme1Cas9 (Rousseau et al., 2018). However, the 
formation of the truncated sgRNA molecules was not mediated by either of the 
nuclease domains of Nme1Cas9 (Figure 2.9E). When the Nme1Cas9 mutants 
were co-expressed with AcrIIA5, the sgRNA was still cleaved in the same 
manner as with the wild-type Nme1Cas9. These results show that the nuclease 
domains of Nme1Cas9 do not catalyze the AcrIIA5-induced cleavage of sgRNA. 
The cleavage of sgRNA induced by AcrIIA5 and its close homologs is also 
observed for SpyCas9 [data not shown; (Garcia et al., 2019)]. Overall, AcrIIA5 
functions as a broad-spectrum anti-CRISPR, and its co-expression with 
Nme1Cas9 results in the truncation of sgRNAs from the 3’ ends. This 
phenomenon was observed consistently in six different AcrIIA5 family homologs 
for both Nme1Cas9 and SpyCas9.  
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Figure 2.9 AcrIIA5 prevents DNA binding and leads to sgRNA cleavage 
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(A) Overview of CRISPRi luminescence assay. A constitutively active promoter 
controls the lux expression and its transcription is blocked when dSpyCas9 
binds, resulting in no luminescence. Anti-CRISPR proteins can inhibit the binding 
of dSpyCas9 to the target DNA and restore the transcription and expression of 
the lux cassette. (B) The luminescence signal (AU, arbitrary units) is measured 
from cells expressing dSpyCas9 targeting the lux promoter in the presence of the 
indicated anti-CRISPRs. Data represent the mean and SD of luminescence 
measurements for three replicates. (C) His6-Nme1Cas9 was co-expressed and 
co-purified without anti-CRISPR (-), or with AcrIIC1 or AcrIIA5. Ribonucleoprotein 
complexes were analyzed by SDS-PAGE gel (top) and polyacrylamide/Urea gel 
(bottom). (D) A schematic of the Nme1Cas9 sgRNA with the target DNA is 
shown. The sgRNA secondary structure is predicted from other Cas9-sgRNA 
structures. Arrows indicate the positions of RNA cleavage in the sgRNA bound to 
the Nme1Cas9 co-expressed with AcrIIA5. The image is representative of at 
least three replicates of sequencing using the NEBnext Small RNA kit. (E) A 
domain architecture of Nme1Cas9 protein with amino acid substitutions in the 
RuvC domain (D16A), the HNH domain (H588A), and the double mutant (dm) 
with substitutions in both domains (D16A/H588A). Nme1Cas9 variants were co-
expressed without Acr, or with AcrIIC1 or AcrIIA5, and then purified by Ni-NTA 
chromatography. Ribonucleoprotein complexes were analyzed by a 15% Tris- 
tricine polyacrylamide gel using SDS-PAGE and visualized by stain-free imaging 
(top). For sgRNA visualization complexes were resolved on a 12.5% 
polyacrylamide/Urea gel and by SYBRTM Gold staining (bottom). 
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2.3 Discussion 
CRISPR-Cas systems and anti-CRISPR proteins that inactivate them are in 
strong accord with the Red Queen hypothesis, which proposes that bacteria must 
evolve new mechanisms to resist invaders while the invaders simultaneously 
evolve countermeasures (Labrie et al., 2010). The widespread prevalence, 
extreme diversity, and sometimes co-occurrence of CRISPR-Cas systems in 
prokaryotic genomes, as well as the adaptive nature of the resulting defenses, 
pose a significant challenge to phages and other MGEs. An in vitro evolution 
study showed that the only way for phages to escape CRISPR-mediated 
extinction is by the expression of an anti-CRISPR gene (van Houte et al., 2016). 
Anti-CRISPR proteins provide phages with an effective tactic to inactivate 
CRISPR-Cas systems and likely contribute to phage persistence in the face of 
host defense mechanisms. 
For the first time, we report the existence of the inhibitors of CRISPR interference 
in Type II systems (AcrIIC1-3 families for Nme1Cas9) (Pawluk, Amrani, et al., 
2016). As a continuous exploration to uncover anti-CRISPR proteins, we report 
AcrIIC4 and AcrIIC5 that inhibit Nme1Cas9, HpaCas9, and SmuCas9. With time, 
our lab and others subsequently found that AcrIIC1-3 families of the Type II-C 
system inhibit Cas9 with varying potency and specificity by employing unique 
mechanisms of actions. Some Type II-C proteins have a narrow spectrum of 
inhibition while others demonstrate a broad-spectrum inhibition. Cross-species 
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inhibition may be graded depending on the similarity of the Cas9 orthologs. One 
prominent example of a broad-spectrum anti-CRISPR is AcrIIC1, which 
inactivates multiple Type II-C Cas9 orthologs (Harrington, Doxzen, et al., 2017). 
This is likely because it binds to the highly conserved HNH domain, whereas 
other Type II-C Acrs may bind to Cas9 domains that are less conserved. On the 
other hand, AcrIIC2 and AcrIIC3 can inhibit only Nme1Cas9 by interfering with 
sgRNA loading and DNA binding and cleavage, respectively (Thavalingam et al., 
2019; Zhu et al., 2019). It remains to be tested whether AcrIIC4 and AcrIIC5 
prevent DNA binding by precluding initial recognition of the PAM, by interfering 
with the R-loop formation and Cas9 structural rearrangement, or a combination of 
both.  
Anti-CRISPR proteins that can inhibit Cas9s across different subtypes (e.g. Type 
II-A, II-B, and II-C) are uncommon. We show that AcrIIA5 can inhibit 9 different 
Cas9 orthologs of both Type II-A and II-C systems, displaying the specificity 
broader than that of AcrIIC1Nme and has a unique feature of resulting in sgRNA 
truncation. However, based on the heterogeneous population of truncated 
sgRNAs that vary in the abundance and identity as well as the presence of a full-
length sgRNA indistinguishable from that bound to Nme1Cas9 in the absence of 
AcrIIA5, we conclude that sgRNA cleavage alone cannot account for the 
inhibitory activity of AcrIIA5. Instead, AcrIIA5 may partially dislodge the sgRNA 
from Cas9, leaving it prone to digestion by intracellular RNases. The portion of 
the sgRNA that we observed to be digested, stem-loops 1 and 2, are the more 
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exposed parts of the sgRNA in the Cas9-sgRNA complex. We speculate that the 
sgRNA truncation may be due to a conformational change in Cas9 that alters the 
integrity of sgRNAs. It may not necessarily be the inhibitory mechanism per se 
but rather results from the interaction between AcrIIA5 and Cas9. 
Another group reported that AcrIIA5 inhibits the RuvC domain of SpyCas9 while 
DNA binding is unaffected (G. Song et al., 2019). We and others previously 
reported that AcrIIA5 hinders DNA binding activity and such discrepancy may 
have resulted because the function of AcrIIA5 was assessed based on the 
indirect measurements by monitoring a reporter gene (Garcia et al., 2019; J. Li et 
al., 2018; Nakamura et al., 2019). The expression and stability of heterologous 
proteins in tested systems may have also influenced the varying results. For 
example, the expression of AcrIIA5 has been shown to reduce the reporter gene 
expression regardless of matching sgRNAs in a dCas9 binding assay (Marshall 
et al., 2018; G. Song et al., 2019). Moreover, we had difficulty purifying AcrIIA5 in 
the active form due to a low expression level of AcrIIA5, which has also been 
documented by Song et al. (2019). Therefore, the results should be interpreted 
with caution. Recently, An et al. reported that a solution structure of AcrIIA5 has 
an N-terminal intrinsically disordered region (IDR) and performed extensive 
truncation and substitution experiments to understand its role in inhibition of 
Cas9 (An et al., 2020). Based on their findings, the length of IDR mediates the 
interaction between the AcrIIA5 and Cas9-sgRNA while the amino acid content of 
AcrIIA5 dictates the catalytic efficiency of the inhibitory complex (An et al., 2020). 
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The conformational plasticity of the IDR may contribute to the broad-spectrum 
inhibition of multiple Cas9 effectors. To tie all the pieces together, AcrIIA5 may 
bind to the guide RNA binding region of Cas9 and the N-terminal IDR may 
extend toward the RuvC domain to inhibit the nuclease activity of Cas9. A co-
crystal structure may help us better understand the whole picture of the inhibitory 
mechanism of AcrIIA5 in the future.  
Although most studies are in agreement with one another, some discrepancies 
are notable as the Acrs may have multiple inhibitory mechanisms and one or the 
other may be revealed depending on how the studies are conducted. Extensive 
efforts combining different approaches spanning from in vitro biochemical studies 
to structural analyses are ongoing to dissect the mechanisms of many anti-
CRISPR proteins that may surprise us with new exciting biology. 
Beyond the host-phage arms race, anti-CRISPR proteins also hold immense 
potential for biotechnological uses. We demonstrate that the anti-CRISPR 
proteins can be used as potent off-switches for mammalian genome engineering 
for both Cas9 and dCas9 applications. Many such applications stand to benefit 
from increasing the numbers, specificities, and inhibitory mechanisms of anti-
CRISPRs, for instance, through combinatorial control over multiple Cas9/dCas9 
proteins. For example, both broad-spectrum (e.g., AcrIIC1, AcrIIA5) and highly-
specific (e.g., AcrIIC3-5) anti-CRISPR proteins could be used to control multiple 
Cas9s simultaneously, or specific Cas9s but not others, upstream or downstream 
 
 
109 
of target recognition, to achieve maximal flexibility of both genome manipulation 
and regulation. Applications of genetically encoded anti-CRISPR inhibitors to 
provide a means to spatially, temporally, or conditionally control Cas9 activity are 
discussed in the next chapters. 
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2.4 Materials and Methods 
Bioinformatics searches for anti-CRISPR proteins 
Putative anti-CRISPR genes were identified using the guilt-by-association 
bioinformatic method. Briefly, BLAST searches were conducted using aca2 and 
aca3 as the query and orthologs of aca genes that had a small, uncharacterized 
hypothetical ORF immediately upstream were curated manually. 
Plasmid vector construction 
Appendix Table 1 contains the protein sequences of Cas9 and anti-CRISPR 
proteins. Appendix Table 2 summarizes plasmids used in this chapter. Plasmid 
maps and sequences are available on Addgene. 
Expression vectors for bacterial expression 
Nme1Cas9 sgRNA was synthesized by GenScript and cloned into the pMCSG7 
expression vector downstream of the Nme1Cas9 ORF. DNA sequences 
encoding candidate anti-CRISPR proteins were synthesized by either GenScript 
and subcloned into pHAT4 vector or IDT and subcloned into the pMCSG7 vector.  
Expression vectors for mammalian expression 
Each Acr ORF was synthesized as a gene block (IDT) and then inserted into the 
pCSDest2 vector (Addgene). The resulting plasmids placed the Acr-encoding 
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genes under the control of the CMV-IE94 promoter. Cas9 expression vectors, 
also pCSDest2 under CMV-IE94 promoter, were identical in all respects except 
for the respective Cas9 ORFs. Similarly, plasmids for the expression of sgRNAs 
in pLKO.1 vectors for each Cas9 ortholog were also identical in all respects 
except for the sgRNA sequences themselves.  
Vectors for fluorescence microscopy 
pHAGE-TO-DEST dSpyCas9-(mCherry)3 and dNme1Cas9-(sfGFP)3 plasmids 
(Ma et al., 2015) were purchased from Addgene and used directly for no-sgRNA 
control experiments. All-in-one versions that also included the sgRNA-expressing 
cassette for targeting telomeric repeats were made by inserting the U6 
promoter/sg-telomere cassette into its cognate dCas9 plasmid via Gibson 
assembly (NEB). To make the Acr plasmids, we amplified a mTagBFP2 cassette 
and incorporated it into pCSDest2 with ACR ORFs by Gibson assembly. To 
generate the control, simply Acr OF was removed and re-ligated. 
Purification of recombinant proteins 
6xHis-tagged recombinant proteins were expressed in E. coli BL21 (DE3). Cells 
were grown in either LB or TB medium at 37 °C to an optical density (OD600 nm). 
Protein expression was induced by the addition of 1 mM IPTG for 16 hr at 16 °C. 
Cells were lysed by sonication in 50 mM Tris pH 7.5, 500 mM NaCl, 20 mM 
imidazole, 0.5 mM DTT and 5% glycerol supplemented with 0.5 mM PMSF, 
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lysozyme and protease inhibitor cocktail (Sigma). Clarified lysates were bound in 
batch to Ni-NTA agarose (Qiagen), and the bound protein was eluted with 300 
mM imidazole. After elution from Ni-NTA resin, anti-CRISPR proteins were 
dialyzed in 10 mM Tris pH 7.5, 250mM NaCl, and 5mM b-mercaptoethanol and 
incubated with His-tagged Tobacco Etch Virus (TEV) protease overnight at 4°C. 
The second round of Ni-NTA purification was used to isolate successfully 
cleaved, untagged anti-CRISPRs by collecting the unbound fraction. Cas9s were 
further purified using cation exchange chromatography using a Sepharose 
HiTrap column (GE Life Sciences). Size exclusion chromatography was used to 
purify Nme1Cas9 further in 20 mM HEPES-KOH (pH 7.5), 300 mM KCl and 1 mM 
TCEP. 
In vitro DNA cleavage 
sgRNA was generated by in vitro T7 transcription (Epicentre). Cas9 was 
incubated with purified, recombinant anti-CRISPR protein in cleavage buffer [20 
mM HEPES-KOH (pH 7.5), 150 mM KCl, 10% glycerol, 1 mM DTT, and 10 mM 
MgCl2] for 10 min. Next, sgRNA was added and the mixture was incubated for 
another 15 min. For target DNA, a plasmid containing the protospacer was 
linearized by enzyme digestion or amplified by PCR. The reactions were 
incubated at 37˚C for 30-60 min, treated with proteinase K, and visualized after 
electrophoresis in a 1% agarose/1xTAE gel. 
Mammalian genome editing 
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Transient transfection 
Plasmids for mammalian expression of Cas9s, their respective sgRNAs, and the 
anti-CRISPR proteins were transiently transfected in approximately 1.5 x 105 
mid-passage HEK293T cells [cultured at 37 ˚C, 5% CO2 in DMEM (Gibco) + 10% 
FBS(Sigma) + 1% Penicillin/Streptomycin (Sigma)] in a 24-well plate using 
PolyFect (Qiagen). The total amount of DNA was equal in all transfections (e.g., 
for the no-sgRNA controls, the sgRNA-expressing plasmids were replaced with 
the same mass of an irrelevant plasmid). 72 hr after transfection, cells were 
harvested and gDNA was extracted with the DNeasy Blood and Tissue kit 
(Qiagen) and then was used for PCR amplification [High Fidelity 2X PCR Master 
Mix (NEB)] with primers flanking the targeted site. PCR products were heat-
denatured, re-annealed, and digested with T7 Endonuclease I (NEB). The 
samples were visualized in a 2.5% agarose/1xTAE gel and quantified with the 
ImageMaster-TotalLab program. Indel percentages (“% lesion” in the figures) 
were calculated as previously described (Guschin et al., 2010). Alternatively, 
indel frequencies were estimated by Sanger sequencing followed by TIDE 
(Brinkman et al., 2014) or the Next-generation sequencing followed by analysis 
with custom scripts. 
Ribonucleoprotein Delivery 
RNP delivery of Nme1Cas9 was performed using a Neon electroporation system 
following the manufacturer’s instructions (ThermoFisher). Briefly, in a 10 μl 
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reaction volume, 15 pmol of Nme1Cas9 and 150 pmol of anti-CRISPR protein 
were mixed in buffer R and incubated at room temperature for 20 min. Then, 
20 pmol of T7 in vitro-transcribed sgRNA was added to the Cas9-Acr complex 
and incubated at room temperature for 30 min. Approximately 50,000 to 100,000 
cells were mixed with the RNP-Acr-sgRNA complex, electroporated (Neon 
nucleofection system), and then plated in 24-well plates. After gDNA collection, 
PCR amplification of the target sites, and column purification, PCR products were 
sent for Sanger sequencing (Genewiz), and trace files (ab1 files) were analyzed 
using TIDE (Brinkman et al., 2014). 
Targeted deep sequencing analysis 
We used a two-step PCR amplification approach to produce DNA fragments for 
each on-target and off-target site. In the first step, we used locus-specific primers 
bearing universal overhangs with ends complementary to the TruSeq adaptor 
sequences. DNA was amplified with High Fidelity 2× PCR Master Mix (NEB) 
using appropriate annealing temperatures for the on-target (NTS1C) and off-
target (NTS1C-OT1) sites. In the second step, the purified PCR pool was 
amplified with a universal forward primer and an indexed reverse primer to 
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reconstitute the TruSeq adaptors. Full-size products (∼250 bp in length) were 
extracted using AMPure beads (Beckman Coulter). The purified library was deep 
sequenced using a paired-end 150 bp MiSeq run. High-throughput sequencing 
data are available at the NCBI Sequence Read Archive (accession no. 
PRJNA505886) 
Fluorescence microscopy 
U2OS cells were cultured at 37 °C (5% CO2) in DMEM (Gibco) supplemented 
with 10% FBS (Sigma) and 1% Pen/Strep (Sigma). For imaging, cells were 
grown on 170 µm, 35 x 10mm glass-bottom dishes (Eppendorf). Cells were co-
transfected with all-in-one plasmids. sgRNA-expressing plasmids, and anti-
CRISPR/mTagBFP2 plasmid using PolyFect (Qiagen). The additional sgRNA-
only plasmid was included because we found the levels of sgRNAs expressed 
from the all-in-one plasmid alone to be sub-saturating. For the no-sgRNA control 
experiments, the additional sgRNA-only plasmids were excluded, and the sgRNA 
cassette was also excluded from the cognate dCas9-expressing plasmid. After 
24 hr of incubation, live cells were imaged with a Leica DMi8 microscope 
equipped with a Hamamatsu camera (C11440-22CU), a 63x oil objective lens, 
and Microsystems software (LASX). Further imaging processing was done with 
Fiji-ImageJ. For the blinded experiments to score cells with telomeric foci, each 
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condition was coded by one experimenter and then scored by another who did 
not know which set of cells were from which condition. Only cells that exhibited 
mTagBFP2 and sfGFP fluorescence, as well as dSpyCas9-(mCherry)3 telomeric 
foci, were assessed for the presence or absence of co-localizing dNme1Cas9-
(sfGFP)3 telomeric foci, and all such imaged cells were included in the 
quantifications. 
PAM determination assay 
A library of a protospacer with randomized PAM sequences was generated using 
overlapping PCRs, with the forward primer containing the 10-nt randomized 
sequence flanking the protospacer. The library was subjected to in vitro cleavage 
by purified recombinant HpaCas9 or SmuCas9 proteins as well as in vitro-
transcribed sgRNAs. The segment of a gel where the cleavage products were 
expected to be was purified and subjected to library preparation as described 
previously (Z. Zhang et al., 2012). The library was sequenced using the Illumina 
NextSeq500 sequencing platform and analyzed with custom scripts. 
Electrophoretic mobility shift assay (EMSA) 
Nme1Cas9 (1 µM) was incubated with 1 µM sgRNA in 1× binding buffer (20 mM 
Tris-HCl [pH 7.5], 150 mM KCl, 2 mM EDTA, 1 mM DTT, 5% glycerol, 50 µg/ml 
heparin, 0.01% Tween 20, 100 μg/ml BSA) for 20 min at room temperature to 
form the RNP complex. Acrs were added to a final concentration of 10 µM and 
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incubated for an additional 20 min. Finally, the FAM-tagged NTS4B protospacer 
oligonucleotide was added to the mixture and incubated at 37°C for 1 hr. The 
mixture was loaded onto a native 6% acrylamide gel, and the FAM-tagged DNA 
was visualized using a Typhoon imager. 
sgRNA EMSA 
Nme1Cas9 (1.5 µM) and anti-CRISPR (20 µM) proteins were preincubated in 1× 
binding buffer for 10 min, and then sgRNA (0.15 µM) was added to the reaction 
mixture for an additional 10 min. The complexes were resolved on a 6% 
polyacrylamide native gel, stained by SYBR Gold (ThermoFisher), and visualized 
with a Typhoon imager. 
Fluorescence polarization assay 
Preformed RNP complex of Nme1Cas9 and sgRNA was added to 1× binding 
buffer (20 mM Tris-HCl [pH 7.5], 150 mM KCl, 5 mM EDTA, 5 mM MgCl2, 1 mM 
DTT, 5% [vol/vol] glycerol, 50 μg/ml heparin, 0.01% Tween 20, and 100 μg/ml 
BSA) and incubated for 30 min followed by the addition of 10 μM Acrs. This 
mixture was incubated for 30 min followed by the addition of an 8 nM FAM-
tagged NTS4B protospacer (34 bp containing only 8-bp PAM duplex). After an 
incubation of 30 min the polarization measurements were made on Victor3 
multilabel plate counters (Perkin Elmer). To calculate fraction-bound values, data 
were normalized by setting the lowest anisotropy to 0 and highest to 1. The curve 
fitting was performed in GraphPad Prism using the following equation: 
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In vivo phage Mu plaquing assays 
E. coli BB101 cells were co-transformed with plasmids expressing Cas9-sgRNA 
combinations targeting phage Mu and a pCDF-1b plasmid expressing the 
different anti-CRISPR proteins. Cells containing both plasmids were sub-cultured 
in LB supplemented with chloramphenicol and streptomycin and grown for 2 hr, 
at which point anti-CRISPR expression was induced with 0.01mM IPTG for 3 hr. 
Cells were then mixed with soft LB-agar and top-plated on LB supplemented with 
both antibiotics and 200 ng/mL aTc, 0.2% arabinose, and 10 mM MgSO4. Serial 
dilutions of phage Mu were spotted on top and the plates were incubated 
overnight at 37°C. Experiments were performed in triplicate. 
dSpyCas9 binding luminescence assay 
 A plasmid in which the J23119 artificial promoter drives constitutive expression 
of the luxCDABE operon from Photorhabdus luminescens (Winson et al., 1998) 
was targeted by dSpyCas9 with its crRNA, which was cloned into the BsaI site of 
the pCRISPathBrick plasmid (Cress et al., 2015). The target DNA plasmid was 
co-transformed into E. coli BL21 cells with pCM-str, a pCDF-1b plasmid 
expressing the anti-CRISPR proteins and a protospacer targeting the J23119 
promoter. Cells containing the three plasmids were grown in LB supplemented 
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with kanamycin, chloramphenicol and streptomycin until they reached OD600 nm 
of 0.6. The cultures were then diluted to an OD600 of 0.1 in LB containing 200 
ng/mL aTc, 0.2% arabinose and 0.01 mM IPTG, and 100 μl was dispensed into a 
96-well plate. The plate was incubated with shaking at 37°C using a Synergy H1 
reader controlled by Gen5 2.09 software (BioTek Instruments Inc.), and the 
OD600 and luminescence was monitored for 24 hr. 
Co-expression and co-purification of Nme1Cas-/sgRNA and anti-CRISPR 
E. coli BB101 cells were co-transformed with 6x-His-tagged Nme1Cas9-sgRNA 
in pMCSG7 or 6x-His-tagged SpyCas9-sgRNA in pMCSG7 and a pCDF-1b 
vector encoding untagged anti-CRISPR protein. Cells were grown in LB at 37°C 
to an OD600 of 0.8. Protein expression was induced by the addition of 1mM IPTG, 
and the cells were incubated for an additional 3 hr at 37°C. Cells were collected 
by centrifugation, resuspended in binding buffer [50 mM Tris-HCl (pH 7.5), 200 
mM NaCl, 5% glycerol, 20 mM imidazole], and lysed by sonication. Clarified 
lysates were incubated with Ni-NTA agarose (Qiagen) for 30 min at 4°C, washed 
with binding buffer supplemented with 30 mM imidazole, and bound protein was 
eluted with binding buffer supplemented with 300 mM imidazole. The purified 
ribonucleoprotein complexes were analyzed by SDS-PAGE using a 15% Tris-
Tricine gel, and the proteins were visualized using Coomassie stain. The co-
purifying sgRNA was examined using a denaturing 12.5% polyacrylamide/Urea 
gel and visualized by SYBR™ Gold (ThermoFisher Scientific) staining. 
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RNA cloning and sequencing 
sgRNAs bound to affinity-purified Nme1Cas9 in the presence or absence of 
AcrIIA5 or in the presence of AcrIIC1 were electrophoresed on a denaturing 
12.5% polyacrylamide/Urea gel and visualized by SYBR™ Gold (ThermoFisher 
Scientific) staining. Bands corresponding to full-length sgRNAs were excised for 
each sample and bands with higher mobility than the full-length sgRNAs were 
excised from the sample of Nme1Cas9 purified from the cells grown in the 
presence of AcrIIA5. The gel slices were soaked in 250 μL of DNA Gel Elution 
Buffer (NEB) supplemented with 1:100 SUPERase⋅ In RNase Inhibitor 
(ThermoFisher Scientific) and rotated overnight at 4°C. The eluate was filtered 
through a Nanosep® MF 0.45 μm column (Pall Laboratory, ODM45C35). RNA 
was ethanol precipitated and reconstituted in ultrapure water. Libraries were 
prepared with the NEBNext Small RNA Library Prep Set for Illumina (NEB) 
following the protocol provided by the manufacturer. The resulting DNA library 
was visualized using 8% PAGE and bands corresponding to the sgRNA 
fragments were excised. DNA was eluted from the excised bands by rotating 
overnight in the DNA Gel Elution buffer at room temperature. The eluate was 
filtered through a Nanosep® MF 0.45 μm column and the DNA was ethanol 
precipitated and resuspended in ultrapure water. DNA fragments were then 
ligated to the TOPO Blunt vector (ThermoFisher Scientific), DNA was purified 
from single colonies, and inserts were sequenced using the M13F or M13R 
primers.  
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Chapter 3 Applications of anti-CRISPR proteins for genome engineering 
3.1 Introduction 
Although RNA-programmable CRISPR-Cas9 genome engineering has 
revolutionized biological research and promises to do so for clinical applications, 
limitations and safety issues remain (Doudna, 2020). The discovery of anti-
CRISPR proteins provides the opportunity to exploit their ability to inhibit Cas9 
and to address some of the limitations of Cas9 genome engineering (Marino et 
al., 2020). In this chapter, I describe a method of improving HDR efficiency and 
controlling various genome editors using anti-CRISPR proteins to demonstrate 
the broader utility of Acrs in genome engineering applications. 
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3.1.1 Precise gene editing using HDR is inefficient 
One of the limitations of the Cas9 genome editing is the inefficiency of precise 
DNA insertions, deletions, or substitutions by HDR due to the competing NHEJ 
repair pathway (Jasin & Rothstein, 2013). To achieve a precise integration of the 
target DNA efficiently, various approaches have been used to promote HDR, 
inhibit NHEJ, or both (M. Liu et al., 2018; Yeh et al., 2019). One of the drawbacks 
of such approaches is that they directly interfere with the cellular DNA repair 
machinery, possibly jeopardizing the cell’s ability to repair endogenous DNA 
breaks in the genome. Studies of DSB repair pathways in eukaryotic cells 
support that the repair pathway choice is largely dependent on the cell-cycle 
phase: HDR is active in late S/G2 phases and suppressed in other cell cycle 
phases whereas NHEJ is active in all cycle phases (Hustedt & Durocher, 2016).  
Suppressing the NHEJ or enhancing the activity of HDR by gene knockdown, 
small molecules (Chu et al., 2015; Maruyama et al., 2015; Pinder et al., 2015; 
Robert et al., 2015; J. Song et al., 2016; Srivastava et al., 2012; Yu et al., 2015), 
or engineered proteins (Canny et al., 2018; M. Charpentier et al., 2018; Nambiar 
et al., 2019) can improve the efficiency of HDR (Yeh et al., 2019). To increase 
the effectiveness of HDR by using the cell-cycle dependence of repair pathway 
choice, different chemical inhibitors have been used to synchronize the cell cycle.  
They function to arrest the cells in G2 and/or M phase and narrow down the 
timing of Cas9 editing (S. Lin et al., 2014; D. Yang et al., 2016). Although this 
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cell-cycle synchronization strategy improves HDR efficiency, it will be difficult to 
implement in animals and humans. An alternate approach to enhance the HDR 
efficiency is an endogenous regulation to control Cas9 activity by restricting the 
Cas9 editing to S/G2 phases and inhibiting Cas9 in the G1 phase by anti-
CRISPR proteins.  
To this end, we adopted the FUCCI (Fluorescence Ubiquitin Cell Cycle Indicator) 
system developed originally by Sakaue-Sawano et al. (2008) for degron-
mediated proteolysis of Cas9 and anti-CRISPR proteins. The FUCCI technology 
takes advantage of two components of the DNA replication control system: the 
licensing factor Cdt1 and its inhibitor Geminin (Sakaue-Sawano et al., 2008; 
Zielke & Edgar, 2015). Cdt1 and Geminin protein abundance oscillate during the 
cell cycle: Geminin levels are high during S/G2 phase, but low in M/G1 phase 
while Cdt1 protein peaks in the G1 phase (with a steep decline in the S phase) 
(Arias & Walter, 2007). This reciprocal expression of Geminin and Cdt1 is 
mediated by E3 ubiquitin ligases APC/CCdh1 and SCFSkp2, respectively. In the 
FUCCI system, degron sequences derived from Geminin (hGem1-110) and Cdt1 
(hCdt130-120) are fused to fluorescent proteins to monitor the cell cycle 
progression (Sakaue-Sawano et al., 2008; Zielke & Edgar, 2015). We 
repurposed this system so that the degrons are transferred to Cas9 and anti-
CRISPR proteins to improve HDR efficiency by restricting Cas9 editing to S/G2 
phases and preventing the editing in other phases using anti-CRISPRs. The 
degrons will promote the degradation of each protein in the respective cell cycle 
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phases: Cas9 with M/G1-specific hGem1-110 degron will be degraded in the M/G1 
phase and Acr with S/G2-specific hCdt130-120 degron will be degraded in the S/G2 
to permit Cas9 editing and HDR. This approach will be described in more detail 
in the section 3.2.1. 
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3.1.2 Enhancing target specificity often requires engineering nucleases  
Another challenge of using CRISPR-Cas9 is a safety concern over off-target 
gene editing. For instance, studies have shown that high expression of Cas9s 
leads to a prolonged activity and increased off-target cleavages (Cameron et al., 
2017; Hsu et al., 2013; S. Kim et al., 2014) and limiting Cas9 concentration may 
help reduce off-target activity (Cameron et al., 2017; Hsu et al., 2013; S. Kim et 
al., 2014). Unlike traditional gene editors such as ZFNs or TALENs, which are 
designer nucleases that have been optimized for highly specific DNA targeting 
via protein engineering, CRISPR systems, though easily programmable, are 
often prone to off-target editing. Various methods have been developed to 
improve the specificity by modifying either guide RNA scaffolds or nucleases 
themselves (D. Kim et al., 2019).  
One interesting protein engineering approach is to combine the CRISPR 
nuclease with a programmable DNA binding domain (pDBD; such as ZFNs or 
another Cas9 ortholog) to ensure enhanced specificity while retaining the robust 
on-target activity (Bolukbasi et al., 2015, 2018). In this platform, Cas9 has 
reduced binding affinity to the target DNA due to the mutations introduced in the 
residues involved in PAM recognition. A PAM-attenuated SpyCas9 (SpyCas9MT3) 
fused to a pDBD enables SpyCas9 binding to be dependent on the pDBDs 
(Bolukbasi et al., 2015). The first step is mediated by pDBD recognition of a 
sequence downstream of the PAM. The increased local concentration of 
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SpyCas9MT upon pDBD binding facilitates the recognition of the PAM and 
unwinding of the target DNA (R-loop formation) and subsequent DNA cleavage 
based on the sufficient complementarity between the sgRNA and the target site. 
These additional licensing steps, therefore, restrict editing by the Cas9 nuclease 
to the intended on-target site while suppressing off-target editing. ZFNs, 
TALENs, or orthogonal dCas9s can serve as the pDBD (Bolukbasi et al., 2015, 
2018). The biggest advantage of using a pDBD is the enhancement of target 
binding and near elimination of off-target activity of Cas9. Although Nme1Cas9 is 
intrinsically hyper-accurate, an extra layer of accuracy can help eliminate even a 
low risk of off-target activities where precision is paramount as is in gene therapy 
applications. For this reason, we previously developed a Nme1Cas9-pDBD 
platform based on the SpyCas9 system (Amrani et al., in preparation). In section 
3.2.2, we show that the inhibition of Nme1Cas9 by anti-CRISPRs proteins can be 
also extended to the chimera Nme1Cas9-pDBD, validating that these anti-
CRISPR proteins can be used as potent off-switches for a large fusion protein in 
genome engineering applications.  
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3.2 Results 
3.2.1 Anti-CRISPRs with cell-cycle-dependent degrons improve HDR 
In eukaryotes, DSB repair pathway choice is largely dependent on the cell cycle: 
HDR is active only in S/G2 phases whereas NHEJ is active throughout the cell 
cycle (Hustedt & Durocher, 2016) (Figure 3.1A). To enhance the efficiency of 
HDR with minimal perturbations in cells, we took advantage of the cell-cycle 
dependence of DSB repair pathway choice and degron-mediated proteolysis 
(Figure 3.1B). One of the proteins that oscillates during the cell cycle is Geminin, 
an inhibitor of a replication licensing factor, Cdt1. Geminin is a direct substrate of 
the anaphase-promoting complex (APC)/Cdh1, a protein-ubiquitin ligase that is 
active in late M/G1 phases and promotes degradation of target substrates by 
ubiquitination (Arias & Walter, 2007). Previously, SpyCas9 was fused to the first 
110 amino acids of Geminin containing a destruction box motif, designated as a 
human Geminin degron (hGem1-110) (Gutschner et al., 2016). This increased the 
HDR efficiency by promoting degradation of SpyCas9 in the G1 phase when 
HDR is not active; however, the effects were modest (<2-fold), probably due to 
residual SpyCas9 activity from the incomplete degradation (Gutschner et al., 
2016). Cas9 editing in the G1 phase may result in indels if DSBs are repaired by 
NHEJ and can reduce the number of available sites that can be targeted for HDR 
(Figure 3.1B). To further restrict Cas9 editing to S/G2 phases by preventing its 
activity in G1 phase, we used anti-CRISPR proteins to inactivate Cas9 in the G1 
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phase, but permit editing in the S/G2 phases by fusing Acr to a degron from the 
licensing factor, Cdt1. 30-120 aa of human Cdt1 (hCdt130-120) is targeted for 
ubiquitination and degradation by Skp, Cullin, F-box containing complex 
(SCF)/Skp2 in S/G2 phases (Zielke & Edgar, 2015). We hypothesized that 
restricting the activity of Cas9 strictly to the S/G2 phases will enhance HDR 
efficiency.  
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Figure 3.1 Cell-cycle dependence of DSB repair pathways. (A) Left: Cell-
cycle dependent DSB repair: NHEJ (blue) and HDR (red). Right: Cas9 editing 
window can be tailored to mirror HDR activity throughout the cell cycle. While 
SpyCas9-hGem is degraded in the M/G1 phase, AcrIIA5-hCdt1 is degraded in 
the S/G2 phase when HDR activity is high. The activity of protein-ubiquitin 
proteases APC/Cdh1 and SCF/Skp2 that mediate cell-cycle progression is 
responsible for cell-cycle-dependent degradation of hGem and hCdt1 fused 
proteins, respectively. (B) A schematic of how Cas9 and anti-CRISPR degron 
fusion proteins would help increase the HDR:NHEJ ratio throughout the cell 
cycle. 
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Engineering AcrIIA5-hCdt1 for cell-cycle-dependent inhibition of Cas9 
Since SpyCas9-hGem construct is already validated and available to test our 
hypothesis using Type II-A anti-CRISPR proteins, we chose to engineer AcrIIA5 
for cell-cycle dependent degradation (Figure 3.2A). AcrIIA5 can work not only 
against SpyCas9 but also other types of Cas9 that are commonly used in 
genome editing, therefore maximizing its utility. Although Acrs are generally small 
and do not require an NLS for efficient nuclear import, we added an NLS on the 
C-terminus of Acr as well as a FLAG epitope tag, followed by hCdt1 degron 
sequences. 
To estimate the efficiency of HDR and NHEJ, we took advantage of the TLR-
MCV1.0 cell line, a modified traffic-light reporter (TLR) system (Certo et al., 2011; 
Iyer, Mir, et al., 2019) (Figure 3.2B). Briefly, a TLR locus consists of a broken 
eGFP cassette interrupted by an artificial fragment of target sites for different Cas 
effector proteins and an out-of-frame mCherry ORF downstream of the eGFP 
and a self-cleaving peptide T2A. Providing Cas9 and sgRNA targeting the broken 
eGFP will result in indels that can be repaired by either NHEJ or HDR if the 
eGFP donor is supplied. Therefore, a DSB will result in eGFP fluorescence if 
repaired by HDR, or mCherry if repaired by NHEJ (Figure 3.2B) (Certo et al., 
2011; Iyer, Mir, et al., 2019; Mir, Alterman, et al., 2018). This system allows us to 
easily evaluate the efficiencies of each repair outcome based on the green or red 
fluorescence by flow cytometry.  
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We generated a stable HEK293T cell line expressing the TLR system as well as 
AcrIIA5-hCdt1 (Figure 3.2B). Then SpyCas9 or SpyCas-hGem plasmids were 
transiently transfected in these cell lines along with donor templates. We tested 
the effect of different exogenous eGFP DNA donor types: a plasmid donor, a 
linear dsDNA, or a TEG-modified dsDNA (Figure 3.2C). 
A plasmid dsDNA donor was used as a template to generate a linear dsDNA and 
a TEG donor by PCR amplification. For TEG donors, custom primers with the 5’ 
end modification were used for PCR. The TEG donor consists of 2′OMe-
RNA::TEG at both 5’ ends of the DNA donor. The 5′ addition of either TEG or 
2′OMe-RNA has been shown to dramatically improve HDR potency and these 
modifications retain its high potency across dsDNA, ssDNA, and ssODN donors 
(Ghanta et al., 2018). 
Next, we tested combinations of the following: 1) TLR cell line or mTLR-AcrIIA5-
hCdt1 cell line, 2) SpyCas9 or SpyCas9-hGem, and 3) plasmid, linear, or TEG 
donor. We then used flow cytometry to score the efficiencies of HDR (GFP+) and 
NHEJ (mCherry+) in the total cell population to determine the absolute and 
relative HDR efficiencies (Figure 3.2D).  
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Figure 3.2 Experimental overview of testing Cas9 and anti-CRISPR proteins 
with cell-cycle-dependent degrons. (A) Schematic of plasmids constructs. 
NLS, nuclear localization signal; HA, Hemagglutinin tag; FLAG, Flag epitope tag. 
(B) Generation of a stable cell line by a lentiviral transduction of a variation of a 
traffic-light reporter (TLR) system from Certo et al. (2011). Resulting HEK239T-
mTLR2.0 expresses AcrIIA5-hCdt1 (mTLR-AcrIIA5-hCdt1). (C) Schematic 
representation of donor types tested in the current study. TEG donor, dsDNA 
donor with 2′OMe-RNA::TEG moieties covalently attached to 5′ ends of each 
DNA strand and PNA::NLS is annealed to the RNA overhangs. Linear dsDNA 
donor is produced by PCR amplification of the circular dsDNA plasmid donor. (D) 
The workflow of transfecting the stable cell lines with plasmids expressing 
SpyCas9 variants and sgRNA targeting the TLR locus and analyzing cells by flow 
cytometry.  
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A combination of AcrIIA5-hCdt1 and TEG donor improve HDR:NHEJ ratio 
To evaluate the effect of SpyCas-hGem in our system, the TLR reporter cell line 
was transiently transfected with either SpyCas9 or SpyCas9-hGem along its 
sgRNA targeting the TLR locus. A TLR cell line expressing AcrIIA5-hCdt1 
(mTLR-AcrIIA5-hCdt1) was also tested with SpyCas9 and SpyCas9-hGem to 
determine if we can observe the effect of AcrIIA5-hCdt1 alone and additive or 
synergistic effects from the combination of two degron systems for Cas9 and 
anti-CRISPR proteins. AcrIIA5 in the stable TLR cell line decreased (~50% 
reduction) the editing efficiencies (mCherry) compared to that of the TLR cell line 
without the AcrIIA5 (Figure 3.3A). The overall editing efficiencies may be 
decreased due to the incomplete degradation of AcrIIA5-hCdt1 in S/G2 phases 
that still may inhibit Cas9 editing. To better visualize the relative efficiency of 
HDR occurrences and the inhibition of NHEJ by AcrIIA5-hCdt1, we calculated the 
ratio of GFP positive cells to mCherry positive cells (HDR:NHEJ) (Figure 3.3B). 
We observed increased events of HDR compared to NHEJ in the following order: 
SpyCas9 = SpyCas9-hGem < SpyCas9 + AcrIIA5-hCdt1 = SpyCas9-hGem + 
AcrIIA5-hCdt1. We anticipated either synergistic or additive effects from 
combining both SpyCas9-hGem and AcrIIA5-hCdt1, however, we could not 
detect any improvement from SpyCas9-hGem alone, to begin with. Therefore, we 
observed a maximum of ~3-fold improvement of HDR:NHEJ ratio primarily due to 
the AcrIIA5-hCdt1 contribution.  
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Based on the HDR:NHEJ ratios for each tested condition, TEG donors 
outperformed other types of donors by ~4-fold (Figure 3.3B). AcrIIA5-hCdt1 
improved the ratio significantly regardless of the donor types, confirming its 
compatibility for various types of applications. The editing with TEG donors alone 
can increase HDR:NHEJ ratio, but in conjunction with AcrIIA5-hCdt1, further 
improvement can be achieved. 
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Figure 3.3 AcrIIA5-hCdt1 and TEG donors improve HDR efficiency. (A) The 
absolute efficiency of repair outcomes is calculated based on the % GFP+ cells 
(HDR) and % mCherry+ cells (NHEJ) after transfecting plasmids encoding 
SpyCas9 or SpyCas9-hGem in either mTLR or mTLR-AcrIIA5-hCdt1 cell line. (B) 
Summary of relative HDR:NHEJ ratios obtained from testing a combination of cell 
lines, Cas9s, and different donors. Statistical significance is determined by 
multiple t-tests. 
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3.2.2 Application of anti-CRISPR proteins for Cas9 fusion platforms 
Cas9-pDBD fusion proteins improve activity and precision of Cas9 
A PAM attenuated SpyCas9 fused to a pDBD offers an expanded platform for 
high specificity and targeting range (Bolukbasi et al., 2015, 2018). Similarly, 
mutations in some residues in the PID attenuate Nme1Cas9 binding to target 
DNA (Amrani et al., in preparation). We used a single mutant (R1025A) and the 
double mutant (K1013A/R1025A) [referred to as single mutant (SM) and double 
mutant (DM), respectively] that show the most prominent weakening of 
Nme1Cas9 intrinsic DNA binding affinity with the canonical PAM (Amrani et al., in 
preparation). Reduced affinity for PAM recognition of Cas9 variants requires an 
additional DNA binding domain to bind and cleave target DNA, which bolsters the 
high binding affinity and accuracy of the nuclease. We tethered Nme1Cas9 
mutants to ZFPs, which are DNA-binding domains that would theoretically 
augment the efficiency and precision of target recognition. This platform 
dramatically improved the precision and efficiency of Nme1Cas9 targeting in 
mammalian genome editing (Amrani et al., in preparation). We tested whether 
these large fusion proteins are still amenable to anti-CRISPR inhibition. 
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Figure 3.4 Type II-C anti-CRISPRs inhibit Nme1Cas9-pDBD fusion proteins. 
(A) Lesion frequencies from NTS25 genomic site by Nme1Cas9 and 
Nme1Cas9SM-Zif268 fusions. TIDE analysis shows that all AcrIIC families inhibit 
Nme1Cas9WT editing, however, AcrIIC2Nme has no inhibitory effect on Zif268-
Nme1Cas9WT while potently inhibiting attenuated Zif268-Nme1Cas9SM. Error bars 
indicate ±s.e.m. from three independent biological replicates. (B) AcrIIC2Nme has 
no inhibition effect on Nme1Cas9WT pDBD fusions at the NTS1C on-target site 
(top) but can inhibit pDBD-Nme1Cas9WT at the NTS1C-OT1 off-target site 
(bottom). 
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Inhibition of Cas9-pDBD proteins by anti-CRISPR proteins 
To examine the ability of Type II-C Acr proteins to inhibit Nme1Cas9-pDBD 
genome editing, we co-transfected HEK293T cells transiently with plasmids 
expressing the anti-CRISPR protein, Nme1Cas9, and sgRNA targeting the 
NTS25 genomic site. We then used both T7E1 and TIDE to estimate genome 
editing efficiencies (Figure 3.4). In agreement with our previous findings, the 
expression of Acrs dramatically reduced Nme1Cas9-mediated mutagenesis in 
the presence of Nme1Cas9WT (Figure 3.4A). As expected for Nme1Cas9SM, we 
did not observe any editing even without any anti-CRISPR proteins since 
Nme1Cas9SM without the pDBD cannot bind to the target DNA. Upon tethering 
the ZFP to Nme1Cas9SM (Zif268-Nme1Cas9SM), the activity of Cas9 cleavage is 
restored and even augmented in the absence of Acrs. The observed increase in 
editing efficiency is nearly eliminated in the presence of anti-CRISPR proteins 
(Figure 3.4B). All Type II-C Acrs, except AcrIIC2Nme, inhibited the cleavage 
activity of the wild-type as well as the ZFP-Nme1Cas9 fusion protein (Figure 
3.4A). Surprisingly, while AcrIIC2Nme inhibits Nme1Cas9WT, it fails to inhibit 
Nme1Cas9WT fused to a ZFP. This observation motivated us to test whether 
AcrIIC2Nme could prevent off-targeting activities of Nme1Cas9WT fused to a pDBD 
without inhibiting on-target site editing. We chose NTS1C genomic site and its 
validated off-target site (NTS1C-OT1) to test how AcrIIC2Nme affects the editing 
efficiency at two distinct sites. We used one of programmed five-finger domains 
(Zif2) to recognize sequences located downstream of GATT PAM of the NTS1C 
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target site. Indeed, when AcrIIC2Nme was co-expressed, Nme1Cas9WT fused to 
either N-terminal or C-terminal ZFP was still able to edit the NTS1C on-target site 
but not the NTS1C-OT1 off-target site (Figure 3.4B). 
Cas9-Cas9 fusion proteins expand the utility of Cas9 genome editing 
In the chimera between the PAM-interaction attenuated Cas9 and pDBD, the 
pDBD provides an additional stage of target site licensing prior to cleavage, thus 
enhancing the targeting range, efficiency, and specificity (Bolukbasi et al., 2015; 
Amrani et al., in preparation). However, the generation of functional pDBD 
fusions is not as easy as Cas9’s programmability using guide RNAs. To this end, 
orthogonal Cas9-Cas9 fusion proteins have also been developed to facilitate the 
adoption of the RNA-programmable binding platform of Cas9 instead of pDBD 
(Bolukbasi et al., 2018). In a single- or a dual-nuclease format, Cas9-Cas9 
fusions have an expanded targeting range as well as high specificity for genome 
editing. In particular, a pair of orthogonal wild-type Cas9s have been combined to 
facilitate precise segmental deletions via simultaneous DNA cleavage events by 
the fused Cas9 orthologs (including SpyCas9-Nme1Cas9) (Bolukbasi et al., 
2018). Since there are anti-CRISPR proteins for a variety of Cas9 orthologs, we 
anticipate their utility in these platforms as well. 
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Figure 3.5 Inhibition of Cas9-Cas9 fusion proteins by anti-CRISPR proteins. 
(A) T7E1 digestion shows editing patterns of wild-type (WT) Nme1Cas9 (lane 
1,4; green asterisks) and SpyCas9 (lane 8; magenta asterisks) at their NTS33 
and STS3 genomic target sites, respectively. (B) With a PAM-attenuated version 
of SpyCas9 (SpyCas9MT3) fused to dNme1Cas9, genome editing by the nuclease 
activity of SpyCas9 was prevented by AcrIIC3Nme, AcrIIC4Hpa, or AcrIIC5Smu. (C) 
Type II-C anti-CRISPR proteins specifically block Nme1Cas9WT editing in a 
fusion of wild-type Cas9 proteins (SpyCasWT/Nme1Cas9WT). Left: A deletion of 
genomic DNA resulting from active SpyCasWT/Nme1Cas9WT is detected by PCR 
(yellow diamonds). Right: The same PCR amplicon analyzed by T7E1 digestion 
shows distinguishable editing patterns of each Cas9. Nme1Cas9 editing (green 
asterisks) is only seen with AcrE2 or AcrIIC2Nme (the least potent inhibitor in 
mammalian cells), while SpyCas9 editing is observed in the presence of all the 
Type II-C Acrs.  
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Inhibition of orthogonal Cas9-Cas9 fusion proteins by anti-CRISPR proteins 
When the wild-type Nme1Cas9 and SpyCas9 were expressed separately as a 
monomeric form, each Cas9 ortholog efficiently cleaved at the respective target 
site within the vicinity of each other as indicated by the unique band cleavage 
patterns for each nuclease (Figure 3.5A). Nme1Cas9WT is inhibited by all AcrIIC 
families (AcrIIC1-5), though less efficiently by AcrIIC2. When SpyCas9MT3 fused 
to dNme1Cas9 (in place of pDBD) was expressed along with its cognate sgRNA, 
only AcrIIC3Nme, AcrIIC4Hpa, and AcrIIC5Smu inhibited genome editing since 
AcrIIC3-5 interfere with DNA binding activity of Nme1Cas9 (Figure 3.5B). The 
suppression of genome editing by SpyCas9MT3-dNme1Cas9 indicates that these 
Type II-C anti-CRISPRs can serve as SpyCas9 editing off-switches in this 
context. As expected, AcrIIC1 orthologs do not inhibit editing by SpyCas9MT3-
dNme1Cas9 since AcrIIC1 does not affect the dNme1Cas9 binding. (Figure 
3.5B). Furthermore, we tested anti-CRISPR proteins against dual-nuclease 
fusion proteins (SpyCas9WT/Nme1Cas9WT) that can create a segmental deletion 
(Figure 3.5C). With non-cognate AcrE2 or a weak inhibitor such as AcrIIC2, a 
band corresponding to the size of the deletion can be detected by PCR (Figure 
3.5C). On the other hand, type II-C anti-CRISPRs that inhibit editing activity of 
Nme1Cas9 in the fusion context led to the appearance of small indels at the 
SpyCas9 site rather than a segmental deletion as shown by the T7E1 assay 
(Figure 3.5C). These data from mammalian cells confirm the potential utility of 
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Type II anti-CRISPRs proteins for modulating Cas9-dependent genome 
engineering. 
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3.3 Discussion 
Unintentional DSBs can induce genomic instability by disrupting gene structure 
and function or by inducing chromosomal rearrangements (Kosicki et al., 2018), 
therefore numerous cellular machinery is in place for immediate repair (Ciccia & 
Elledge, 2010). In principle, all DSB repair pathways may compete for access to 
free DNA ends. However, the two major DSB repair pathways, canonical NHEJ 
and HDR, are dominant in the repair of a conventional DSB. In addition to two 
major DSB repair pathways, there are other competing error-prone pathways 
such as single-stranded annealing (SSA), alternative end-joining (a-EJ), or 
microhomology-mediated end-joining (MMEJ) (Scully et al., 2019). The choice of 
repair pathway is dependent on various cellular factors including the cell-cycle 
stages and the local chromatin environment (Chapman et al., 2012). 
In the first half of this chapter, our goal was to take advantage of the cell-cycle-
dependence of the HDR pathway for controlling Cas9 activity to improve precise 
genome editing. We adopted the degron-mediated FUCCI system (Sakaue-
Sawano et al., 2008) to sync the expression of Cas9 and anti-CRISPR proteins 
to cell cycles. Using a TEG-modified donor and AcrIIA5-hCdt1 with SpyCas9, 
HDR increased up to 2.4-fold. A TEG donor showed the highest ratio of 
HDR:NHEJ compared to plasmid or linear dsDNA donors. Previously, SpyCas9-
hGem has been shown to improve HDR by ~1.8-fold in mammalian cells 
(Gutschner et al., 2016), however, we did not observe any improvement using 
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SpyCas9-hGem alone. We believe this may be a result of overexpression of 
SpyCas9-hGem due to the nature of transient transfection, while AcrIIA5-hCdt1 
is expressed at lower levels from endogenous loci in a stable cell line. 
The current study is limited to testing in an artificial reporter cell line, therefore 
making it difficult to generalize the overall performance of our system. Future 
studies will require testing in different model systems (e.g. cell lines, organisms) 
as well as at endogenous loci for different target sites to thoroughly investigate 
the efficacy of using the cell-cycle-dependent degron system. Variations in 
different sites and cell lines will reflect how differences in genomic architecture 
and cellular DNA repair availability affect HDR. 
Although we observed improvement of the HDR:NHEJ ratio using AcrIIA5-hCdt1, 
we also lost overall editing activity. One way to mitigate the issue of improving 
HDR efficiency at the cost of reduced overall editing efficiency is to use a weaker 
promoter to drive Acr expression or a less potent Acr in mammalian cells. This 
fine-tuning process will optimize Acr activity to inhibit Cas9 in the G1 phase, but 
allow maximal editing in other cell cycle stages for efficient HDR. 
Although the HDR:NHEJ ratio increased when AcrIIA5-Cdt1 was used, the slight 
increments did not achieve significant improvement with this strategy. Current 
methods were proposed to minimize the external perturbation to the systems, as 
a balance of DSB repair pathways is necessary for maintaining genomic stability 
in normal cellular states (Ciccia & Elledge, 2010). Harnessing the cellular repair 
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machinery and pathway choice to our advantage may require complementary 
methods such as NHEJ inhibitors or HDR promoting small molecules (Chu et al., 
2015; G. Li et al., 2017; Maruyama et al., 2015; Yeh et al., 2019). Overall, we 
have demonstrated that anti-CRISPRs can be fused to a cell-cycle-dependent 
degron to increase HDR events relative to NHEJ in human cells. 
In the second half of this chapter, we show evidence that engineered variants of 
Cas9 nucleases are amenable to anti-CRISPR off-switches, demonstrating their 
utility across multiple applications and editors. Catalytically inactive Cas9 
enabled the expansion of numerous applications for tethering any types of 
effector proteins of interest (Adli, 2018). In addition to the platforms that rely on 
dCas9 fused to heterologous proteins such as fluorescent proteins, 
transcriptional regulators, and epigenetic modifiers, there are other Cas9 fusion 
platforms. One such example is a chimeric protein between PAM-attenuated 
SpyCas9 and a pDBD that has been shown to increase targetability and 
accuracy (Bolukbasi et al., 2015). 
We show that the fusion of a pDBD likewise augments the binding and nuclease 
activity of Nme1Cas9 (Amrani et al., in preparation). Although Nme1Cas9 is 
naturally hyper-accurate, Nme1Cas9 generally exhibits lower nuclease activity 
than SpyCas9, possibly due to inefficient unwinding of the target DNA (E. Ma et 
al., 2015). Tethering a pDBD confers Nme1Cas9 high-affinity binding to 
suboptimal genomic sites to provide sufficient residence time to facilitate the 
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efficient R-loop formation. Thus, Nme1Cas9WT-pDBD chimera can serve as both 
an efficient and precise editor. 
From our studies, all known Type II-C Acrs dramatically reduced Zinf268-
Nme1Cas9WT mediated mutagenesis except AcrIIC2Nme. A plausible explanation 
for this observation may be attributed to how AcrIIC2Nme inhibits Nme1Cas9. 
AcrIIC2Nme interacts with the bridge helix motif of Nme1Cas9, thereby interfering 
with sgRNA loading onto the Cas9 and binding to the target DNA. For this 
reason, as well as a low level of protein accumulation, AcrIIC2Nme has been 
previously documented as the weakest inhibitor among the Type II-C Acrs 
(Pawluk, Amrani, et al., 2016). It is plausible that the Nme1Cas9 brought to the 
target site via a ZFP increases the local concentration of the Nme1Cas9 that 
could lead to cleavage when engaged with its sgRNA. AcrIIC2Nme inhibits 
Nme1Cas9WT but fails to completely inhibit Zinf268-Nme1Cas9WT, suggesting 
that the binding conferred by the ZFP may help Cas9 overcome the AcrIIC2Nme 
inhibitory barrier and increase the probability of engaging with the target site for 
cleavage. 
A combination of Nme1Cas9WT-pDBD and AcrIIC2Nme could be useful for 
reducing off-target editing without inhibiting cleavage of the on-target site. Since 
off-target sites lack ZFP binding sites, Nme1Cas9WT-pDBD fusion protein most 
probably does not lead to off-target editing, however, using anti-CRISPR proteins 
in this context will also reduce the efficiency of on-target editing. Unlike other 
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potent Acrs, AcrIIC2Nme still permits editing by Nme1Cas9WT-pDBD since Cas9 
can recognize the PAM, bind to a target DNA, and uses the sgRNA 
complementarity for cleavage of the on-target site. This observation is somewhat 
analogous to reducing off-target editing using an artificially weakened anti-
CRISPR protein fused to SpyCas9 (Aschenbrenner et al., 2020). Using a 
relatively weaker anti-CRISPR protein allows editing at the on-target site, but not 
at the off-target site, due to differential Cas9 binding affinity and cleavage 
kinetics. Such strategies can be useful alternatives since they bypass the 
difficulty faced in other approaches such as timed delivery of anti-CRISPR 
proteins to reduce off-targeting (Shin et al., 2017). 
Furthermore, the specificity of an anti-CRISPR protein to inhibit its cognate Cas9 
in the orthogonal Cas9-Cas9 fusion context enables precise control of the Cas9 
of interest to achieve the desired editing outcome. For instance, the co-
expression of Acrs for both Cas9 orthologs will inhibit deletion altogether, while 
the expression of only one Acr for each Cas9 will result in indels.  
In summary, we demonstrate that the inhibition of Nme1Cas9 by anti-CRISPR 
proteins can be extended to Nme1Cas9-pDBD, specifically, Nme1Cas9 fused to 
a ZFP or to another orthogonal Cas9. Validating that these anti-CRISPR proteins 
can be used as potent off-switches for larger fusion Cas9 proteins opens the 
door to regulating broad applications in the genome engineering field.  
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3.4 Materials and Methods 
Plasmid vector construction 
Appendix Table 2 contains plasmids used in this chapter.  
Plasmid vectors for Cas9 and anti-CRISPR with cell-cycle-dependent degron 
A pCSDest2-SpyCas9-hGem construct is a gift from Dr. Scot A. Wolfe. AcrIIA5 
sequence was codon-optimized for mammalian expression and ordered as a 
gene block (IDT). To make AcrIIA5-hCdt1 expression plasmid, the hCdt1 
sequence was amplified from an ES-FUCCI plasmid, a gift from Pierre Neveu 
(Addgene #62451) and inserted into the pEJS1004-pCSDest2-AcrIIA5-FLAG-
NLS vector by Gibson assembly (NEB). For a lentiviral transduction plasmid, 
pLenti-vector with a hygromycin selection marker was used to make a version 
that has hCdt1 using Gibson assembly (NEB), resulting in pEJS1033-pLenti-
AcrIIA5-Cdt1-HygR. 
HDR donor constructs 
An eGFP plasmid donor is pEJS716-GFP from the Sontheimer lab. The linear 
dsDNA donor was generated by PCR amplification using the plasmid donor. The 
TEG donor was similarly made but using custom primers that have 5’ end 
modifications for each primer (IDT). After amplification, PCR fragments were 
directly used after column purification. 
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Plasmid vectors for Nme1Cas9-pDBD experiments 
An all-in-one plasmid was used for the expression of Nme1Cas9 variants and 
sgRNAs for NTS25 or NTS1C target sites (Amrani et al., 2018). Anti-CRISPR 
expressing vectors are the same as plasmids previously described in Chapter 2. 
Cell culture 
Lentiviral transduction 
A version of a traffic light reporter in HEK293T cells (mTLR-MCV2.0) was 
previously generated in the Sontheimer lab. The lentiviral transduction was 
performed as follows. Viruses were produced and collected by transfecting 
HEK293T (ATCC) with the lentiviral vector plasmid pEJS1033-pLenti-AcrIIA5-
Cdt1-HygR that expresses AcrIIA5-hCdt1 and packaging helper plasmids (VSV-
G and ΔR8.2). HEK293T-mTLR-MCV2.0 target cells were transduced with the 
viruses and then selected with hygromycin, resulting in the mTLR-AcrIIA5-hCdt1 
cell line. 
Transient transfection 
For mTLR reporter experiments, stable cell lines were transiently transfected with 
SpyCas9 or SpyCas9-hGem, sgRNA targeting the TLR locus (pEJS760-
Spy.sgRNA.STS118), and donor templates (plasmids or PCR fragments) using 
PolyFect (Qiagen). For genome editing experiments, plasmids for Cas9s, 
 
 
150 
respective sgRNAs, and anti-CRISPRs were transiently transfected in HEK293T 
cells using PolyFect (Qiagen). The total amount of DNA was equal in all 
transfections. 
Flow Cytometry 
48 hr post-transfection cells were analyzed on a MACSQuant® VYB from 
Miltenyi Biotec. FlowJo® v10.4.1. was used for gating single cells based on FSC-
A and FSC-H. The percentage of cells expressing mCherry and GFP was used 
to estimate the Cas9-mediated editing efficiency of NHEJ and HDR, respectively. 
Genome editing assay 
72 hr post-transfection, cells were harvested and gDNA was extracted with the 
DNeasy Blood and Tissue kit (Qiagen) and then was used for PCR amplification 
[High Fidelity 2X PCR Master Mix (NEB)] with primers flanking the targeted site. 
PCR products were heat-denatured, re-annealed, and digested with T7 
Endonuclease I (NEB). For the detection of a deletion outcome, T7E1 was 
omitted. The samples were visualized in a 2.5% agarose/1xTAE gel and 
quantified with the ImageMaster-TotalLab program. Indel percentages were 
calculated as previously described (Guschin et al., 2010). Alternatively, indel 
frequencies were estimated by Sanger sequencing followed by analysis using 
TIDE (Brinkman et al., 2014) or ICE (Synthego).  
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Chapter 4 Tissue-restricted genome editing in vivo by miRNA-repressible 
anti-CRISPRs 
4.1 Introduction 
Despite Cas9’s potential in gene therapy, many hurdles must be overcome 
before it can be used in clinical applications: delivery of Cas9, off-target editing, 
non-target tissue editing, and persistent activity after the intended editing (Carroll, 
2014). Therapeutic uses of Cas9 often require editing only in certain cell types or 
tissues, which have been aided by use of tissue-specific promoters and AAVs 
that have some selectivity in tissue tropism. However, these promoters can be 
weak or leaky and AAV serotypes still have imperfect tissue specificity (Kanegae 
et al., 2011; Zincarelli et al., 2008). Tissue-specific Cas9 editing is necessary to 
protect against undesired chromosomal breaks in non-target tissues. For 
example, Cas9-induced DSB can elicit translocations, which are often associated 
with heritable disorders or various kinds of cancer (J. Jiang et al., 2016; Maddalo 
et al., 2014). Although tissue-specific promoters can be used, some target 
tissues lack promoters that are highly specific and strong enough to drive a 
transgene expression (Kanegae et al., 2011). Moreover, tissue tropic AAV 
serotypes widely used for delivery of therapeutic transgenes can still infect a 
broad range of tissues in vivo (Gao et al., 2004), necessitating additional 
methods of regulation to enforce tissue specificity. Acrs will provide another 
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safeguard against the undesired editing in non-target tissues by inhibiting Cas9 
activity in all ancillary tissues. 
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4.1.1 Background on AAV 
An rAAV is widely used for therapeutic gene delivery due to its minimal 
immunogenicity, rare integration events in the host genome, and long-term 
expression of transgenes (D. Wang et al., 2019). Notably, there is already an 
rAAV gene therapy drug (Luxturna) approved by the US Food and Drug 
Administration (FDA) (Russell et al., 2017) and many other rAAV platforms are 
currently in clinical trials (Mendell et al., 2017). AAVs can package a single-
stranded DNA genome of ~ 4.7kb and specify a tissue-tropism by capsid 
proteins. The single-stranded rAAV (ssAAV) genome is released in the nucleus 
and then converted into a double-stranded form by second-strand synthesis or 
strand annealing (Nakai et al., 2000; Zhong et al., 2008; Zhou et al., 2008). This 
step is required for transcription and is a rate-limiting step. Alternatively, a self-
complementary rAAV genome (scAAV), which has a mutated ITR, enables faster 
and higher gene expression than ssAAV albeit of a half the size of the packaging 
capacity (~2.3kb) (McCarty et al., 2003; Z. Wang et al., 2003). After intra- and 
inter-molecular circularization and concatemerization of dsDNA, the AAV 
genome persists as episomal DNA (D. Duan et al., 1998, 1999).  
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4.1.2 Enhancing tissue-specificity of transgene expression  
Many natural tropisms of AAVs are useful for gene therapy programs that focus 
mainly on the liver, muscles, and the Central Nervous System (CNS) (D. Wang et 
al., 2019). Almost all natural AAV capsids can transduce the liver efficiently and 
some other serotypes such as AAV8 and AAV9 can have broader tropisms, 
targeting multiple muscle types throughout the body (D. Wang et al., 2014).  
Gene expression in off-target tissues or cell types may lead to toxicity or trigger 
an unwanted immune response. Conventional strategies to confine the gene 
expression to targets of interest include using tissue- or cell type-specific 
promoters (Gray et al., 2011). Tissue-specific promoters drive the expression of 
transcripts under the control of native or composite promoters. A native or 
minimal promoter is composed of a core promoter and its natural 5’ untranslated 
region (UTR) (sometimes containing an intron), whereas a composite promoter is 
engineered by combining different promoter elements (e.g. enhancers). More 
compact promoters that usually do not exhibit high specificity are often used for 
gene editing due to the large size of Cas proteins and sometimes guide RNAs as 
well as the donor.  
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4.1.3 A strategy for miRNA-mediated transgene de-targeting 
Another method of restricting transgene expression is using a class of small non-
coding RNAs known as microRNAs (miRNAs), which were first discovered in 
Caenorhabditis elegans (R. C. Lee et al., 1993; Wightman et al., 1993). The 
miRNAs regulate gene expression posttranscriptionally by directing Argonaute 
(AGO) proteins to bind to and repress complementary mRNA targets (Bartel, 
2018; Jonas & Izaurralde, 2015). The mammalian genome encodes four AGO 
proteins (Ago1-4) and Ago2 is the only AGO protein able to cleave the target that 
is fully complementary to the guide strand of the miRNA (J. Liu et al., 2004). 
Some miRNAs are often produced only in specific cell or tissue types (Lagos-
Quintana et al., 2002). Among many other potential miRNA therapeutics, a “de-
targeting” strategy using such tissue-specific miRNAs has opened a new avenue 
in gene therapy to ensure the expression of the therapeutic transgene in the 
correct tissue types while minimizing its expression elsewhere (Broderick & 
Zamore, 2011). The de-targeting strategies incorporate miRNA binding sites in 
the 3′-UTR of a transgene to prevent its expression in cells that are enriched for 
the miRNA while the transgene will be expressed in the intended cell type in 
which the miRNA is not expressed (Brown et al., 2006; Geisler et al., 2011; Qiao 
et al., 2011; Xie et al., 2011).  
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4.2 Results 
4.2.1 A strategy for microRNA-regulated anti-CRISPR proteins 
Delivery of Cas9 and sgRNA via AAV has the potential to induce editing in 
multiple transduced tissues (e.g., heart, skeletal muscle, and elsewhere); 
however, co-delivery of the miRNA-repressible Acr will inhibit editing in such non-
target tissues due to the latter's lack of particular tissue-specific miRNAs. Key 
advantages of regulating the anti-CRISPR expression in the target tissue post-
transcriptionally using tissue-specific, endogenous miRNAs include: 1) strong 
repression will be achieved via mRNA cleavage by using perfectly 
complementary miRNA response elements (MREs), which have been used to 
efficiently repress the expression of transgenes in vivo (Geisler et al., 2011; Qiao 
et al., 2011; Xie et al., 2011); 2) there is a well-established repository for tissue-
specific miRNAs (Landgraf et al., 2007; Ludwig et al., 2016; Rahman et al., 
2020); 3) the system provides the flexibility to switch or multiplex tissue 
specificities by simply changing or combining different MREs; 4) the short length 
of MRE sequences (~22nt) do not burden the packaging capacity of an AAV 
vector. As an example of endogenous miRNA-mediated, post-transcriptional 
repression of anti-CRISPR protein for liver-specific editing, we took advantage of 
microRNA-122 (miR-122), a well-validated miRNA that is highly expressed only 
in hepatic cells. In the target liver tissue, the acr gene with miR-122 MREs (used 
interchangeably with miRNA binding sites) will be repressed, enabling Cas9-
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mediated editing while extrahepatic tissues that lack miR-122 will fail to silence 
the Acr expression (Figure 4.1A). To validate this concept, we chose two well-
established Cas9-Acr combinations: AcrIIC3Nme and Nme1Cas9/Nme2Cas9 
(Type II-C) as well as AcrIIA4Lmo and SpyCas9 (Type II-A). For our in vitro 
validations, Acr expression vectors were identical in every aspect except for the 
presence or absence of MREs in the 3′ UTR. We placed three tandem miR-122 
binding sites (3xmiR122BS) in the 3′ UTR of each Acr gene, which also included 
a carboxy-terminal mCherry fusion to enable expression to be detected by 
fluorescence microscopy or flow cytometry (Figure 4.1B).   
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Figure 4.1 Overview of the Cas9 and microRNA-repressible anti-CRISPR 
system. (A) An example of achieving liver-specific editing using the anti-CRISPR 
repressible by miR-122. Upon systemic delivery of Cas9 in vivo (e.g., via viral 
vectors), tissues receiving Cas9 and sgRNA potentially result in genome editing; 
however, co-delivery of miRNA-repressible anti-CRISPR proteins will prevent 
such editing in non-target tissues that lack miR-122, as depicted in the heart 
(left). In the liver, anti-CRISPR transcripts with perfectly complementary miR-122 
binding sites will undergo Ago2-mediated mRNA degradation, and the resulting 
silencing of the Acr will permit Cas9 editing in the liver (right). (B) A schematic of 
expression vectors for Cas9 orthologs from Type II-A (SpyCas9) and II-C 
(Nme1Cas9 and Nme2Cas9) systems, along with their respective anti-CRISPR 
proteins, AcrIIA4 and AcrIIC3. The Acr expression constructs were generated 
with or without three tandem, perfectly complementary miRNA-122 binding sites 
in the 3′ UTR. CMV, cytomegalovirus promoter; NLS, nuclear localization signal; 
AAAA, poly(A) tail. 
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4.2.2 In vitro validation of microRNA-repressible anti-CRISPR vectors 
We used a human hepatocellular carcinoma cell line (Huh-7) that expresses miR-
122 in high levels in contrast to non-hepatic cell lines such as human embryonic 
kidney (HEK293T) cells (Fukuhara et al., 2012). We transfected cells with 
plasmids expressing AcrIIC3-Flag-mCherry-3xmiR122BS, AcrIIA4-Flag-mCherry-
3xmiR122BS, or their respective control vectors lacking the miR-122 binding 
sites (Figure 4.1B). A separate GFP expression plasmid was also included to 
indicate transfection efficiency in each cell line. When these vectors were 
transiently transfected, the expression of mCherry-fused Acr with miR-122 MREs 
was dramatically suppressed in Huh7 cells whereas Acr-mCherry lacking the 
3xmiR122BS cassette was still well expressed (Figure 4.2A). In HEK293T cells, 
there was no discernible difference in mCherry signal from the Acr and Acr-
3xmiR122BS constructs based on both fluorescence microscopy and flow 
cytometry (Figure 4.2B). The Acr expression was also confirmed by anti-Flag 
western blot analysis. Compared to HEK293T cells, transfection efficiency was 
lower in Huh-7 cells as indicated by a decrease in the overall GFP and mCherry 
signals (Figure 4.2). Nevertheless, fluorescence microscopy, flow cytometry, and 
western blot analysis consistently revealed effective reductions of both AcrIIC3-
3xmiR122BS and AcrIIA4-3xmiR122BS expression in Huh-7, but not in HEK293T 
cells. The expression of Acrs lacking miR-122 MREs was unaffected in both cell 
lines, consistent with effective regulation of Acr by miR-122 only in hepatic cells. 
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Figure 4.2 Validation of miRNA regulation of anti-CRISPR expression in 
cultured cells.   
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(A,B) Hepatocyte-specific silencing of anti-CRISPR expression. Plasmid vectors 
encoding either AcrIIC3-mCherry or AcrIIA4-mCherry, with or without miR-122 
MREs, were transfected into (A) Huh7 cells or (B) non-hepatic HEK293T cells; 
only the former express miR-122. The expression of mCherry and GFP was 
visualized by fluorescence microscopy (top) and analyzed by flow cytometry 
(bottom left). The percentage of mCherry-positive cells in each transfection was 
normalized to the transfection of the control GFP-expressing plasmid. Anti-
CRISPR protein expression was also confirmed by western blot against the 
1xFlag epitope (bottom right). Heat shock protein 60 (HSP60) was used as a 
loading control. Scale bar, 100 µm. 
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4.2.3 Acr repression by miR-122 precludes inhibition in hepatocytes 
Having demonstrated that anti-CRISPR repression in hepatocyte-derived cells 
can be conferred by miR-122 MREs, we then tested whether this repression is 
sufficient to allow genome editing by Cas9 orthologs (Nme1Cas9, Nme2Cas9, 
and SpyCas9). We transiently transfected separate expression plasmids for each 
Cas9, its respective sgRNA, and the cognate Acr, with the latter construct either 
including or omitting miR-122 binding sites. We chose validated, endogenous 
sites in the human genome for each Cas9 ortholog (Figure 4.3). In HEK293T 
cells, AcrIIC3 and AcrIIA4 robustly inhibited genome editing by Nme1/2Cas9 and 
SpyCas9, respectively (Figure 4.3). The presence or absence of miR-122 MREs 
had no significant effect on editing inhibition in HEK293T cells lacking miR-122 
expression. Despite the overall lower transfection efficiencies and variable editing 
efficiency among Cas9 orthologs at the tested target sites, AcrIIC3 and AcrIIA4 
also prevented editing in Huh7 cells when expressed from constructs that lack 
miR-122 MREs. In contrast, Acr plasmids bearing miR-122 MREs in the 3′UTRs 
failed to inhibit Cas9 editing in Huh-7 cells, as indicated by editing efficiencies 
that were similar to the no-Acr control (Figure 4.3). This observation was true for 
all three Cas9 orthologs tested. 
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Figure 4.3 Hepatocyte-specific genome editing by Cas9 orthologs.  
(A-C) HEK293T and Huh7 cells were transiently transfected with plasmids 
encoding cognate sgRNAs for (A) Nme1Cas9, (B) Nme2Cas9, and (C) SpyCas9. 
(A, B) AcrIIC3 constructs with or without 3xmiR122BS were co-transfected. (C) 
AcrIIA4 with or without 3xmiR122BS were co-transfected with SpyCas9. Data 
represent mean ± SD with at least three replicates. Editing efficiencies are 
measured by targeted deep sequencing. 
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4.2.4 MiR-122-dependent genome editing conferred by Acrs in vivo 
For our in vivo tests, we focused on Nme2Cas9 due to its compact size, high 
target site density, and relative lack of off-target editing (Edraki et al., 2018), all of 
which are advantageous for therapeutic development. We used a previously 
validated all-in-one AAV vector that expresses Nme2Cas9 from the minimal U1a 
promoter, as well as a U6 promoter-driven sgRNA targeting Rosa26 (Figure 
4.4A) (Edraki et al., 2018; Ibraheim et al., 2018). We also generated AcrIIC3 
expression plasmids driven by the strong CB-PI promoter that is composed of a 
chicken-beta actin promoter and an intron from SV40 to enhance its ubiquitous 
and robust expression. In addition, these AcrIIC3 constructs either included or 
omitted the three tandem miR-122 MREs in the 3′-UTR (Figure 4.4A). For in vivo 
delivery, we first used hydrodynamic tail vein injection, which is a nonviral 
method of transient hepatocyte transfection that allows expression from naked 
DNA plasmids (G. Zhang et al., 1999). This injection method delivers DNA to 
∼10%-20% of hepatocytes for transient expression and leads to minimal 
transgene expression in organs other than the liver. Since miR-122 is abundant 
in the liver, and because Cas9 delivered to the liver by hydrodynamic injection 
can induce editing (Xue et al., 2014), this experimental approach enables tests of 
liver-specific editing and inhibition of editing in the presence or absence of Acr 
expression. Plasmids were injected into adult, wild-type C57BL/6 mice via tail 
vein and liver tissues were collected at 7 days post-injection(Figure 4.4B). To 
determine the effective dose of Acr plasmid needed to inhibit Nme2Cas9 editing 
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in vivo, we coinjected varying Cas9:Acr plasmid ratios (1:1, 1:1.5, and 1:2). 
AcrIIC3 efficiently inhibited Nme2Cas9 editing at all ratios tested (Figure 4.4C). 
Once we defined the necessary plasmid dose, we subjected three groups of mice 
to hydrodynamic injection with plasmid combinations that included Nme2Cas9 
with (i) no Acr, (ii) AcrIIC3, and (iii) AcrIIC3-3xmiR122BS (Figure 4.4A). In the 
livers of mice receiving no Acr, Nme2Cas9 yielded a mean editing efficiency of 
5.2 ± 1.7% (n = 6 mice), similar to levels seen previously with this and other Cas9 
orthologs upon hydrodynamic injection (Ibraheim et al., 2018; Xue et al., 2014). 
As expected, the coinjection of AcrIIC3 plasmid strongly reduced the editing 
efficiency to 0.33 ± 0.09% (P < 0.0001). In contrast, AcrIIC3-3xmiR122BS failed 
to inhibit Nme2Cas9 editing, with the indel efficiency comparable to no Acr group 
(7.1 ± 3.5%, Fig. 4D). In accordance with our results in human Huh-7 cells, 
endogenous miR-122 in mouse hepatocytes in vivo can be exploited to repress 
Acr expression, and therefore allow tissue-specific Cas9 genome editing, in the 
liver. 
  
 
 
166 
 
Figure 4.4 Anti-CRISPR inhibition of Nme2Cas9 editing in vivo is released 
by liver-specific miR-122. (A) Plasmids used for in vivo studies to drive the 
expression of Nme2Cas9 + sgRNA and AcrIIC3, respectively. U1a, murine 
promoter; BGH, bovine growth hormone poly(A) signal; CB-PI, cytomegalovirus-
enhancer, chicken β-actin (CB) promoter with SV40-derived mini-intron. (B) A 
schematic of mouse tail vein injection studies. Plasmid vectors shown in (A) are 
administered into 8- to 10-wk-old C56BL/6 mice by hydrodynamic injection. Liver 
tissues were collected 1 wk after injection. (C) Dose titration of Nme2Cas9 + 
sgRNA plasmid to AcrIIC3 plasmid in vivo. The percentage of indels at the 
Rosa26 target in the livers of C57Bl/6 mice was measured by targeted deep 
sequencing after hydrodynamic injection of Nme2Cas9 + sgRNA and AcrIIC3 
plasmids at mass ratios of 1:1, 1:1.5, and 1:2. (D) Genome editing in the liver by 
Nme2Cas9 is inhibited by AcrIIC3 but restored when AcrIIC3-3xmiR122BS is 
silenced. Indel percentages at the Rosa26 locus in the livers of C57Bl/6 mice 
were measured by targeted deep sequencing after hydrodynamic injection of 
Nme2Cas9 + sgRNA plasmid, along with AcrIIC3 plasmids with or without 
3xmiR122BS. n = 6 mice per group. ns = not significant, P < 0.05 by unpaired, 
two-tailed t-test.  
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4.2.5 MiRNA-repressible anti-CRISPR inhibits off-tissue genome editing 
To demonstrate that the miRNA-repressible anti-CRISPR proteins can inhibit 
editing in a non-target tissue upon systemic delivery, we designed a dual-AAV 
system in which a ssAAV vector expressing Nme2Cas9 is co-delivered with a 
scAAV expressing an anti-CRISPR protein and a cognate sgRNA (Figure 4.5A). 
We used the scAAV for AcrIIC3 expression to enable the earlier onset of 
transcription (before second-strand synthesis) (McCarty et al., 2003; Z. Wang et 
al., 2003). This expedited AcrIIC3 expression maximizes the likelihood that 
inhibitory levels of the anti-CRISPRs can accumulate before significant ssAAV-
based Nme2Cas9 expression occurs since the latter requires prior synthesis of 
the complementary vector strand. Furthermore, we transferred the U6-driven 
sgRNA cassette from our previously developed all-in-one ssAAV-Nme2Cas9 
vector (Edraki et al., 2018) to the Acr-expressing scAAV vector to ensure that 
editing cannot occur in cells that fail to receive the Acr transgene. These vectors 
were packaged as serotype AAV9, which is known to have a particularly broad 
tissue tropism in mice (Zincarelli et al., 2008). The tail veins of three groups of 
mice were injected with 4 × 1011 genome copies (GC) of ssAAV9-Nme2Cas9 
vector, along with 4 × 1011 GC of either (i) scAAV9-AcrIIC3-sgRNA, (ii) scAAV9-
AcrIIC3-3xmiR122BS-sgRNA, or (iii) scAAV9-AcrIIA4-sgRNA vector (Figure 
4.5B). AcrIIA4 was used as a non-cognate, negative-control anti-CRISPR. Both 
liver and heart tissue samples were collected for indel analysis and histology at 
5-wk post-injection. Consistent with in vivo delivery by hydrodynamic injection, 
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editing in the liver was inhibited by AcrIIC3 but not by AcrIIC3-3xmiR122BS, in 
accord with miRNA silencing of the latter in hepatocytes (Figure 4.5C). In 
contrast, off-target tissue editing in the heart was inhibited by both AcrIIC3 and 
AcrIIC3-3xmiR122BS vectors, indicating that the latter was effectively expressed 
in the absence of miR-122 in cardiomyocytes (Figure 4.5D).  
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Figure 4.5 AAV delivery of a miRNA-repressible AcrIIC3 inhibits Nme2Cas9 
editing in non-target tissue. (A) Design of a dual-AAV9 system for the 
expression of Nme2Cas9, sgRNA, and anti-CRISPR. A ssAAV9 vector encodes 
Nme2Cas9 and a scAAV9 vector encodes an anti-CRISPR protein (AcrIIC3, 
AcrIIC3-3xmiR122BS, or AcrIIA4) as well as a U6-driven sgRNA targeting 
Rosa26. (B) A schematic of mouse studies for AAV9 delivery of the dual AAV 
system shown in (A). Liver and heart tissue samples were collected at 2- and 5-
wk post-injection. (C) Genome editing in liver and heart tissue samples 5-wk after 
AAV delivery. Indel percentages at the Rosa26 locus were measured by targeted 
deep sequencing. For the 5-wk time points, n = 5 mice per group. ns = not 
significant; P < 0.05 by unpaired, two-tailed t-test. Control, PBS-injected. 
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4.2.6 Lack of editing in vivo is not due to lack of Nme2Cas9 expression 
We confirmed the expression of Nme2Cas9 in all three groups by 
immunohistochemistry (IHC) against the 3xHA epitope (Figure 4.6A). Robust 
Nme2Cas9 expression detected by IHC in the liver as well as the cardiac 
muscles at both time points indicates that the lack of editing was indeed due to 
AcrIIC3 inhibition and not due to lack of Nme2Cas9 expression. We were unable 
to detect AcrIIC3 by IHC against the Flag epitope in mice injected with AcrIIC3, 
likely because antibody binding by the 1xFlag tag is too weak for IHC detection 
under these conditions. However, we ruled out the possibility of injection failures 
by using RT-PCR to confirm mRNA expression of Acr transcripts both in the liver 
and heart tissues (Figure 4.6B). Collectively, these results demonstrate that Type 
II anti-CRISPRs can be used as AAV-deliverable off-switches for genome editing 
in vivo, and that they can be effectively rendered miRNA-repressible to enforce 
the tissue specificity of genome editing activity.  
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Figure 4.6 Confirmation of Nme2Cas9 expression and Acr transcripts. (A) 
IHC of the liver and heart tissues from mice injected with dual AAV9 vectors 
expressing Nme2Cas9 and either AcrIIA4, AcrIIC3, or AcrIIC3-3xmiR122BS. 
Anti-HA was used for 3xHA-tagged Nme2Cas9 detection. Control, PBS-injected. 
Scale bar, 100 µm. (B) RT-PCR analysis of AcrIIC3 or AcrIIA4 mRNA using 
primers specific for each Acr. GAPDH was used as an internal control. Tissue 
samples collected at both 2-week (n = 1) and 5-week (n = 2) time points were 
analyzed. 
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4.2.7 Expression of anti-CRISPRs in vivo does not elicit adverse effects 
To our knowledge, this is the first demonstration of in vivo expression of Acr 
proteins in a vertebrate model to inhibit Cas9 editing activity. No apparent liver 
and cardiac muscle damage were detected from staining with hematoxylin and 
eosin (H&E) when we co-delivered AAV9 expressing Nme2Cas9 and anti-
CRISPR proteins (Figure 4.7A). To investigate the immunogenicity of anti-
CRISPR and Nme2Cas9 expression, we looked for humoral IgG1 immune 
response in injected mice using enzyme-linked immunosorbent assay (ELISA) 
(Figure 4.7B). Similar to previous reports of antibodies raised against SpyCas9 
and SauCas9 (Charlesworth et al., 2019; Simhadri et al., 2018; Wagner et al., 
2019), we detected the reactivity indicative of immunoglobulins raised against 
Nme2Cas9 (Figure 4.7C). In contrast, we could not detect any signals for AcrIIC3 
or AcrIIA4 (Figure 4.7D). From this study, we did not observe overt toxicity in the 
examined tissues, although the safety and immunogenicity profiles of delivered 
Acr proteins will need to be investigated over longer periods of time and in 
additional biological contexts. 
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Figure 4.7 Acr and Cas9 expression in vivo has no overt adverse effects. 
(A) H&E staining of liver and heart tissue sections collected from mice 5-wk after 
AAV9 injection. Scale bar, 100 µm. (B) Experimental overview of serum 
collection and ELISA. Serum from injected mice were added to the wells of the 
pre-coated plate with purified proteins (Nme2Cas9, AcrIIC3 or AcrIIA4). (C-D) 
ELISA to detect anti-Nme2Cas9 (C) and anti-AcrIIC3/anti-AcrIIA4 (D). Data are 
presented as mean ± SD of two technical replicates. The number indicates the 
individual mouse coinjected with Nme2Cas9 and AcrIIC3 (1-5), 
AcrIIC3+miR122BS (6-10), or AcrIIA4 (11-15). PBS, PBS-injected mouse serum 
was used as a control. 
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4.3 Discussion 
Despite Cas9’s potential in gene therapy, many hurdles must be overcome in 
order for it to be used in clinical applications. Safeguarding against undesired, 
persistent editing in non-target tissues and protecting all ancillary tissues are 
paramount to ensure the clinical safety profile of CRISPR-based therapeutics for 
in vivo applications. Although AAV capsids with different tissue tropisms can be 
used, they often differ only in the tropism strength but not absolute specificity. 
Serotypes widely used for the delivery of therapeutic transgenes can still infect a 
broad range of tissues in vivo (Gao et al., 2004). Moreover, tissue-specific 
promoters are not always a viable option as some target tissues lack promoters 
that are highly specific and strong enough to drive transgene expression. Anti-
CRISPR proteins are powerful off-switches for Cas nucleases and have potential 
advantages for implementation as regulators. Since anti-CRISPR proteins are 
genetically encodable, they can be used for long-term inactivation of Cas9. 
Preventing the persistence of Cas9 expression and activity after the AAV delivery 
will require likewise durable and effective inhibitors. To this end, we exploited 
anti-CRISPR proteins and endogenous tissue-specific miRNAs to restrict Cas9-
mediated genome editing to a target tissue as a complementary method of 
reinforcing tissue specificity of genome editing in vivo.  
In preliminary work, we demonstrated that miRNA-mediated inhibition of anti-
CRISPRs bearing hepatocyte-specific miR-122 MREs allows genome editing in 
human hepatocytes but inhibits editing in a non-hepatic cell line. The miRNA-
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repressible Acr system affords great flexibility in changing the Cas9-Acr pairs, 
given the discovery of new Acrs for different nucleases, as well as changing the 
tissue specificity, given the ease of swapping MREs. Furthermore, because 
MREs are so small, this approach is well-suited for AAV delivery and could 
confer specificity for some tissues that lack vector-compatible, tissue-specific 
promoters. 
Previously, the endogenous miRNA repertoire has been combined with the 
CRISPR-Cas machinery to regulate the expression of Cas9 itself (Hirosawa et 
al., 2017; Senís et al., 2014). Delivery to tissues that highly express the miRNA 
will silence Cas protein expression, whereas other tissues lacking the miRNA will 
express the Cas protein for genome editing. For example, de-targeting Cas9 
expression from the liver (e.g. with miR-122) allows editing everywhere but the 
liver, while our strategy will instead restrict Cas9 activity to the liver itself and 
protect other tissues from unwanted editing events. It will be particularly useful to 
restrict Cas9 genome editing to a single desired tissue following systemic Cas9 
delivery by AAV. Our results complement a strategy that exploits miRNAs to 
release sgRNAs from longer, inactive precursors (X.-W. Wang et al., 2019), 
though this approach has not yet been validated in tissue-specific editing 
applications in vivo. While our manuscript was in preparation and revision, two 
reports also described miRNA-regulated Acr strategies that enable cell-type-
specific editing in cultured hepatocytes and myocytes (Hirosawa et al., 2019; 
Hoffmann et al., 2019).  
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Our studies extend this work by establishing that miRNA-repressible anti-
CRISPRs indeed enforce the tissue specificity of genome editing in discrete 
organs of adult mammals in vivo. To our knowledge, this is the first 
documentation of anti-CRISPR efficacy during Cas9-mediated editing in vivo in 
adult mammals. We did not observe any adverse tissue damage in the examined 
tissues or humoral responses against the foreign proteins. The inability to detect 
immunoglobulins against anti-CRISPRs does not necessarily mean a lack of their 
existence. The safety and immunity profiles of delivered Acr proteins will need to 
be further investigated over longer periods of time and in additional biological 
contexts. In case of immunogenicity of bacterial and viral proteins, we can apply 
a similar de-targeting strategy using miR-142-3p to mitigate immune response by 
preventing exogenous protein expression in antigen-presenting cells (APCs) 
(Boisgerault et al., 2013; Majowicz et al., 2013; Xiao et al., 2019). 
In summary, we have developed a “plug-and-play” miRNA-repressible anti-
CRISPR platform to confine Cas9 activity to target cells and tissues of interest. 
This is particularly useful in the context of clinical development as it is highly 
desirable to prevent unforeseen adverse effects associated with off-tissue and 
off-target editing in vivo.  
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4.4 Materials and Methods 
Appendix Table 2 contains plasmids used in this chapter. Plasmid maps and 
sequences are available on Addgene. 
Vector construction 
Codon-optimized AcrIIC3 and AcrIIA4 sequences were ordered as gBlocks (IDT) 
and amplified using the primers with overhangs to the pCSDest vector by 
NEBuilder HiFi DNA Assembly (NEB). Similarly, an mCherry ORF was fused to 
the carboxyl terminus of each Acr by HiFi DNA assembly (NEB). To insert 
3xmiR122 MREs in the 3′ UTR of each Acr, top and bottom strands were ordered 
as oligos (IDT) with restriction sites for SacI and HindIII and annealed before 
ligating into the vector linearized with the same restriction enzymes. For in vivo 
experiments involving a hydrodynamic injection, we used the Nme2Cas9-
sgRNA_Rosa26 all-in-one AAV vector (Edraki et al. 2018). To make scAAV 
vectors expressing Acr proteins, the original scAAV plasmid encoding an EGFP 
ORF [a kind gift from Jun Xie and Guangping Gao (UMass Medical School)] and 
pCSDest-Acr plasmids were digested with SacI and AgeI restriction enzymes 
and then ligated. For AAV vector preparation, a U6-driven sgRNA cassette was 
removed from the Nme2Cas9 vector by restriction digestion with MluI and 
assembled into linearized scAAV-EGFP by Hifi DNA assembly (NEB). This 
vector was digested with SacI and AgeI for AcrIIC3, AcrIIC3-3xmiR122BS, or 
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AcrIIA4 inserts made from pCSDest plasmids using the same restriction 
enzymes. 
Cell culture and transfection 
HEK293T and Huh-7 cell lines were cultured in Dulbecco's modified Eagle's 
medium supplemented with 10% fetal bovine serum (Sigma) and 1% penicillin-
streptomycin (Gibco). For editing experiments in vitro, a total of 150 ng of Cas9, 
150 ng of sgRNA, and 50 ng of Acr or an empty plasmid were transiently 
transfected in a 24-well format using Lipofectamine 2000 (Invitrogen) according 
to the manufacturer's protocol. The total DNA amount was kept constant by 
adding a stuffer plasmid in all cases. For western blot and flow cytometry 
analysis, 500,000 cells/well were seeded onto a six-well plate, and 500 ng of 
each Acr vector and GFP plasmid (the latter used as a transfection control) were 
transfected using Lipofectamine 2000 (Invitrogen) following the manufacturer's 
protocol. Prior to flow cytometry analysis, cells were imaged using an EVOS Cell 
Imaging System (Thermo Fisher). 
Flow cytometry 
Cells were trypsinized 48 hr post-transfection, washed with PBS, and 
resuspended in PBS. A total of 100,000 cells were analyzed on a MACSQuant® 
VYB (Miltenyi Biotec). A yellow laser (561 nm) with a 615/20 nm filter and a blue 
laser (488 nm) with a 525/50 nm filter were used for mCherry and GFP detection, 
respectively. Subsequent analysis was performed using FlowJo v10.4.1. Cells 
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were first sorted based on forward and side scattering (FSC-A vs. SSC-A), and 
then single cells were gated using FSC-A and FSC-H. Finally, mCherry-positive 
cells were recorded to estimate the expression level of anti-CRISPR proteins 
after gating for GFP-positive (transfected) cells. 
Western blots 
Proteins were collected 48 hr post-transfection and their concentrations were 
measured using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). 
Western blots were performed as described previously (Lee et al. 2018) with 
primary mouse anti-Flag (AbClonal, 1:5000) used for Acr detection and rabbit 
anti-HSP60 (1:5000) used for loading control. After incubation with secondary 
anti-Rabbit or anti-Mouse antibodies (LI-COR IRDye, 1:20,000), blots were 
visualized using a LI-COR imaging system. 
Mouse studies 
C57BL/6 mice were obtained from Jackson Laboratory and all animal 
maintenance and procedures were performed following the guidelines of the 
Institutional Animal Care and Use Committee of the University of Massachusetts 
Medical School. Plasmids for hydrodynamic tail vein injection were prepared 
using the EndoFreeMaxi kit (Qiagen). For hydrodynamic liver injection, a total of 
90 µg of endotoxin-free plasmids was suspended in 2 mL of injection-grade 
saline and injected via the tail vein into 8- to 10-wk-old C57BL/6 mice. Mice were 
euthanized 7-day post-injection and liver tissues were collected and stored at 
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−80°C for analysis. For AAV injection, 4 × 1011 GC of ssAAV-Nme2Cas9 and 4 × 
1011 GC of scAAV-U6_sgRNA-Acr (a total of 8 × 1011 GC per mouse) were 
resuspended in 200 µL PBS and administered via tail vein injection. Tissue 
samples from heart and liver were collected and stored at −80°C for indel 
analysis and histology at 2- and 5-wk post-injection. 
Indel analysis 
Genomic DNA from cells or tissues were collected using a DNeasy Blood and 
Tissue Kit (Qiagen). Indel frequencies were measured by targeted deep 
sequencing. Targeted deep sequencing analyses were done as previously 
described (Bolukbasi et al. 2015). Briefly, target sites were amplified using High 
Fidelity 2× PCR Master Mix (NEB) in a two-step PCR amplification with locus-
specific primers in the first step and then with universal index primers to 
reconstitute TruSeq adapters. Full-size products were gel-extracted and purified 
using a DNA Clean and Concentrator Kit (Zymo). The purified library was 
sequenced using a paired-end 150 bp MiniSeq run using a Mid-output cartridge 
(Illumina). 
Immunohistochemistry 
Liver tissues were fixed in 4% formalin overnight, paraffin-embedded, and 
sectioned at the UMass Morphology Core. For Figure 5C and Supplemental 
Figure S2A, sectioned slides were stained with H&E for pathology analysis. For 
IHC, liver sections were dewaxed, rehydrated, and stained following standard 
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protocols previously described (W. Xue et al., 2011) with primary antibodies 
against 3xHA-tagged Nme2Cas9 (anti-HA; Cell Signaling) and mCherry (anti-
RFP; Rockland). Representative images are shown. 
RT-PCR analysis 
Total RNA (0.5-1 µg) from mouse tissues were collected by TRIzol (Invitrogen) 
and then reverse-transcribed to cDNA using random hexamer primers and 
SuperScript III First-Strand Synthesis System (Invitrogen) following the 
manufacturers’ protocols. cDNA templates were directly used for PCR 
amplification using primers specific for (1) Nme2Cas9, (2) AcrIIC3, and (3) 
GAPDH. The resulting RT-PCR amplicons were visualized by 2.5% 
agarose/1×TAE gel electrophoresis. 
ELISA 
Humoral IgG1 immune response to Nme2Cas9 and anti-CRISPR proteins was 
measured by ELISA (Bethyl; Mouse IgG1 ELISA Kit, E99-105) following the 
manufacturer’s protocol with a few modifications. In a 96-well plate (Corning 
Costar 3603 Polystyrene), each well was coated with 0.5 μg of a recombinant 
protein in 150 μL of coating buffer (Bethyl, cat#E107) for 12 hr on rocker at 4°C. 
The wells were washed 3× times for 5 min, blocked with 1× BSA Blocking 
Solution (Bethyl cat#E104) for 2 hr at room temperature, then washed again 3× 
times. Serum samples (diluted 1:40) were added in duplicate and incubated at 
4 °C for 5 hr. Then, the plates were washed 3× times for 5 min and 100 μL of 
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HRP-conjugated anti-mouse IgG1 antibody (Bethyl; 1: 100,000 in 1 x BSA 
Blocking Solution) was added to each well. After incubating for 1 hr at room 
temperature, the plates were washed 3× times and 100 μL of TMB substrate was 
added. After development 20 min in dark at room temperature, 100 μL of ELISA 
Stop Solution was added to each well. The absorbance was measured at 450 nm 
using a BioTek Synergy HT microplate reader. 
Statistical analysis 
Standard deviations are derived from each group that has a minimum of three 
independent replicates unless otherwise noted. Unpaired, two-tailed t-tests were 
used to determine the statistical significance between each group. Resulting P 
values <0.05, 0.01, 0.001, 0.0001 are indicated by one, two, three, or four 
asterisks, respectively.  
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Chapter 5 Discussion 
5.1 The prospects of CRISPR genome engineering 
5.1.1 A summary of CRISPR-Cas applications 
The CRISPR-based toolbox has greatly expanded to enable genome editing, 
base editing, gene regulation, and other uses (Anzalone et al., 2020; Doudna, 
2020; Porteus, 2019). In typical gene editing applications, RNA-guided Cas9 or 
Cas12a introduces a DSB that can be resolved by cellular repair mechanisms to 
yield an insertion or deletion via NHEJ or integration or replacement of a donor 
DNA via HDR (Pickar-Oliver & Gersbach, 2019). In base editing, a fused 
deaminase domain converts a single base through deamination and followed by 
repair, which allows C to T or A to G transitions (Komor et al., 2018; Rees & Liu, 
2018b; B. Yang et al., 2019). Moreover, gene regulation can be modulated by 
fusing other domains such as transcriptional activators or repressors and 
epigenetic modifiers (Adli, 2018; Dominguez et al., 2016; Pickar-Oliver & 
Gersbach, 2019; Thakore et al., 2016). More recent advances in the field gave 
rise to platforms such as prime editing (Anzalone et al., 2019), Cascade effector 
complexes from Type I systems for large genomic deletions (Cameron et al., 
2019; Dolan et al., 2019; Morisaka et al., 2019), as well as DNA insertion 
directed by CRISPR effectors and transposases (S. P. Chen & Wang, 2019; 
Klompe et al., 2019; Strecker et al., 2019). New tools will continue to emerge as 
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we uncover and harness the natural prokaryotic gold mine in this fast-moving 
field. The only limit is one’s creativity.  
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5.1.2 Considerations for human therapeutics 
In less than a decade, CRISPR gene editing technologies have rapidly advanced 
into or close to clinical trials (Finn et al., 2018; Maeder et al., 2019). Although ex 
vivo and in vivo therapeutic gene editing approaches using CRISPR have 
unprecedented potential for treating human diseases, a few important issues 
must be considered (Doudna, 2020). First, introducing proteins of bacterial origin 
raises immunogenicity issues that are currently under active investigation 
(Charlesworth et al., 2019; A. Li et al., 2020; Simhadri et al., 2018; Wagner et al., 
2019). This will not be a concern for ex vivo approaches since cells are corrected 
in vitro and engrafted back into patients. Since the safety profile of an ex vivo 
approach is more appealing, the ongoing Phase1/2 clinical trials for sickle cell 
diseases will likely have success if proven efficacious (CTX001; NCT04208529). 
Whether the pre-existing immunity will be problematic in humans remains to be 
revealed in future clinical trials involving direct delivery of editing reagents into 
patients. Other than blood disorders, many diseases affect tissues inside the 
body that cannot be removed, requiring in vivo editing. Among the many 
complications for in vivo therapeutics is the possibility of immunogenicity, though 
delivery of the editing reagents may be the biggest obstacle. An ideal delivery 
modality will combine the benefits of different strategies: cheap and easy 
production, efficient tissue targeting capabilities, and transient expression (Glass 
et al., 2018). To date, AAV is a clinically well-established delivery vector for in 
vivo transgene expression, however, AAV poses restrictions for CRISPR-
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mediated gene editing because of its limited cargo size, potential genomic 
integration, and the likelihood of off-targeting due to long-term expression (D. 
Wang et al., 2019). To evaluate the clinical relevance of AAV-delivered Cas9, 
preclinical assessment must be conducted in large animal models such as dogs 
and nonhuman primates using clinical-grade AAV vectors. Furthermore, many 
factors should be considered to minimize potential immune responses in 
humans: the inflammatory nature of the AAV vector, the dose, the tissue-specific 
expression of transgene, as well as route of administration. 
Last but not least, although the immediate outcomes of the therapeutic gene 
editing may be successful, no one can predict the unforeseeable consequences 
of gene editing without long-term evaluation, and only time will tell. Therefore, 
precaution should be taken at every step of CRISPR technology development 
and implementation in humans. 
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5.1.3 Heritable germline editing and ethics 
Germline genome editing is already in widespread use in animals and plants and 
has been approved for research purposes only in human embryos (Fogarty et al., 
2017; P. Liang et al., 2015; H. Ma et al., 2017; Tang et al., 2017). For therapeutic 
purposes, all genome editing technologies are currently directed at treating 
patients’ somatic cells (Porteus, 2019). A distinction between somatic and 
germline editing is that the heritable genetic modifications will pass onto future 
generations in the germline editing. While correcting disease-causing mutations 
in the embryo may seem powerful, creating a “disease-free” baby, germline 
editing of a human embryo that resulted in pregnancy and birth of Chinese twin 
babies sparked widespread controversies (Baltimore et al., 2015; Lanphier et al., 
2015). Human germline editing is faced with many challenges both scientifically 
and ethically (Ledford, 2019). Notably, the latest research suggests large 
genomic rearrangements or deletions induced by DSBs and underscores that we 
have not fully grasped DNA repair mechanisms in human embryos (Alanis-
Lobato et al., 2020; D. Liang et al., 2020; Zuccaro et al., 2020). Moreover, 
studies based on germline editing in mice may not be easily translatable due to 
differences between mice and humans in early embryo development (Fogarty et 
al., 2017). This leads to the next point: while apprehension about embryo editing 
is understandable, human embryo editing in research must not be completely 
banned. With strict regulations in place for biomedical research, germline editing 
will facilitate research on possible future clinical applications (Araki & Ishii, 2014). 
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Lastly, the scientific community must address societal concerns and establish 
and comply with the appropriate guidelines. In the future, if the germline editing is 
ever used, we must ensure that the merit of an unmet medical need outweighs 
the risks by evaluating the urgency, safety, and ethical justification (Ormond et 
al., 2017). 
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5.2 The new and emerging field of anti-CRISPRs 
5.2.1 The biology of anti-CRISPRs 
Since the discovery of anti-CRISPRs in 2013, the number of published reports on 
this topic has dramatically increased in the past few years (Bondy-Denomy, 
2018; Davidson et al., 2020; S. Hwang & Maxwell, 2019; Koonin & Makarova, 
2018; Pawluk et al., 2018; Sontheimer & Davidson, 2017). Many aspects of anti-
CRISPR research focused heavily on discovery for different types of CRISPR-
Cas systems and dissecting their inhibitory mechanisms (Borges et al., 2017; 
Davidson et al., 2020; Stanley & Maxwell, 2018). The prevalence of anti-CRISPR 
proteins that inactivate almost all types of CRISPR-Cas systems (Types I, II, III, 
V, and VI), and the diversity in sequences and structures that perhaps explain 
the unique strategies they employ (Wiegand et al., 2020; Yuwei Zhu et al., 2018), 
suggest the importance of anti-CRISPR proteins in shaping the microbial world 
(Samson et al., 2013; Wiedenheft, 2013). More recently, we began to uncover 
the diversity of archaeal Acrs as well (Peng et al., 2020). Furthermore, studies 
are underway to understand how anti-CRISPRs operate in the host-pathogen 
interactions occurring in a more complex population of natural environments 
(Nussenzweig & Marraffini, 2018; van Gent & Gack, 2018). There is still so much 
unknown in this emergent field and future studies will be necessary to shed light 
on the evolutionary origins and their implications as well as on the discovery of 
anti-CRISPR proteins that function at different stages of CRISPR immunity such 
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as adaptation. The ongoing battle opens up the possibilities to more exciting 
discoveries such as “anti-anti-CRISPRs.”  
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5.2.2 A summary of anti-CRISPR protein applications 
While CRISPR technologies are widely adopted for numerous applications 
(Anzalone et al., 2020), anti-CRISPR proteins have not yet been extensively 
used in genome engineering (Q. Liu et al., 2020; Marino et al., 2020). The 
versatility of anti-CRISPR proteins in regulating all types of CRISPR-based 
technologies warrants an enormous potential as a safeguard against undesired 
editing. For example, anti-CRISPR proteins can be used to eliminate editing at 
off-target sites (Aschenbrenner et al., 2020; Shin et al., 2017). In addition, 
undesired editing in non-target cell types (Hirosawa et al., 2019; Hoffmann et al., 
2019) or tissues in vivo (J. Lee et al., 2019) can be achieved by using tissue-
specific miRNAs that regulate the expression of anti-CRISPR proteins. Other 
methods of post-transcriptional regulation such as alternative splicing or mRNA 
stability and decay can be explored (Corbett, 2018). These processes have been 
implicated in gene regulatory potential in different cell or tissue types as well as 
healthy versus diseased conditions (Carey and Wickramasinghe, 2018) although 
implementing such complex system for transgene regulation may be tricky and 
require more extensive studies.  
Furthermore, anti-CRISPR proteins may serve as a safety measure in reducing 
the cytotoxicity of the CRISPR/Cas9 complex in human hematopoietic stem cells 
(C. Li et al., 2018), or stopping the propagation of gene drive (Basgall et al., 
2018). The application of Acrs is not limited to regulating gene editing, for 
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example, anti-CRISPR can be used as a ligand biosensor to detect and quantify 
the CRISPR-Cas9 RNP (Johnston et al., 2019). Applications of anti-CRISPR 
proteins may face similar challenges that CRISPR-Cas technologies currently 
have (Doudna, 2020). Alternative technologies are being developed to inhibit the 
activity of Cas9, such as nucleic acid-base inhibitors (Barkau et al., 2019) and 
small-molecule inhibitors (Maji et al., 2019). However, these inhibitors may 
require substantial efforts in proper designing through screening or optimization 
to minimize the risk of interaction with other targets in mammalian cells 
(Schneider, 2018). Overall, development of anti-CRISPR-based tools will provide 
a unique capacity to make CRISPR technologies more useful, effective, and 
safe. Applications of anti-CRISPR proteins are still at an early stage, and many 
innovations will arise moving forward. 
Concluding Remarks 
The overarching goal of this thesis was to mine for natural anti-CRISPR protein 
inhibitors of Cas9 (Chapter 2) and repurpose these proteins to complement 
current Cas9 technologies in basic and clinical research by developing anti-
CRISPR application tools (Chapters 3 and 4). 
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Appendix  
Appendix 1 Characterization of additional Type II-C anti-CRISPRs  
In Chapter 2, we discovered anti-CRISPR proteins for Type II-C systems that can 
inhibit various Cas9 orthologs. After we published that AcrIIC5 inhibits the 
originally reported Nme1Cas9 (Hou et al., 2013), a closely related Nme2Cas9 
from our lab was reported (Edraki et al., 2018). Nme1Cas9 and Nme2Cas9 share 
a high identity except for the divergent PID (Edraki et al., 2018). While all other 
previously reported AcrIIC families inhibit Nme2Cas9, AcrIIC5Smu failed to inhibit 
gene editing (Edraki et al., 2018). We reported that there are few homologs of 
AcrIIC5 in different Neisseria species with varying percent identity (Figure 
A1.1A). We also tested a new Type II-C (AcrIIC6) from Neisseria spp. 
(HMSC056A03). Surprisingly when we evaluated genome editing inhibition by 
AcrIIC5 homologs and AcrIIC6, none of the anti-CRISPR proteins were able to 
inhibit Nme2Cas9 very efficiently in T7E1 assays while completely inhibiting 
Nme1Cas9 (Figure A1.1B). To measure the indel efficiencies more quantitatively, 
we performed TIDE analysis for Nme2Cas9 editing (Figure A1.1C). Similar to 
T7E1, tested anti-CRISPR proteins failed to completely inhibit Nme2Cas9 
genome editing although at varying potency (Figure A1.1C). AcrIIC5N10 does not 
inhibit Nme2 and both AcrIIC5Nwa and AcrIIC6 inhibit Nme2Cas9 modestly, 
although all three Acrs potently inhibit Nme1Cas9. Based on this observation, the 
inhibitory mechanism of AcrIIC5 may involve interaction with the PID of 
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Nme1Cas9, while the interaction of AcrIIC5 with the PID of Nme2Cas9 may be 
suboptimal. From our earlier investigation as presented in Chapter 2, AcrIIC5 
most likely prevents Nme1Cas9 from binding to the target DNA. It remains to be 
elucidated whether AcrIIC5 interacts with the PID of Nme1Cas9 via DNA mimicry 
similar to AcrIIA4. Anti-CRISPRs from the current study must be accompanied by 
biochemical and/or structural studies for additional characterization. It will be 
interesting to further investigate how one of the two closely related Cas9 
orthologs is susceptible to anti-CRISPR inhibition while the other escapes. This 
will help us understand the ongoing arms race in the battle between bacterial 
Cas9 and phage anti-CRISPRs. 
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Figure A1.1 Type II-C anti-CRISPR inhibition of Nme1Cas9 and Nme2Cas9. 
(A) AcrIIC5 homologs pairwise percent identity. (B) Comparison of inhibition of 
Nme1Cas9 (left) and Nme2Cas9 (right) by AcrIIC5 homologs and AcrIIC6 using 
T7E1 assays. (C) Indel frequency of Nme2Cas9 genome editing and inhibition by 
AcrIIC5 homologs and AcrIIC6 using TIDE analysis.  
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Appendix 2 Optimization of the miRNA-repressible anti-CRISPR system 
In Chapter 4, we demonstrated robust repression of anti-CRISPRs by miR-122 in 
the liver. However, since many miRNAs are not expressed as highly as miR-122 
in the liver, and certain miRNAs are differentially expressed in various tissues 
rather than an all-or-none fashion, we decided to investigate the effect of varying 
endogenous miRNA abundances on silencing efficiency. Moreover, we also 
aimed to optimize the existing strategy to be least disruptive for endogenous 
miRNAs and their target transcripts. 
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A2.1 Transgene repression requires a threshold level of miRNAs 
To better understand the expression level (i.e. copy number of a specific miRNA) 
that is required for efficient repression of anti-CRISPR with MREs, we profiled 
miRNA abundance in a reporter cell line and evaluated miRNA representatives of 
different copy number groups (Figure A2.1). 
We performed small RNA sequencing of a HEK293T reporter cell line (HEK293T-
TLR-MCV) to profile miRNA abundance, then ranked and binned miRNAs into 5 
groups depending on the miRNA molecules per cell: the highest (~20,000 
molecules /cell) to the lowest (2 molecules /cell), with each bin representing a log 
fold difference. We estimated the number of miRNA molecules by including 
spike-in controls. Then a miRNA representing each bin was used to clone a 
vector expressing anti-CRISPR fused to mCherry and 3xMRE for each miRNA in 
the 3’ UTR. We transfected the HEK293T-TLR-MCV reporter cells with these 
vectors by titrating the dosage of plasmids and performed flow cytometry (Figure 
A2.1).
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Figure A2.1 Experimental overview of miRNA profiling. (A) Workflow: after 
small RNA sequencing and data analysis, we ranked endogenous miRNAs in 
HEK293T-TLR-MCV based on their occurrences. To clone the anti-CRISPR 
protein-mCherry fusion construct, miRNAs that differ in abundance (~ 20,000 
copies to 2 molecules per cell) were randomly chosen. We transiently transfected 
the HEK293T-TLR-MCV cells with each construct and evaluated the efficiency of 
repression by flow cytometry. (B) Schematic of AcrIIC3-mCherry-MRE 
transcripts. Three MRE sequences are placed in tandem with each MRE having 
a perfect complementarity to a full-length miRNA sequence. (C) Randomly 
picked 5 unique miRNAs from the rank of 10-fold difference in abundance. 
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As expected, the most abundant miR-92a showed the lowest level of mCherry 
expression, indicative of potent silencing activity. Similarly, the amount of the 
plasmid that expresses AcrIIC3-mCherry-MRE affected the efficiency of silencing 
mCherry expression: fewer targets (low) available resulted in more efficient 
silencing. We observed efficient silencing for the highest miRNA group (~20,000 
molecules /cell) while 2-2,000 molecules /cell did not significantly reduce the 
expression of mCherry. Although we could observe a general correlation, targets 
containing miR-22 MREs consistently showed no sign of silencing activity (Figure 
A2.2A). To test if miR-22 was an exception for low or undetectable silencing 
activity, we picked another miRNA from the same abundance ranking group 
(miR-107) and repeated the titration experiment (Figure A2.2B). This time, we 
observed a gradual increase of mCherry expression for targets containing less 
abundant miRNA, demonstrating the dosage effect of endogenous miRNAs 
indeed correlates with the silencing efficiency (Figure A2.2B). Based on our 
observation, we believe ~20,000 copies or more would be needed for potent 
silencing activity and a miRNA that has an abundance of fewer than 2,000 copies 
/cell may not be sufficient.  
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Figure A2.2 Effects of miRNA and target abundance on silencing activity. 
(A-B) AcrIIC3-mCherry with fully complementary MREs for each miRNA was 
tested with miR-22 (A) and miR-107 (B) for a ranking group of 200 molecules 
/cell. The mCh+/(total BFP+) ratio indicates miRNA silencing activity. 
  
 
 
201 
A2.2 Optimizing the length of the MRE to bypass the TDMD pathway 
A competitive endogenous RNAs (ceRNAs) hypothesis proposes that strong 
overexpression of natural or artificial RNAs harboring miRNA target sites can act 
as sponges for miRNAs by titrating miRNAs away from natural targets and 
thereby de-repressing these transcripts (Ebert et al., 2007; Franco-Zorrilla et al., 
2007; Hansen et al., 2013; Memczak et al., 2013; Mukherji et al., 2011). This 
presents a potential caveat of the miRNA-repressible anti-CRISPR system since 
the exogenous targets containing MREs may impact the endogenous transcripts 
that are regulated by the same miRNAs. Although the hypothesis is still debated, 
extensive studies on endogenous transcripts and miRNA regulation suggest that 
changes in target abundance are unlikely to cause significant effects on gene 
expression via a sponge effect (Denzler et al., 2014, 2016).  
Another pathway in which the abundance of miRNA itself may be altered and 
potentially impact the de-repression of targets is target RNA-directed miRNA 
degradation (TDMD) (Ameres et al., 2010). When there is extensive pairing 
between the RNA target and miRNA, TDMD causes instability and depletion of 
miRNAs (Wightman et al., 2018; Pawlica et al., 2020). In the initial miRNA-
repressible anti-CRISPR system, we used the full-length MRE that has perfect 
complementarity to the miRNA sequence (21-22nt) to achieve cleavage of mRNA 
targets for strong repression. When a miRNA and its target are perfectly 
complementary, Ago2 mediates cleavage of the target, which is then quickly 
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degraded by cellular exonucleases. However, when a target exhibits extensive 3’ 
base-pairing, the miRNA becomes subjected to degradation by the cellular 
ribonucleases that function in TDMD (Wightman et al., 2018). 
In light of the TDMD pathway, we questioned how we can design our targets to 
minimize the perturbations to the endogenous cellular miRNAs and their 
regulatory functions. To define the parameters for designing MREs that are 
effective in the target repression without eliciting TDMD, we decided to test 
shorter MREs. A previous study showed that complementarity past guide base 
g16 is unnecessary for efficient cleavage by mammalian AGO2 (Becker et al., 
2019). Thus, based on the requirement for g2-g16 complementarity for target 
cleavage, we decided to test a shortened MRE instead of a full-length sequence. 
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Comparison between full-length vs. g2-g16 complementarity 
We used the identical vectors and experimental setup that we used above for the 
sensitivity assay, but this time the vectors encoding AcrIIC3-mCherry-MRE have 
g2-g16 complementarity to the miRNAs. We then compared side-by-side the 
silencing efficiency of each miRNA that only differs in MRE length (Figure 
A2.3A). We again observed that the miR-92a reduced mCherry expression the 
most for both short and full-length MRE containing vectors compared to other 
miRNAs that belong to less abundant groups. Shorter MREs were still able to 
efficiently silence the transgene albeit at slightly lower efficiency than the full-
length MRE (Figure A2.3B) 
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Figure A2.3 Comparison of full-length vs. g2-g16 MREs on silencing activity 
of miRNAs. (A) Schematic of DNA vectors that encode transcripts for AcrIIC3-
mCherry with either full-length or g2-g16 MREs of miR-92a as an example. 
Target:Guide pairing is shown in blue and orange colors. (B) AcrIIC3-mCherry 
expression levels are compared between the 22nt and g2-g16 MREs for various 
miRNA copy numbers. mCh+/(Total BFP+) ratio indicates silencing efficiency. 
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Ultimately, the silencing of anti-CRISPR transcripts bearing MREs should enable 
Cas9-mediated genome editing. To evaluate the genome editing outcome of 
variable silencing efficiency seen with full-length and g2-g16 MREs, we 
transfected HEK293T-TLR-MCV cells with Nme2Cas9, sgRNA, and an AcrIIC3 
vector harboring 22nt or g2-g16 MREs (Figure A2.4). Without any anti-CRISPRs, 
~10% of indels were seen at TS126, however, co-transfecting AcrIIC3 that is 
regulated by different miRNAs reduced the editing efficiency. Only the full-length 
MRE containing AcrIIC3 (miR-92a; Figure A2.4A) restored the editing levels 
comparable to cells that were transfected with only Nme2Cas9 and sgRNA 
(TS126; Figure A2.4A) while AcrIIC3 bearing the g2-g16 MREs for miR-92a 
partially restored editing levels (Figure A2.4B).  
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Figure A2.4 Anti-CRISPR repression by full-length or g2-g16 MREs leads to 
genome editing. (A) Nme2Cas9 and its sgRNA targeting TS126 were co-
transfected with miRNA repressible AcrIIC3-mCherry with either full-length (A) or 
g2-g16 MRE (B) constructs. TIDE analysis was performed to estimate the 
genome editing efficiency. pscAAV-AcrIIC3 and pCDestAcrIIC3 are used as 
AcrIIC3 controls without MREs. TS126 indicates the Nme2Cas9 sgRNA target 
site without the expression of any Acr, serving as a ‘No Acr’ control. 
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A2.3 Future directions 
In our studies, we attempted to address two main questions we initially raised: 
1) What is the level of abundance required for robust repression of anti-
CRISPR transgene to enable Cas9-mediated gene editing? 
2) Will expressing exogenous targets bearing MREs affect endogenous 
miRNAs and their natural targets? 
From our preliminary studies conducted in HEK293T reporter cells, it appears 
that ~20,000 copies of miRNA should be sufficient for anti-CRISPR silencing to 
allow genome-editing. We note that other contributing factors were not 
considered in the current study. Other determinants of target:miRNA interactions 
may depend on the genomic sequence context such as the location and 
accessibility of the miRNA binding sites (Grimson et al., 2007; Hausser & 
Zavolan, 2014). Therefore, exceptions may exist for different types of miRNAs. 
For example, we consistently observed that miR-22 did not perform as well as 
other less abundant miRNAs previously also seen by another group 
(Mullokandov et al., 2012), suggesting that the abundance alone cannot be the 
sole determinant for silencing efficiency. Due to the complexity of miRNA 
regulation, mechanisms responsible for differential miRNA activity are likely to be 
combinatory effects of many factors. To select the best miRNA for relevant target 
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tissue or cell types of interest, future studies will require in vivo profiling of 
“functional” miRNAs (miRNome) (Mullokandov et al., 2012). 
Furthermore, we endeavored to optimize the MRE sequences to minimize any 
potential complications due to long-term expression of targets harboring perfectly 
complementary MREs from AAV vectors. One way such a case can potentially 
be an issue is the depletion of endogenous miRNAs via the TDMD pathway. 
Artificial targets with extensive complementarity to the miRNA can trigger TDMD 
through tailing and trimming of the miRNA 3′ terminus (Ameres et al., 2010; 
Baccarini et al., 2011; de la Mata et al., 2015; Denzler et al., 2016; Xie et al., 
2012). This raised our concern and we attempted to address this by changing the 
perfect complementarity of MREs to shorter g2-g16 lacking 3’ extensive pairing 
to avoid being targeted for TDMD (Becker et al., 2019). We show that shorter 
MREs can repress the AcrIIC3 to allow gene editing although not as efficiently as 
the full-length MREs we originally used. Further optimization may be needed for 
improving efficiency by other design parameters such as spacing between the 
MREs. It remains to be tested in the future whether there is a benefit of using g2-
g16 at the cost of modest loss of silencing activity so that we can bypass TDMD 
that may perturb the endogenous miRNA pool and transcriptional regulation. 
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Appendix 3 Immunogenicity of anti-CRISPR proteins 
To the best of our knowledge, the in vivo studies presented in Chapter 4 were the 
first to introduce anti-CRISPR proteins into mammalian models. The utility of anti-
CRISPR proteins in vivo may be compromised if they are immunogenic or faced 
with pre-existing immunity (A. Li et al., 2020). During our 5-week study after AAV 
delivery, there was no apparent toxicity or abnormal tissue histology. We 
collected sera of mice injected with AAV expressing Nme2Cas9 and anti-
CRISPR proteins (AcrIIC3 and AcrIIA4) and performed ELISA to test if there are 
any IgG antibodies raised against these foreign proteins. We did not observe any 
humoral immune response against AcrIIC3 and AcrIIA4, two of the most potent 
anti-CRISPR proteins that can inactivate NmeCas9 and SpyCas9, respectively. 
As previously reported for other Cas9 orthologs, a strong IgG response was 
observed for Nme2Cas9 as well. To further investigate whether we can raise 
antibodies against anti-CRISPR proteins, we performed an immunization assay 
(Figure A3.1). 
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Figure A3.1 Immunization assay via subcutaneous injection of recombinant 
Cas9 and anti-CRISPR proteins. (A) A timeline of mouse immunization studies. 
Mice were pre-bled at day 0 before Intraperitoneal injections of recombinant 
proteins. Serum was collected at day 22 (3-wk) and 36 (5-wk). (B) Overview of 
ELSIA. 
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A3.1 No IgG immune response against anti-CRISPR proteins is detected 
Groups of 4 mice each (sex- and gender-matched for each group) were bled 
before subcutaneous injection of five recombinant proteins: Nme2Cas9, 
SpyCas9, AcrIIC3, AcrIIC4, and AcrIIA4. PBS-injected mice served as our control 
group. Mice were then bled at 3- and 5-wk post-injection to collect serum, and 
ELISA was performed for detecting IgG in the serum (Figure A3.1). Consistent 
with our earlier observations, both Nme2Cas9 and SpyCas9 showed 
immunoreactivity, confirming the humoral response raised against Cas9 
orthologs similar to AAV injected mice (Figure A3.2A-B). All PBS-injected mice 
did not show any signs of IgGs against the recombinant Cas9 proteins that we 
tested (Figure A3.2C-D).  
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Figure A3.2 IgG immune response against Nme2Cas9 and SpyCas9 
proteins. Serum was collected from each mouse injected with (A) Nme2Cas9 or 
(B) SpyCas9. Serum from 4 PBS injected mice were tested against (C) 
Nme2Cas9 and (D) SpyCas9 as well. As a reference, we plotted Nme2Cas9 
(AAV) and AcrIIC3 (AAV) serum samples from mouse WX2716 injected with AAV 
from the previous experiment in Chapter 4 and used here as positive and 
negative controls, respectively.  
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Next, we assessed whether IgG immunoglobulins were raised against anti-
CRISPR proteins that were introduced into mice by subcutaneous injection. We 
did not see significant signals for each of the tested anti-CRISPR proteins for 
most mice (Figure A3.3A-C), corroborating our results from mice that were 
injected with AAV. All PBS injected mice did not show any signs of IgGs against 
any of the recombinant proteins we tested (Figure A3.3D-F).  
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Figure A3.3 IgG immune response against anti-CRISPR recombinant 
proteins.  
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Serum was tested against (A) AcrIIC3, (B) AcrIIC4, and (C) AcrIIA4 for any 
presence of IgG. Sera collected from PBS injected mice were also tested against 
(D) AcrIIC3, (E) AcrIIC4, and (F) AcrIIA4. Samples from an AAV-injected mouse 
(WX2716) were used as a reference for positive and negative signals. 
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A3.2 Future directions 
Previous studies raised concern over pre-existing adaptive immunity against 
Cas9 (Charlesworth et al., 2019; A. Li et al., 2020; Simhadri et al., 2018; Wagner 
et al., 2019). Immune responses to Cas9 or anti-CRISPR proteins can be 
problematic as antibodies raised against the proteins can result in their 
clearance, affect their activities, have cross-reactivity with endogenous proteins, 
and cause anaphylactic reactions in serious cases (Sauna et al., 2018). From our 
preliminary studies on the immunogenicity of anti-CRISPR proteins, we primarily 
investigated the presence of IgGs using ELISA assays. However, we note that 
more systematic studies must be conducted to provide more conclusive evidence 
for the lack of antibodies against anti-CRISPR proteins. Since the anti-CRISPR 
proteins are much smaller than Cas9 proteins, ELISA optimization such as 
coating conditions may be necessary.  
Moreover, future studies will require conducting assays for a comprehensive 
understanding of both humoral and cellular immunity. We used two different 
delivery methods: intravenous injection of AAV and subcutaneous injection of 
recombinant proteins. In the former case, delivery of AAV encoding DNA would 
produce intracellular proteins, and the peptides could potentially be processed by 
major histocompatibility complex (MHC) class I to elicit a cytotoxic CD8+ T cell 
response. In the latter, directly delivered exogenous proteins could potentially be 
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processed by MHC class II and engage with CD4+ T cells to elicit an antibody 
response.  
Overall, whether there is a clinical relevance of humoral and cellular responses 
and how these may impact the efficacy and safety of CRISPR and anti-CRISPR 
reagents remains to be evaluated.  
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Appendix 4 Muscle-specific genome editing in vivo for DMD  
A4.2 Background on Duchenne’s Muscular Dystrophy 
In Chapter 4, we showed liver-specific genome editing using a miRNA-
repressible anti-CRISPR system as a proof-of-principle. To continue expanding 
our platform, we envisioned a therapeutic application. A few criteria were 
considered for choosing the next therapeutic target:  
1.  Well-validated microRNAs 
2.  Availability of disease models (cell lines, mouse models) 
3.  AAV deliverables 
Tissue-specific editing is even more critical when therapeutic reagents must be 
delivered systemically to tissues impacted throughout the body such as in 
Duchenne’s muscular dystrophy (DMD). DMD is a muscle degenerative disease 
affecting 1 in 5,000 newborn males every year in the United States (McGreevy et 
al., 2015; Mendell & Lloyd-Puryear, 2013). DMD arises from mutations in the 
dystrophin gene (Dmd), which is located on the X chromosome and is comprised 
of 79 exons. Diverse types of mutations are found in a large cohort of patients: 
deletion, insertion, duplication, or point mutations that change the reading frame 
or result in a premature stop codon (Flanigan et al., 2009). The current genetic 
interventions such as antisense oligonucleotides to skip mutated exons, delivery 
of mini-/micro-dystrophin, and CRISPR-Cas9-mediated exon deletion (Duan, 
2018; Mendell & Rodino-Klapac, 2016; Mitrpant et al., 2009), produce partially 
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functional proteins to create a less severe Becker muscular dystrophy 
phenotype. Since there is 1) a list of well-validated miRNAs that are expressed in 
high abundance specifically in muscle (e.g. miR-1), 2) availability of multiple 
murine models of DMD (e.g. mdx), and 3) a myriad of examples of CRISPR 
technologies being developed in the field using AAV, testing the miRNA-
repressible strategy in cardiac/skeletal muscles as a new therapeutic target 
would be desirable. To this end, we decided to pursue therapeutic genome 
editing for DMD. 
Exon skipping and deletion are two common strategies for therapeutic DMD gene 
correction that are currently being developed using CRISPR-Cas9 (Min et al., 
2018) (Figure A4.1). Both strategies rely on the observation of a relatively mild 
disease course of Becker Muscular Dystrophy (BMD) patients with deletion 
mutations. This is also supported by the capacity of FDA-approved ASO drugs 
for DMD which mask splice donor or acceptor sequences of mutated exons in 
dystrophin mRNA to restore biologically active dystrophin proteins in humans 
(Kinali et al., 2009; van Deutekom et al., 2007).   
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Figure A4.1 Two strategies for the therapeutic targeting of DMD. (A) 
Skipping of the mutated exon 50 in Dmd using a single sgRNA targeting the 
intron 50 is shown as an example. (B) Two sgRNAs targeting introns 50 and 51 
flanking the mutated exon 50 will delete out the exon 50.  
 
  
 
 
221 
A4.2 Exon skipping strategy for therapeutic editing in DMD 
With the initial success of CRISPR-Cas9 gene editing to induce exon skipping 
(Long et al., 2016; Nelson et al., 2016), different mutated exons have become 
targets of such a strategy with a prominent example of targeting exon 51 using 
SpyCas9 showing efficacy in preclinical studies of large animal models (Amoasii 
et al., 2018; Moretti et al., 2020). As rapid advances in a clinical setting are 
projected, we aim to incorporate highly accurate Nme2Cas9 and miRNA-
repressible anti-CRISPR as safety measures. First, we designed several target 
sites in exon 51 for Nme2Cas9 that, in theory, should disrupt exonic splicing 
enhancer (ESE) elements and induce skipping of exon 51 (Figure A4.2A). To 
screen a highly active sgRNA we transfected HEK293T cells with seven different 
sgRNAs for Nme2Cas9 and measured editing efficiencies at each target site by 
targeted deep-sequencing (Figure A4.2B). We also included two validated 
SpyCas9 sgRNAs to use as a benchmark for Nme2Cas9 editing. Out of seven 
Nme2Cas9 sgRNAs, two (sgRNA #3 and 6) showed editing levels comparable to 
that of SpyCas9 (Figure A4.2B). 
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Figure A4.2 Exon 51 skipping strategy: target site design and validation. (A) 
Target sites for Nme2Cas9 and SpyCas9 for skipping exon 51. ESE, an exonic 
splicing enhancer annotated in Amoassi et al. (2017). Arrows indicate the 
cleavage site for Cas9. (B) Editing efficiency of each sgRNA for Nme2Cas9 and 
SpyCas9 is measured by targeted deep sequencing. Four biological replicates 
(N=4). 
  
 
 
223 
A4.3 Exon deletion strategy for therapeutic editing in DMD 
As an alternative to exon skipping using a single sgRNA, two sgRNAs can be 
used simultaneously for introducing an exon deletion (Tabebordbar et al., 2016) 
(Figure A4.1B). Initially, we used a scAAV that expresses a single sgRNA driven 
by a U6 promoter along with a miRNA-repressible anti-CRISPR expression 
cassette (Figure A4.3A). Since scAAV has a packaging limit of ~2.5 kb, the 
current vector design can accommodate an extra sgRNA-expression cassette. 
Even after the addition of a second sgRNA, the “dual sgRNA scAAV” vector is ~ 
2.4 kb, which is well within the packaging capacity (Figure A4.3B). To minimize 
recombination between highly similar sequences, we can take advantage of 
other pol III promoters such as the H1 promoter instead of U6. 
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Figure A4.3 Exon deletion strategy: a design of a scAAV vector encoding 
two guides. (A) A schematic of a scAAV encoding a U6 driven sgRNA and a 
separate promoter driving AcrIIC3 as in the original vector design. (B) A 
schematic of a scAAV encoding an additional H1 driven sgRNA cassette along 
with U6-sgRNA and anti-CRISPR expression cassettes. 
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A4.4 Future directions 
To extend the existing platform for therapeutic application, we aimed to 
repurpose our tools to reinforce muscle-specific editing, which will greatly 
facilitate the treatment of DMD by Cas9. Following in vitro validation of guide 
RNAs in HEK293T cells, top-performing sgRNAs must be assessed to determine 
if the editing outcome indeed results in the skipping of exon 51 at the transcript 
level and truncated dystrophin at the protein level in relevant cell types. The next 
step is to test the sgRNAs in human patient-derived induced pluripotent stem 
cells (iPSCs) for evaluating exon skipping efficiency in differentiated myocytes. 
Lastly, it would be important to test whether myomiRs regulate the anti-CRISPR 
regulation in muscle cell lineages. Based on our preliminary data as well as 
another study showing myocyte-specific editing using miR-1 (Hoffmann et al., 
2019), myomiR-repressible anti-CRISPR proteins (with miR-1 or miR-208) will be 
feasible for in vivo context for evaluating the efficacy in mdx or other DMD mouse 
models for AAV dual delivery as we have previously done for liver-specific 
editing. 
In addition to multiplexing sgRNAs in a scAAV, MREs themselves can be easily 
swapped for targeting different tissues; for example, neuronal miRNAs such as 
astrocyte-specific miRNAs for targeting GFAP in Alexander disease (Jovičić et 
al., 2013) or endothelial cell-specific miR-126 for targeting cardiovascular 
diseases (S. Wang et al., 2008). Furthermore, the platform can be extended to 
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multiple tissues that are affected by a genetic disease, necessitating systemic 
delivery of therapeutic reagents as in the case of a Muscle-eye-brain (MEB) 
disease, also known as muscular dystrophy-dystroglycanopathy congenital with 
brain and eye anomalies A3 (MDDGA3). By multiplexing different miRNAs, for 
example, such as muscle- and brain- targeting miRNAs, we can restrict CRISPR-
mediated genome editing to muscles and brain while avoiding off-target tissue 
editing in other tissues such as the liver. Numerous applications can be explored. 
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Appendix Table 1. Protein sequences of anti-CRISPR and Cas9 
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Appendix Table 2. Plasmids used in Chapters 2, 3, and 4 
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